Efficacy and safety of small extracellular vesicle interventions in wound healing and skin regeneration: A systematic review and meta-analysis of animal studies

Maimonah Eissa Al-Masawa¹, Mohammed Abdullah Alshawsh², Chiew Yong Ng¹, Angela Min Hwei Ng¹, Jhi Biau Foo³, Ubashini Vijakumaran¹, Revatyambigai Subramaniam¹, Nur Azurah Abdul Ghani⁴, Kenneth Whitaker Witwer⁵, Jia Xian Law¹

1. Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, 56000, Kuala Lumpur, Malaysia.
2. Department of Pharmacology, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
3. School of Pharmacy, Faculty of Health and Medical Sciences, Taylor’s University, 47500, Subang Jaya, Selangor, Malaysia.
4. Department of Obstetrics and Gynaecology, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, 56000, Cheras, Kuala Lumpur, Malaysia.
5. Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology and Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Corresponding author: E-mail: lawjx@ppukm.ukm.edu.my; Tel.: +603-9145 7677.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

Small extracellular vesicles (sEVs) have been proposed as a possible solution to the current lack of therapeutic interventions for endogenous skin regeneration. We conducted a systematic review of the available evidence to assess sEV therapeutic efficacy and safety in wound healing and skin regeneration in animal models. 68 studies were identified in Web of Science, Scopus, and PubMed that satisfied a set of prespecified inclusion criteria. We critically analyzed the quality of studies that satisfied our inclusion criteria, with an emphasis on methodology, reporting, and adherence to relevant guidelines (including MISEV2018 and ISCT criteria). Overall, our systematic review and meta-analysis indicated that sEV interventions promoted skin regeneration in diabetic and non-diabetic animal models and influenced various facets of the healing process regardless of cell source, isolation methods, dosing regimen, and wound size varied among the studies. Modification of sEVs was achieved mainly by manipulating source cells via preconditioning, nanoparticle loading, genetic manipulation, and biomaterial incorporation to enhance sEV therapeutic potential. Evaluation of potential adverse effects received only minimal attention, although none of the studies reported harmful events. Risk of bias as assessed by the SYRCLE’s ROB tool was uncertain for most studies due to insufficient reporting, and adherence to guidelines was limited. In summary, sEV therapy has enormous potential for wound healing and skin regeneration. However, reproducibility and comprehensive evaluation of evidence are challenged by a general lack of transparency in reporting and adherence to guidelines. Methodological rigor, standardization, and risk analysis at all stages of research are needed to promote translation to clinical practice.

Key words: extracellular vesicle, exosome, wound healing, skin regeneration, animal models

Introduction

Poor skin healing continues to have a substantial impact on the quality of life of millions of individuals around the globe. Skin is the body’s first line of defense. In response to injury, skin activates a series of intricately orchestrated events controlled by numerous signals [1], with the goal of restoring the multi-layered structure and the continuum of the skin and reinstating its protective, thermogenic, endocrine and sensory functions [2]. Generally, wounds heal through four distinct but overlapping phases. These phases are: 1) hemostasis (platelet aggregation and fibrin clot formation); 2) inflammation (recruitment of inflammatory cells); 3) tissue regeneration (restoration of skin structure via cell proliferation, extracellular
matrix deposition, new blood vessel, and appendage formation, resulting in granulation and re-epithelialization; and 4) remodeling (long-term maturation of the newly formed tissue to closely resemble the native equivalent) [2-4]. Disruption of any of these phases—due to systemic or local causes—may result in a prolonged healing process or suboptimal recovery, marked by a failure to restore the architecture and function of the healing tissue [5]. Due to population aging and comorbidities, the prevalence of chronic non-healing wounds has risen dramatically, affecting millions of individuals each year. This imposes an increasing burden on health systems and economies [5]. Acute wounds are also widespread, accounting for millions of medical treatment facility visits and hospital admissions annually. Deep wounds can result in permanent disability and scarring, while burn injuries require lengthy hospitalization, incur high costs, and have high morbidity and fatality rates [6]. Unfortunately, currently available remedies for skin wound healing are incapable of meeting the urgent clinical needs [3, 7]. Even though standard therapies such as routine debridement, infection management, and dressings may demonstrate some benefits, they fall short of addressing the pathophysiology of dysfunctional healing. Hence, researchers have placed great emphasis on developing biologically active formulations to rescue inadequate repair [3]. Of these, single bioactive factors that target specific wound indications—such as cytokines [8] and growth factors [9]—have garnered research interest, with a few gaining regulatory approval [3]. However, therapeutic modalities that target multiple inherent deficits in non-healing lesions might be more effective in addressing their complex pathophysiology that may include vascular, neurologic, inflammatory, and metabolic impairments [10].

Extracellular vesicles (EVs), which transfer cocktails of functional cargo (such as proteins, lipids, miRNAs, other RNAs, and DNA) horizontally between cells [11, 12] may be multipotent stimulants of endogenous tissue repair [13]. EVs are a class of natural anuclear cell-released particles delimited by a phospholipid bilayer. As colloid members of the cell secretome [14], EVs are produced by almost all types of cells, in varying sizes and with different subcellular origins [15]. Each EV displays surface molecules that may target recipient cells. EVs are believed to communicate signals by fusing with target cells or simply binding to cell receptors [16], ultimately causing recipient cells to undergo phenotypic changes [12]. EVs can interact with target cells residing in the microenvironment or be carried to distant cells via biological fluids, and their internal and external cargo contribute to intercellular communication [17]. Recent studies have recognized the role of EVs in the pathogenesis of diseases [18] and in various natural physiological processes [19]. Indeed, the potent effects that were once credited to stem cells, for instance, are now thought to be partially mediated by EVs [20], making EVs a promising alternative to potentially risky cell therapies [21]. Moreover, EVs from certain sources may benefit from relative immunological tolerance in cross-species and interindividual transfer [22]. In the absence of functional definitions, EVs were classically categorized according to combinations of size, biogenesis, and biophysical separation process. For example, as microvesicles (100-1000nm, budding from the plasma membrane, also called ectosomes); apoptotic bodies (1-5μm, released from fragmented apoptotic cells) and exosomes (30-150nm, endosomal multivesicular body-derived nanovesicles) [23, 24]. However, due to the increasingly recognized overlap in size between these categories [25] and the absence of universal differentiating markers, the term EVs is preferred [14, 26]. This systematic review will focus on the therapeutic applications of a nanosized subclass termed small EVs (sEVs, ~30-200 nm), which includes but is not limited to endosome-origin exosomes. sEVs have been demonstrated to enhance tissue regeneration [27] and to modulate the immune system [28]. They have also been used for drug delivery [29, 30], as vaccines [31] as biomarkers [32], and as therapeutic targets in “vesicle-mediated pathogenesis” [33]. EVs mediate signaling in all phases of physiological cutaneous wound healing (reviewed extensively in [34]). Platelet-[35] and monocyte-derived EVs [36] regulate clot formation and thus hemostasis. Neutrophil-derived EVs modulate inflammation [37], Macrophage-[38] and endothelial progenitor cell-derived EVs [38] drive angiogenesis, and myofibroblast-derived EVs remodel the extracellular matrix (ECM) [39]. In recent years, the number of studies examining the therapeutic potential of sEVs in wound healing and skin regeneration has expanded dramatically.

The rapid progression of sEV therapeutic modalities toward clinical applications prompted us to critically appraise the available preclinical evidence for the benefits and adverse effects of sEVs in skin healing and regeneration. In our approach, we emphasized methodological rigor and reporting quality in accordance with field guidelines, including the Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018) [14] and the criteria for MSC identification of the International Society for Cell and Gene Therapy (ISCT) [40]. We used a systematic review methodology for inclusive, bias-free coverage of existing studies, which could not be achieved by a
conventional narrative review approach [41]. We further performed a meta-analysis for a quantitative pooled estimate of sEV efficacy across a vast body of literature, while assessing the heterogeneity of study outcomes and the likelihood of publication bias. Our work thus informs the scientific community of the available evidence from preclinical animal research and provides insights into the likelihood of clinical translation.

Results

Search results

This systematic review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. On November 11th, 2019, a search on Web of Science, Scopus, and PubMed retrieved a total of 664 articles. All articles were pooled into Endnote X9.3.3 software, and 315 duplicates were removed. Titles and abstracts were screened to include articles investigating the therapeutic application of sEVs in skin repair, rejuvenation, and wound healing in mammalian models. We excluded 273 studies that were in vitro studies, reviews, reports, commentaries, conference proceedings, or articles written in languages other than English. The remaining 76 articles were read in full to determine satisfaction of the eligibility criteria. As a result, 48 studies were excluded, of which two studies were not in English (Chinese), 20 studies did not characterize sEVs by size and/or at least one sEV protein marker, and 26 studies exclusively reporting in vitro findings. Additionally, on March 1st, 2021, we updated our search to include another 40 studies, bringing the total number of manuscripts eligible for this systematic review to 68. The flow chart in Figure 1 summarizes the study selection approach.

General characteristics of the included studies

The 68 studies identified as eligible for inclusion were published between 2015 and March 1st, 2021. Approximately 56% (n = 38) were published in 2020 or later, reflecting a surge in interest in sEVs to promote wound healing and skin regeneration. The studies originated from nine different countries, with China accounting for 84% (n = 57). Figure 2 depicts year of publication (2a) and region according to the corresponding author's affiliation (2b).

Characteristics of wound healing animal models

Animal species

Animal models have been used to reveal the intricate physiological and biochemical processes involved in wound healing and skin regeneration, as well as to assess the efficacy and safety of proposed therapeutic interventions. Rodents were used in 66 studies (97%): mice (36 studies) and rats (30 studies). One study tested a non-human primate model (macaque) [42], while another used the New Zealand rabbit model [43] (Figure 3A).

Disease models

Non-diabetic wounds and diabetic wounds were investigated in 41 (60.3%) and 28 (41.2%) studies, respectively. One study examined both wound models [44]. 22 used streptozotocin (STZ)-induced diabetic rats (n = 15) or mice (n = 7) as a type 1 diabetes model. Six studies utilized genetically modified diabetic db/db mice to represent type 2 diabetes (Figure 3B).

Wound models

Full-thickness excisional wounds were the most-studied models (n = 63, 92.6%), of which 58 were “dorsal”, three were diabetic foot ulcer (DFU), one was leg, and one was ear excisional wounds. Other models (n = 6, 8.8%) included burns (n = 3) [45-47], photoaging (n = 1) [48], pressure ulcer (n = 1) [49], and excisional ischemic wounds (n = 1) [50]. Wound size ranged in diameter from 4 to 20 mm.

Intervention characteristics

Cellular origin of sEVs

For comprehensiveness, all sEV source types were included, resulting in a diverse array of sources (Figure 4). In 64 studies (94.1%), sEVs were prepared from a single cultured cell type. We broadly categorized these into MSCs (n = 43, 63.2%), other stem cells (n = 7, 10.3%), and non-stem cell sources (n = 14, 20.6%). Only eight studies (11.8%) used immortalized cell lines. Adipose tissue-derived sEVs were examined in a single study [51]. Biofluids—peripheral blood, cord blood, platelet-rich plasma (PRP), and saliva—were the EV source in the remaining investigations, representing a more heterogeneous source of sEVs (n = 4, 5.9%). 58 studies (85.3%) used sEVs from human sources, while ten (14.7%) used non-human sources, i.e., rodent (n = 8), pig (n = 1), and macaque (n = 1).

Modification of sEVs

Preconditioning

Nine studies (13.2%) exposed sEV-producing cells to preconditioning regimens prior to sEV separation. Parent cells were primed with growth factors such as PDGF-BB, TGFβ1, and FGF2 [52]; enzymes such as thrombin [53]; and stressors such as the pro-inflammatory agent lipopolysaccharide (LPS) [50, 53], hypoxia [44, 53], hypoxia mimetic agent
deferoxamine (DFO) [54], and hydrogen peroxide (H₂O₂) [53]. Priming was also done with hormones like melatonin [55] and parathyroid-hormone related peptide (PTHrP-2) [56] or with pharmacological drugs such as Atorvastatin (ATV), an HMG-CoA reductase inhibitor [57]. A single study preconditioned source cells with neonatal and adult serum-derived sEVs [58].

**Genetic modification**

Genetic modification of sEV-producing cells was performed in 11 studies (16.2%) to enhance endogenous loading of sEVs with active ingredients such as nucleic acids and proteins/peptides and thus potentiate sEV efficacy. Nucleic acids were introduced by transduction with lentiviruses [47, 59-62]; transfection of plasmids [63] or miRNA mimic sequences [64]; or electroporation of miRNA sequences [65]. Specific noncoding RNAs included 1) miRNAs (miR-126-3p [60, 62], miR-135a [66], miR-21-5p [65], and miR-126 [64]); 2) long non-coding RNA (lncRNA H19 [67]), and 3) circular RNA (mmu_circ_0000250 [68]). Overexpressed specific proteins included the transcription factor nuclear factor-E2-related factor (Nrf-2) [63], tumor necrosis factor (TNF)-stimulated gene-6 (TSG-6) [59], angiopoietin-2 (Ang-2) [47], and PD-L1 [61].

---

**Figure 1.** PRISMA flow chart summarizing study screening and selection procedure. Web of Science, PubMed and Scopus were searched for relevant articles from inception to March 1st, 2021.
Loading sEVs with nanoparticles

Two studies loaded superparamagnetic iron oxide nanoparticles (Fe₃O₄-NPs) into sEVs by incubating the nanoparticles with the parent cells before sEV isolation [46, 69]. Following intravenous administration of nanoparticle-loaded sEVs, Li et al. magnetized the nanoparticles using an external magnetic guide positioned beneath the wound site to improve targeting and distribution capabilities [46]. In that experiment, nanoparticle-loaded sEVs were introduced locally to the wound via subcutaneous injection.

Loading sEVs into biomaterial scaffolds

20 studies (29.4%) loaded sEVs into biomaterial scaffolds. Hydrogels were the most preferred choice (n = 18). The remaining studies used polyvinyl alcohol (PVA) (n = 1) [51] and human acellular amniotic...
membrane (HAAM) \((n = 1)\) [49]. Seven studies used synthetic hydrogels: Pluronic F-127 based \((n = 4)\) [61, 70-72], peptide nanofiber (HydroMatrix, \(n = 2\)) [73, 74] and gelatin methacryloyl (GelMA) hydrogel [75]. Eleven studies used natural hydrogels: chitosan-based \((n = 5)\), plain \((n = 1)\) [62] or incorporated with silk \((n = 1)\) [76], hydroxyapatite \((n = 1)\) [60], glycerol \((n = 1)\) [77], or methylcellulose \((n = 1)\) [78]. Alginate-based hydrogels were investigated in three studies [79-81]. Hydrogels were usually pre-mixed with sEVs prior to application. Injectable hydrogel formulations were introduced to wound beds in seven studies [44, 70-74, 78].

**sEV preparation**

**sEV collection conditions**

62 studies (91.2%) separated sEVs from conditioned medium. Since serum contains sEVs, 22 studies (32.4%) collected sEVs from serum-free medium. Others prepared culture medium with sEV-depleted FBS \((n = 22, 32.4\%)\) or platelet lysate \((n = 1, 1.5\%)\). However, only six studies revealed the details of FBS-EV depletion protocols, and without reporting before-and-after particle counts. Chemically defined serum replacements were used in nine studies (13.2%), while autologous serum was the supplement of choice in a single study [82]. 11 studies (16.2%) did not report how they dealt with the issue of contaminating sera. 15 studies (22.1%) did not disclose the duration of cell culture conditioning before harvest. In the remaining studies, sEVs were collected after 24 hours \((10.3%, n = 7, 11\%)\) or 48 hours \((n = 33, 48.5\%)\) of conditioning.

**Figure 4.** Sources of sEVs used to promote wound healing and skin regeneration. sEVs were isolated from cells, biofluids and tissues.
sEV separation techniques

There is no gold standard separation technique for sEVs, and sEV separation methods varied considerably across the studies (Figure 5A). Ultracentrifugation ($n = 43, 63.2\%$) was the most widely used technique, but with various centrifugation protocols. Ultrafiltration by membranes of pore size 0.22 µm ($n = 43, 63.2\%$) or 100 kDa ($n = 27, 39.7\%$) was often done as an adjunct to other separation steps. Commercial precipitation-based isolation kits, density gradient ultracentrifugation, and size exclusion chromatography (SEC) were used in 16 ($23.5\%$), six ($8.8\%$), and two ($2.9\%$) studies, respectively. Additional washing steps were reported in 20 studies ($29.4\%$). No study used tangential flow filtration (TFF), asymmetrical flow field, flow fractionation, or microfluidics. 32 studies ($47.1\%$) combined two or more separation techniques to achieve higher purity (Figure 5B).

Characterization of sEV preparations

MISEV2018 recommends characterizing EVs using complementary approaches [14] to evaluate the outcome of separation methods, assess properties of EVs, and assess the extent to which biological functions can be attributed to sEVs versus co-separated materials. A diverse array of characterization procedures was used in the studies we reviewed (Figure 5C). Size distribution was determined by single-particle analysis methods such as nanoparticle tracking analysis (NTA) ($n = 34, 50\%$), tunable resistive pulse sensing (TRPS) ($n = 5, 7.4\%$), and atomic force microscopy (AFM) ($n = 1, 1.5\%$), while others used ensemble methods such as dynamic light scattering (DLS) ($n = 20, 29.4\%$). Morphology was checked by transmission electron microscopy (TEM) ($n = 60, 88.2\%$), scanning EM (SEM) ($n = 6, 8.8\%$), and cryo-TEM ($n = 1, 1.5\%$). Protein quantification was done by bicinchoninic acid assay (BCA) ($n = 36, 52.9\%$) or Bradford assay ($n = 2, 3\%$). Surprisingly, most studies did not report sEV total protein yield.

EV-specific markers were detected by Western blot (62 studies, 91.2\%), flow cytometry (12 studies, 17.7\%), or both (six studies). The tetraspanin transmembrane proteins CD63 ($n = 52$), CD9 ($n = 40$), and CD81 ($n = 38$) were the most frequently examined markers (Figure 5D). Other positive markers included the cytosolic proteins TSG101 ($n = 33$), Alix ($n = 17$), and HSP70 ($n = 7$). Only 17 studies ($25\%$) checked for the presence of negative or depleted non-EV markers,
including Calnexin (n = 8), Grp94 (n = 3), GM130 (n = 4), Lamin (n = 1), and Calregulin (n = 1). A total of 26 studies (38.2%) examined four or more protein markers. Only one study evaluated the lipidomic profile of sEVs [83]. Broader profiling of EV proteins [53, 83-86] or RNA (mainly miRNA) [44, 50, 52, 54, 69, 73, 74, 86-90] was also reported.

### Table 1. Summary of the methods used for separation and characterization of small extracellular vesicle used by the reviewed studies for treatment of wounds in animal models

| Ref | Source | Collection Medium | Supplementation | Isolation | Characterization | EV characteristics | Morphology | Detected |
|-----|--------|-------------------|-----------------|-----------|-----------------|-------------------|------------|----------|
| [52] | Primary human fibrocyte (preconditioned with PDGF-BB, TGF/1, IGF2, ITS) | 5% exosome depleted FBS, 48 h | Ultrafiltration | Protein concentration: BCA assay; Morphology: TEM; Size distribution and concentration: NTA; sEV markers: Western blot TSG101, flotillin-1, GM130, calnexin; Flow cytometry: CD9, CD63, CD81 | 50-100 nm | Cup-shaped | Positive for: CD9, CD63, CD81, TSG101, and flotillin-1; Negative for: GM130 and calnexin |
| [50] | Primary hUC-MSCs (preconditioned with 100ng/ml LPS) | Serum free medium, 48 h | -Filtration: 0.22µm filter; -Centrifugation: 10,000g for 30min; -Ultra centrifugation: 100,000g for 3h | Protein concentration: BCA assay; Morphology and size: TEM; sEV markers: Western blot (CD9, CD63, CD81) | 40-90 nm | Cup-shaped | Positive for: CD9, CD63, CD81 |
| [45] | Primary hUC-MSCs and HFL1 | Serum free medium (DMEM) | -Differential centrifugation: 1000g for 20min, 2000g for 20min, 10,000g for 20min; -Ultrafiltration/Concentration: 100kDa at 10,000g for 30min; -Density gradient centrifugation: 100,000g for 60 min in 30% sucrose-D2O cushion; -Washed (x3) in PBS at 1000g for 20 min; -Ultrafiltration: at 4000×g for 20 min; -Centrifugation: 10,000×g for 3h | Protein concentration: BCA assay; Morphology: TEM; Size distribution and concentration: NTA; sEV markers: Western blot; CD63, CD9, CD81 | 100 nm | Spherical | Vesicle | Positive for: CD3, CD9, CD81 (both hUC-MSC and HFL1 derived exosomes) |
| [98] | hu-iPS-derived MSCs | Chemically defined medium, 48 h | -Ultrafiltration: 0.22µm filter; -Differential centrifugation: 300×g for 10min, 2000g for 10min; -Filtration: 0.22µm filter; -Ultra centrifugation: 100,000g for 2h; -Ultra centrifugation/Concentration: at 4000×g | Protein concentration: BCA assay; Morphology: TEM; sEV markers: Western blot; CD63, CD9, CD81 | 30-100 nm | Spherical | Positive for: CD63, CD9, CD81 |
| [73] | Primary hUC-MSCs | Exosome depleted FBS (UCG: 120,000g for 3h) | -Differential centrifugation: 300×g for 10 min, 16,500×g for 20 min; -Filtration: 0.22µm filter; -Ultra centrifugation: 120,000×g for 70 min | Protein concentration: BCA assay; Size distribution and concentration: NTA; sEV markers: Western blot CD81, CD63; microRNA profiling: HTC | 55 nm | NS/NR | Positive for: CD81, CD63 |
| [94] | Primary hADMSC (subcutaneous fat) | Serum-free medium, 24h | -Centrifugation: 3,000×g for 15 min; -Filtration: 0.22µm filter; -Ultrafiltration: 100kDa MWCO filter; -Precipitation: Exosome precipitation (kii); -Ultra centrifugation: 0.22µm filter | Protein concentration: BCA assay; Morphology: TEM; Size distribution and concentration: NTA; sEV markers: Western blot CD63, CD9, tubulin and lamin A/C | 30-100 nm (85%) | Cup-shaped | Positive for: CD63, CD9; Negative for: Tubulin and lamin A/C |
| [60] | Primary SMSCs-126 (transfected with miR-126-3p) | Chemically defined medium, 48 h | -Centrifugation: 2,000×g for 30 min; -Filtration: 0.22µm filter; -Ultrafiltration: at 4000×g for 30 min; -Washing with DPBS: 4000×g for 30 min; -Density gradient centrifugation: 100,000g for 60 min in 30% sucrose-D2O cushion; -Washing with PBS: 4000×g for 30 min | Protein concentration: BCA assay; Morphology: TEM; Size distribution: DLS; sEV markers: Western blot CD9, CD63, CD81, and TSG101 | 85 nm | Spherical | Positive for: CD9, CD63, CD81, and TSG101 |
| [62] | Primary human | Chemically defined medium, 48 h | -Centrifugation: 300×g for | -Morphology: TEM; Size distribution: NTA; sEV markers: Western blot CD63, CD9, CD81 | 30-150 nm | Spherical | Positive for: CD9, |
| Ref | Source | Collection Medium Supplementation | Isolation | Characterization | EV characteristics |
|-----|--------|-----------------------------------|-----------|-----------------|-------------------|
|     |        |                                   |           | Size Markers    | Morphology        | Detected          |
| [SMSCs] 126 | transfected with miR-126-3p | defined medium, 48 h | 15 min, 2,000 g for 15 min; - Filtration: 0.22 µm filter; - Washing pellet in PBS; - Ultrafiltration: at 4000 g; - Density gradient centrifugation: 100,000 g for 60 min in 30% sucrose-D2O cushion; - Washing pellet in PBS: at 4000 g | - Size distribution: DLS; - EV markers: Western blot CD9, CD63, CD81, and TSG101, Alix. | CD63, CD81, and TSG101, Alix |
| [93] Primary hUCB-EPCs | Deprived medium of FBS+ 1 × serum replacement, 24 h | Deprived centrifugation: 300 g for 10 min, 2000 g for 10 min; - Filtration: 0.22 µm filter; - Ultrafiltration/Concentration: at 4000 g; - Washing (x2) in PBS; - Ultrafiltration/Concentration: at 4000 g; - Density gradient centrifugation: 100,000 g for 60 min in 30% sucrose-D2O cushion; - Ultrafiltration/Concentration: at 4000 g; | - Morphology: TEM; - Size distribution and concentration: TRPS; - EV markers: Western blot CD63, CD9, CD81, epithelial marker CD31 | 50-60 nm | Cup- or round-shaped | Positive for: CD63, CD9, CD81, EPC marker CD31 |
| [105] Primary hADMSCs | Serum-free DMEM, 48 h | - Differential centrifugation: 3000 g for 7 min, 1000 g for 15 min, 10,000 g for 40 min, 15 min at 1000 g; - Ultra centrifugation: 100,000 g for 70 min (x2); - Pellet washed (3x) with PBS; - Pellet activated; 3000 g for 10 min; 2000 g for 10 min; - Filtration: 0.22 µm filter; - Ultrafiltration: at 4000 g; - Washing pellet in PBS (3x); - Ultrafiltration: at 4000 g; | - Protein concentration: Bradford method; - Size distribution and concentration: NTA; - EV markers: Western blot (Alix and CD9) | 135 nm | Na/Na | Positive for: Alix and CD9 |
| [80] hPRP (freshly isolated) | NA | - PRP centrifuged at 250 x g for 15 min; - Pellet washed (3x) with PBS; - Pellet activated; 3000 g for 10 min; 2000 g for 10 min; - Filtration: 0.22 µm filter; - Ultrafiltration: at 4000 g; - Washing pellet in PBS (3x); - Ultrafiltration: at 4000 g; - Density gradient UG: 100,000 g for 70 min in 30% sucrose-D2O cushion; - Washing in PBS at 100,000 g for 70 min | - Morphology: TEM; - Size distribution and concentration: DLS; - EV markers: Western blot CD9, CD63, CD81, and the source marker CD41, VEGF, TGFβ1, bFGF, PDGFβ | 40-100 nm | Cup- or sphere-shaped | Positive for: CD9, CD63 and CD81, CD41 (platelet marker) VEGF, TGFβ1, bFGF, and PDGFβ |
| [70] Primary hGMSCs | 10% exosome-free FBS, 48 h | - Centrifugation; - Filtration: 0.22 µm filter; - Ultrafiltration: 10kDa filter at 5000 g for 30 min; | - Protein concentration: BCA assay; - Morphology: TEM; - Size distribution and concentration: TRPS; - EV markers: Western blot (CD9 and CD81) | 127 ± 55.9 nm | Spherical | Positive for: CD9 and CD81 |
| [109] Primary hADMSC (subcutaneous) | Serum-free medium, 24 h | - Centrifugation: 3000 g for 15 min; - Ultrafiltration: 10kDa filter; - Filtration: 0.22 µm filter; - Precipitation: Exosome precipitation (kit) at 1500 g for 30 min; - Filtration: 0.22 µm filter | - Protein concentration: BCA assay; - Morphology: TEM; - Size distribution and concentration: NTA; - EV markers: Western blot (CD63, CD9) | NR | NR | Positive for: CD9, CD63 |
| [91] Primary hAECs | 10% exosome-free FBS medium | - Centrifugation: 3000 g for 5 min; - Filtration: 0.22 µm filter; - Ultrafiltration: 100,000 g for 12 h; - Ultrafiltration/Concentration: at 4000 g | - Size distribution, morphology: SEM; - EV markers: Western blot CD9, CD63, Alix and TSG101; - Flow cytometry CD9, CD63, CD81 and HLA-G | 50-150 nm | Round or oval | -Western blot: Positive for CD9, CD63, Alix and TSG101; - Flow cytometry: Positive for CD9 (88.8 ± 6.1%), CD63 (98.1 ± 1.2%), CD81 (91.7 ± 3.4%) and HLA-G (95.6 ± 3.4%). |
| [84] Primary hUSCs (transfected with shRNA DMBT1) | Exosome free FBS, 48 h | - Differential centrifugation: 3000 g for 10 min, 2000 g for 30 min, 10,000 g for 30 min; - Filtration: 0.22 µm filter; - Ultrafiltration: 10kDa filter at 4000 g; - Washing (x2) w PBS at 4000 g; - Precipitation: Exosome | - Protein concentration: BCA assay; - Morphology: TEM; - EV markers: Western blot (CD9, CD63, CD81 and TSG101); - Flow cytometry (CD63, TSG101); -Proteomic analysis: TMT labeling, HPLC fractionation, | 51.57 ± 2.93 nm | Cup- or sphere-shaped | Positive for CD9, CD63, CD81 and TSG101 |

https://www.thno.org
| Ref | Source | Collection | Medium Supplementation | Isolation | Characterization | EV characteristics | Detected |
|-----|--------|------------|-------------------------|-----------|-----------------|-------------------|----------|
| [64] | Primary hUCBMSCs | Serum-free medium | +Flt-3+tem-cell factor, 18h | -Differential centrifugation: 300 g for 10 min, 2000 g for 20 min, 10000 g for 30 min; -Ultra-centrifugation: 100000 g for 70 min; -Washing: pellet in PBS (2x); -Ultra-centrifugation: 100000 g for 70 min; -Concentration: NTA; -Protein concentration: DC assay, BCA assay; -Size distribution and surface charge: DLS; -sEV markers: Western blot CD63, GAPDH, Flow cytometry; TSG101, CD81, CD9, CD45; -RNA: profiling; HTC | Morphology and size: TEM; -Detection: of CD45 (hematopoietic marker) and GAPDH | Heterogeneous | Positive for: CD9, CD63, TSG101, and CD81 with low levels of CD45 and DFO-Exo. |
| [65] | Primary hMMSCs (preconditioned with 200 µM DFO, 48h) | Serum-free medium | +Flt-3+tem-cell factor, 18h | -Differential centrifugation: 300 g for 10 min, 2000 g for 20 min, 10000 g for 30 min (2x); -Ultra-centrifugation: 100000 g for 70 min; -Washed in PBS at 100000 g for 120 min | Morphology and size: TEM; -Detection: of CD45 (hematopoietic marker) and GAPDH | Heterogeneous | Positive for: CD9, CD63, TSG101, and CD81 with low levels of CD45 and DFO-Exo. |
| [66] | Primary macaque -fibro-iPSCs | Serum-free medium | +Flt-3+tem-cell factor, 18h | -Differential centrifugation: 300 g for 10 min, 2000 g for 20 min; -Ultra-centrifugation: 100000 g for 70 min; -Concentration: DC assay, BCA assay; -Size distribution and surface charge: DLS; -sEV markers: Western blot CD63, CD63 Alix, and β-actin | Protein concentration: DC assay, BCA assay; -Size distribution and surface charge: DLS; -sEV markers: Western blot CD63, GAPDH; Flow cytometry; TSG101, CD81, CD9, CD45; -RNA: profiling; HTC | 95 ± 9.9 nm | Spherical | Positive for: CD63 and Alix positive for β-actin |
| [67] | Primary sOMECs (clinical grade sheets of oral mucosa epithelial cells) | Serum-free medium | 5% autologous serum | -Differential centrifugation: 300 g for 10min; -Ultra-centrifugation: 100000 g for 70 min; -Concentration: 100KDa filter Pooled; -Concentration: 10KDa filter, Size exclusion chromatography; -Concentration: 10KDa filter | Protein concentration: DC assay, BCA assay; -Size distribution and surface charge: DLS; -sEV markers: Western blot CD63, CD63 Alix, and β-actin | 125±23.8 nm (mode) | NR/NS | Positive for: CD9, CD63, and CD81 |
| [68] | Primary rat-ADMSCs | FBS-free EGM-2MV media +1x serum replacement solution, 24h | -Differential centrifugation: 300 g for 10 min, 2000 g for 20 min, 10000 g for 30 min; -Ultra-centrifugation: 100000 g for 70 min; -Washed in PBS at 100000 g for 120 min | Protein concentration: DC assay, BCA assay; -Size distribution and surface charge: DLS; -sEV markers: Western blot CD63, GAPDH; Flow cytometry; TSG101, CD81, CD9, CD45; -RNA: profiling; HTC | Protein concentration: DC assay, BCA assay; -Size distribution and surface charge: DLS; -sEV markers: Western blot CD63, GAPDH; Flow cytometry; TSG101, CD81, CD9, CD45; -RNA: profiling; HTC | 100-130 nm | Heterogeneous | Positive for: CD9, TSG101, CD63, and CD81, with low levels of CD45 (hematopoietic marker) and GAPDH |
| [69] | Primary rat-ADMSCs | FBS-free EGM-2MV media +1x serum replacement solution, 24h | -Differential centrifugation: 300 g for 10 min, 2000 g for 20 min, 10000 g for 30 min; -Ultra-centrifugation: 100000 g for 70 min; -Washed in PBS at 100000 g for 120 min | Protein concentration: DC assay, BCA assay; -Size distribution and surface charge: DLS; -sEV markers: Western blot CD63, GAPDH; Flow cytometry; TSG101, CD81, CD9, CD45; -RNA: profiling; HTC | Protein concentration: DC assay, BCA assay; -Size distribution and surface charge: DLS; -sEV markers: Western blot CD63, GAPDH; Flow cytometry; TSG101, CD81, CD9, CD45; -RNA: profiling; HTC | 95 ± 9.9 nm | Spherical | Positive for: CD63 and Alix positive for β-actin |
| [70] | RAW 264.7 (mouse macrophage cell line) | FBS-free EGM-2MV media +1x serum replacement solution, 24h | -Differential centrifugation: 300 g for 10 min, 2000 g for 20 min, 10000 g for 30 min; -Ultra-centrifugation: 100000 g for 70 min; -Washed in PBS at 100000 g for 120 min | Protein concentration: DC assay, BCA assay; -Size distribution and surface charge: DLS; -sEV markers: Western blot CD63, GAPDH; Flow cytometry; TSG101, CD81, CD9, CD45; -RNA: profiling; HTC | Protein concentration: DC assay, BCA assay; -Size distribution and surface charge: DLS; -sEV markers: Western blot CD63, GAPDH; Flow cytometry; TSG101, CD81, CD9, CD45; -RNA: profiling; HTC | 95 ± 9.9 nm | Spherical | Positive for: CD63 and Alix positive for β-actin |

**Note:** The table above provides a summary of various cell types and their isolation methods, along with characterization and detection metrics. The detected markers include CD9, CD63, and TSG101, among others, indicating the presence of exosomal markers. The morphology and size distribution are also noted, with some samples showing spherical morphology. The table highlights the use of various isolation and characterization techniques, including centrifugation, precipitation, and filtration, to isolate and characterize exosomes from different sources.
| Ref  | Source | Collection Medium Supplementation | Isolation | Characterization | EV characteristics |
|------|--------|-----------------------------------|-----------|-----------------|-------------------|
|      |        |                                   |           |                 | Size Markers      | Morphology        | Detected          |
| [53] | Primary hUCB-MSCs (preconditioned with LPS) | Serum free medium                   | -Centrifugation: 3,000 g for 30 min; -Ultrafiltration: 100,000 g for 120 min, Wash (x2) w PBFF | -Protein concentration: Bradford; -Morphology: TEM, SEM; -Size distribution and concentration: NTA; -Single size count: (LUNA-FL); -SeV markers: Western blot (CD9, CD63, CD81, Cytochrome C, GM130 and fibrillin) | 30-100 nm | Round shaped | Positive for: CD9, CD63, CD81, Negative for: GM130 and fibrillin; Positive in H2O2- and hypoxia-preconditioned SeVs but negative in native SeVs or the thrombin or LPS-preconditioned SeVs: Mitochondrial Cytochrome C |
| [70] | Primary mouse-ADMSC (4wk old mice, epididymis-fat derived) | NR | -Centrifugation: 800 g for 5 min, 2000 g for 10 min; -Ultrafiltration: 100 kDa filter; -Ultrafiltration: 100,000 g for 90 min | -Protein concentration: BCA assay; -Morphology: TEM; -Size distribution and concentration: DLS; -SeV markers: Western blot (CD9, CD63, CD81, Alix) | 60-80 nm | Cup-round shaped | Positive for: CD9, CD63, CD81, Alix |
| [71] | Primary mouse-ADMSC (4wk old mice, epididymis-fat derived) | NR | -Centrifugation: 800 g for 5 min, 2000 g for 10 min; -Ultrafiltration: 100 kDa filter; -Ultrafiltration: 100,000 g for 90 min | -Protein concentration: BCA assay; -Morphology: TEM; -Size distribution and concentration: DLS; -SeV markers: Western blot (CD9, CD63, CD81, Alix) | 200 nm | NR | NR |
| [108] | Primary hDFMSCs (human fetal skin) | Serum free medium, 48 h | -Centrifugation: 3000 g for 15 min; -Ultrafiltration: 0.22 µm filter, Ultrafiltration; -Precipitation: Exosome Precipitation (kit) at 1500 g for 30 min | -Protein concentration: BCA assay; -Morphology: TEM; -Size distribution and concentration: NTA; -SeV markers: Western blot (CD63, CD81, TSG101, Calnexin) | 100 nm | Cup-shaped | Positive for: CD63, Alix, TSG101 |
| [100] | Primary hMSCs | 10% exosome-free FBS | -Centrifugation: 300 g for 10 min, 2000 g for 10 min, 10,000 g for 30 min; -Ultrafiltration: 100,000 g for 70 min; -Washed (x1) in PBS: 100,000 g for 70 min; -Ultrafiltration: 0.22 µm filter | -Morphology: TEM; -Size distribution and concentration: NTA; -SeV markers: Western blot (CD9, CD63, CD81, TSG101) | 63.8 and 125 nm (90%, average = 94.4 nm) | Cup-shaped | Positive for: CD63, Gyr94, TSG101 |
| [102] | Primary hUC-MSCs (transfected with miR-27b-inhibitor) | EV-depleted FBS, 48 h | -Centrifugation: R G force: to remove debris and apoptotic studies; -Ultrafiltration: 110,000 g for 70 min; -Ultrafiltration: 0.22 µm filter | -Morphology: TEM; -Size distribution and concentration: NTA; -SeV markers: Western blot (CD63, CD81, TSG101, Calnexin) | 30-100 nm | Cup-shaped or cystic-shaped | Positive for: CD63, CD81 and TSG101; Negative for: Calnexin |
| [51] | rat-AT, or p-AT (Adipose tissue extract) | NA | -Centrifugation: 2000 rpm for 20 min: to remove cells and debris; -Ultrafiltration: 40 µm filter, 0.2 µm filter; -Ultrafiltration: 3kDa MWCO, 5000 g for 30 min, Total Exosome Isolation overnight, 10,000 g for 1 hr; -Ultrafiltration: 0.2 µm filter | -Protein concentration: BCA assay; -Morphology: TEM; -Particle size and size distribution: DLS; -SeV markers: Western blot (CD9, CD63, Grp94, TSG101) | Both samples: 80-200 nm (130nm) | Both had round shaped vesicles | Positive in both: CD9, CD63, and TSG101 CD9 at different molecular weights 28kDa vs 50kDa; Negative for: Actin |
| [74] | hEPSCs (cell line) | Serum-free medium, 48 h | -Centrifugation: 300 g for 10 min; -Ultrafiltration: 100 kDa MWCO; -Density gradient UG: 100,000 g for 70 min in 30% sucrose-D2O cushion, Washed in PBS at 1500 for 30 min | -Protein concentration: BCA assay; -Morphology: TEM; -SeV markers: Western blot (CD9, CD63, GAPDH) | 30-100 nm | Round | Positive in both: CD9 and CD63 negative for GAPDH |
| [66] | hAMSC (transfected with hAMSC-miR-135 OE; or hAMSC-miR-135 KD) | 10% exosome depleted FBS, 48 h | -Centrifugation: 300 g for 10 min; -Ultrafiltration: 0.22 µm filter; -Ultrafiltration: 120,000 g for 10 h | -Protein concentration: BCA assay; -Morphology: TEM; -Particle size and size distribution: DLS; -SeV markers: Western blot (CD9, CD63, CD81, α-tubulin) | 30-150 nm (103 nm) | Circular or elliptical in shape | Positive for CD9, CD63 and CD81, negative for α-tubulin |
| [83] | HS-5 (cell line) | Serum-free medium, 48 h | -Centrifugation: Centrifuged at 4 °C and 2000 g for 5 min, 1000 g for 15 min; -Ultrafiltration: 100,000 g for 10 h | -Protein concentration: BCA assay; -Morphology: Cryo-TEM, TEM; -Particle size and size distribution: NTA; -SeV markers: Western blot (TSG101, CD9, CD63, Calregulin and CD73, GAPDH); -Proteomics Analysis: LC-MS; Lipidomic Analysis | 89 ±7 nm | Round shaped | Positive for: TSG101, CD9, CD63, and CD73; GAPDH; Negative for: Calregulin |
| Ref | Source | Collection Medium Supplementation | Isolation | Characterization | EV characteristics |
|-----|--------|----------------------------------|-----------|-----------------|-------------------|
| [59] | hBMMSCs (transfected to overexpress TSG-6) | Exosome-depleted FBS, 96h | -Centrifugation: 2000g for 30 min; - Filtration: 0.22-μm filter; - Total exosome isolation reagent: Incubation overnight + centrifuge at 10,000g for 1h | - Protein concentration: BCA assay; - Morphology and size: TEM; - EV markers: Western blot (Alix, CD63, CD9 and TSG101) | 20-100 nm Cup-shaped Positive for: Alix, CD63, CD9 and TSG101 |
| [67] | Mouse-myeloid-MSCs | Serum-free, overnight | -Centrifugation: 2000g for 20 min; 10,000 g for 1 h; Suspended in serum free DMEM and 25 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl] Ethanesulfonic acid (pH 7.4); 10,000 g for 1 h | -Size distribution and concentration: DLS; - EV markers: Western blot; CD63, CD81, TSG101, heat shock protein 70 (HSP70), GRP94; Flow cytometry CD63; qRT-PCR: Expression of mir-152-3p | 30-120 nm Round or oval Positive for: CD63, CD81, TSG101, heat shock protein 70 (HSP70); Negative for: GRP94 |
| [46] | hUC-MSCs (loaded with 50 μg/mL of Fe3O4 NPs) | 10% Exo-depleted FBS, 48h | -Centrifugation: 1500 rpm for 15 min; - Filtration: 0.22-μm filter; - Ultrafiltration: 100kDa MWCO filter; Membrane affinity spin column method (kit) | -Protein concentration: BCA assay; - Morphology: TEM; - Size distribution: NTA; - EV markers: Flow cytometry (CD63, CD81) | NTA: Exosomes only: 98.5±1.4 nm; Exosomes+ NPs: 116.7±1.3 nm Round, cup-shaped vesicles Positive for Alix and CD9 proteins |
| [48] | Primary hADMSCs | Serum free media, 48h | - Differential centrifugation: 300 x g, 10 min; 10,000 x g, 60 min; - Filtration: 0.22-μm filter; - Ultrafiltration: 120,000 x 2h; Washed (x2) with PBS and ultrafiltration repeated | - Protein concentration: BCA assay; - Morphology: TEM; - Size distribution: NTA; - EV markers: Flow cytometry (CD63, CD81) | 30-150 nm Biconcave disc-shaped vesicles Positive for CD63 and CD81 |
| [47] | Primary hUC-MSCs (transfected with Lenti-Ang-2) | Exosome-free FBS depleted medium (UC at 10,000g for 16h at 4°C), 48h | -Centrifugation: 2000g for 20 min; - Concentration/ Ultrafiltration: 100 kDa MWCO at 1500g for 30 min; - Filtration: 0.22-μm filter; - Overnight incubation with exosome isolation reagent and centrifugated at 1,500 x g for 15 min at 4°C | - Protein concentration: BCA assay; - Morphology: TEM; - Size distribution and concentration: NTA; - EV markers: Flow cytometry (CD63, CD81) | 55nm Spherical Positive for: CD9, CD63, and CD81 |
| [55] | Primary hiBMSCs (preconditioned with melatonin 1μmol/L, 48h) | Serum free medium, 48h | - Differential centrifugation: 300 x g/ 15 min; 2000 x g/ 20 min; - Filtration: 0.22-μm filter; - Ultrafiltration: 100,000 x g/ 2 h (x2) | - Morphology: TEM; - Size distribution and concentration: NTA, sEV markers: Western blot (CD9, CD63, and CD81) | TEM: 120nm; NTA: 30-150 nm Oval Positive for: CD81, Tsg101, Alix and Calnexin |
| [101] | Primary hADMSCs | EVs-depleted FBS and PL (70,000 g and 4°C overnight), 24-48h | - Differential centrifugation: 500 x g for 10 min (2x); 2,000 x g for 15 min (2x); 10,000 x g for 30 min (2); - Ultrafiltration: 70,000 x g for 1 h (2x) | - Protein concentration: BCA assay; - Morphology: TEM; - Size distribution and concentration: NTA; - EV markers: Western blot (CD9, CD63, TSG101) | 30-100 nm Cupyiform or spherical Positive for: CD63 and TSG101; Negative for: endoplasmic reticulum marker calnexin |
| [65] | Primary hADMSCs | Exosome free medium, 48h | - Differential centrifugation: 400 g for 10 min; 2,000 g for 15 min; - Filtration: 0.22μm filter; - Ultrafiltration/concentration: 100kDa MWCO, 4000g; Ultrafiltration: 100,000 x g for 70 min | - Protein concentration: BCA assay; - Morphology: TEM; - Size distribution: NTA; - EV markers: Western blot (CD9, CD63, and TSG101) | 41-130 nm (105.2 nm) Spherical shape Positive for: CD63, CD9, and TSG101 |
| [88] | Saliva-Exos (unstimulated) | NA | - Differential centrifugation: 2,000 g for 30 min; 12,000 g for 45 min; - Filtration: 0.45 μm filter; - Ultrafiltration: 110,000 g for 70 min; Washing in PBS and 110,000 g for 70 min | - Morphology: TEM; - Size distribution: Flow NanoAnalyzer, NanoFCM; sEV markers: Western blot (CD81, TSG101, Calnexin) | 30-150 nm Spherical Positive for: CD81, Tsg101; Negative for: Calnexin |
| [77] | Primary hENSC | Exosome free serum, 24h | - Differential centrifugation: 300 x g for10 min; 2000 x g for10 min; 10,000 x g for 30 min; - Ultrafiltration: 100,000 x g for 70 min | - Morphology: TEM, SEM; - Size distribution: DLS; - EV markers: Western blot (CD63) | 40-150nm Cup-shaped Positive for CD63 |
| [85] | mAPCs (3t311, cell line) | NM | - Differential centrifugation: 300 g for 10 minutes; 2000 g for 20 minutes; 10,000 g for 40 min; - Ultrafiltration: 100,000 g for 120 minutes | - Protein concentration: BCA assay; - Morphology: TEM; - Size distribution: DLS; - EV markers: Western blot (CD9, CD63, GDPD1) | 30-300 nm NR Positive for: Hsp70, CD9, CD63, and CD81, GAPDH |

https://www.thno.org
| Ref | Source | Collection Medium | Supplementation | Isolation | Characterization | EV characteristics | Morphology | Detected |
|-----|--------|-------------------|-----------------|-----------|-----------------|------------------|------------|----------|
| [58] | Mouse BM-MSCs (pre-treated with either neonatal or adult serum exosomes) | FBS-free medium, 48h | - | - | Hsp70) | 1-MSC-exosome: NR; 2-Serum exosomes: a) neonatal serum- 109.5 ± 2.1 nm; b) adult serum- 91.3 ± 2.3 nm | Spherical or cup-shaped | Positive for CD81, CD63 and TSG101 |
| [56] | Primary, HUVEC (preconditioned with PTH1-2) | Serum-free medium, 48h | - | - | - | 40-100 nm (DLS) | Spherical or cup-shaped | Positive for Alix, CD9 and TSG101 |
| [68] | Primary hADMSCs (transfected with mmu_circ_0000250) | FBS-free, EGM, 1% serum replacement solution, 48h | - | - | - | 50-120 nm | Cup-shaped or spherical | Positive for CD81, CD63 |
| [61] | Mouse melanoma B16F10 (cell line, transfected with mouse PD-L1 Gene/ or stimulated with 10 ng/mL IFN-γ) | 0.5% exosome-free FBS+ 1% P/S, 48h | - | - | - | Peak at 100nm | Round-shaped and membrane-bound | Positive for CD81, CD63 and Alix |
| [78] | Primary hPMSCs | NR | | | | 62.2 nm | Round | Positive for CD9, CD63, CD 81 |
| [103] | hPEC (from venous blood) | NA | - | - | - | 123 ± 8 nm | Cup-shaped, round | Positive for: CD63, CD81, TSG101 and VCAM-1; Low GPV1 |
| [89] | Primary hAMSC | 10% exosome-depleted-FBS, 48h | - | - | - | 105.89/10.36 nm | Cup- and sphere-shaped | Positive for CD63 and TSG101 |
| [69] | hiMMSCs (exposed to 100 μM Sn(III) and 50 μg/mL Fe3O4 NPs or naïve) | 10% exosome-free FBS, 48h | - | - | - | 50-150 nm | Cup- or sphere-shaped | Positive for CD9, CD63, CD81 and TSG101; Negative for Calnexin |
| [191] | Peripheral blood (from DFU and non-diabetic subjects) | NA | - | - | - | 30-150 nm | Cup- or sphere-shaped | CD9 and TSG101 (both groups similar features, size, cd markers, shape) |
| [107] | Primary hADMSC | Serum-free medium, 24h | - | - | - | 100 nm | Spherical shaped | Positive for: CD63, CD81 |
| [72] | hUC-MSCs (cell) | 10% exosome free | - | - | - | 30-150 nm (44%) | Saucer-like | Positive for CD63 and |
| Ref | Source | Collection Medium Supplementation | Isolation | Characterization | EV characteristics |
|-----|--------|----------------------------------|-----------|-----------------|-------------------|
|     |        |                                  |           |                 | Size Markers      | Morphology | Detected |
| [57] | Primary hBM-MSCs (preconditioned with 1μM-ATV for 48h) | Serum free culture medium, 48h | Differential centrifugation: 300 g for 5 min; 2000 g for 10 min; Filtration: Filter (0.22 μm); Ultracentrifugation: 100,000 g for 1.5 h (2x) | -Morphology: TEM; -Size and shape distribution: DLS; -EV markers: Western blot (CD9, CD63 and HSP70) | 80-120 nm | Spherical | Positive for CD9, CD63, CD81 and HSP70 |
| [64] | hBM-MSCs (transfected with miR-126 mimic) | Exosome free media, 48h | Differential centrifugation: 300 g for 10 min; 2000 g for 30 minutes; 10,000 g for 30 minutes; Ultracentrifugation: 100,000 g for 70 minutes (2x) | -Morphology: TEM; -Size: Western blot; -EV markers: Western blot (CD81, CD9, Alix) | 30-200 nm | Sphere or cup-shaped | Positive for CD81, CD9, Alix |
| [75] | HUVECs | 1 × Serum replacement solution, 48h | Differential centrifugation: 300 g for 10 min; 2000 g for 10 min; 10,000 g for 30 min; Ultra-filtration: 15 mL Amicon Ultra-15 Centrifugal Filters 400 kDa for 20 min; Ultracentrifugation: 110,000 g for 70 min | -Morphology: TEM; -Size: Western blot; -EV markers: Western blot (CD9, CD63, HSP70) | 50-140 nm | Cup or spherical | Positive for CD9, CD63, CD81 and HSP70 |
| [99] | Primary hUC-MSCs | 2% exosome depleted FBS (120,000 g overnight), 24h | Differential centrifugation: 300 g for 10 min; 16,500 g for 4 °C for 30 min; Filtration: 0.22-μm filter; Ultracentrifugation: 120,000 g for 90 min | -Protein concentration: BCA assay; -Morphology: TEM; -Size and shape distribution: TRPS; -EV markers: Western blot (CD9, CD63, Alix, TSG101, and HSP70) | 20-200 nm (85%) | Cup-shaped | Positive for CD9, CD63, Alix, TSG101, and HSP70 |
| [104] | Primary hDPSCs, P. hDPSCs (matched pairs, 5 n) | Serum-free medium, 48h | Differential centrifugation: 300 g for 10 min; 2000 g for 10 min; 10,000 g for 30 min; Ultracentrifugation: 100,000 g for 70 min (2x) | -Morphology: TEM; -Size and shape distribution: NTA; -EV markers: Western blot (ALIX, HSP70, CD9, and CD81) | 30-200 nm | Cup-shaped | Positive for CD9, CD63, CD81 and HSP70 |
| [43] | Primary hADMSC | Serum free medium, 48h | Differential centrifugation: 500 g for 5 min; 3000 g for 15 min; Ultracentrifugation: 100,000 g for 4 °C for 1 hour; Filtration: 0.22-μm filter; Ultrafiltration: (pore size: NR) | -Protein concentration: BCA assay; -Morphology: TEM; -Size and shape distribution: NTA; -EV markers: Western blot (CD9, CD63, TSG101, and Alix) | (95%) 50-200nm | Circular | Positive for CD63, TSG101, and Alix |
| [192] | Primary hADMSC (transfected with NC or miR-19b inhibitor) | Serum free medium, overnight | Ultracentrifugation: 2000 g for 30 min; 100,000 g for 4 °C for 60 min | -Protein concentration: BCA assay; -Morphology: TEM; -Size and shape distribution: NTA; -EV markers: Western blot (CD63, TSG101 and Alix) | 100nm | Oval-shaped membrane vesicles | Positive for CD63, CD81 |
| [49] | Primary hUSCs | Serum free medium, 48h | Differential Centrifugation: 300g for 10 min; 2000 g for 10 min; Filtration: 0.22 μm; Ultra-centrifugation: 100,000 g for 70 min (2x) | -Morphology: TEM; -Size and shape distribution: TRPS; -EV markers: Western blot (CD9, CD63, TSG101 and GM130) | 80-200 nm | Cup-shaped | Positive for CD9, CD63, TSG101 and negative for GM130 |
| [90] | Primary hAMSCs | Serum free medium, 48h | Differential Centrifugation: 800 g for 5 min; 2000 g for 10 min; Filtration: 0.1 mm pore; Ultrafiltration and concentration: 100,000 MWCO; Ultra-centrifugation: 100,000 g for 1 h (2x) | -Morphology: TEM; -Size and shape distribution: TRPS; -EV markers: Western blot (CD9, CD63, TSG101 and GM130) | Peak at 106 and 130 nm | Cup-shaped | Positive for CD9, CD63, CD81, CHAMP4, GAPDH |
| [79] | Primary hUC-MSCs | 10% exosome free FBS (100,000 g for 70 min) | 15,000 rpm for half an hour; Filtration: 0.22 μm filter; Ultra-centrifugation: 57,000 rpm for 60 minutes | -Morphology: TEM; -Size and shape distribution: DLS; -EV markers: Western blot (TSG101, CD63 and CHAMP4, GAPDH) | 50 to 200 nm | Round | Positive for TSG101, CD63 and CHAMP4, GAPDH |

**Notes:**
- **AFL:** atomic force microscopy; **calnexin:** the endoplasmic reticulum protein; **CDM:** chemically defined medium; **conf.:** degree of confluency; **D (+) markers:** detected positive sEV markers; **D (-) markers:** detected negative sEVs markers; **DFO:** deferoxamine; **DLS:** dynamic light scattering; **ELISA:** enzyme-linked immunosorbent assay; **FBS:** fetal bovine serum; **FiPoSCs:** iPSCs derived from fibroblasts; **FNA:** Flow NanoAnalyzer; **FSEM:** field-emission scanning; **GF:** growth factors; **GM130:** cis-Golgi matrix protein, a negative exosomal marker; **Grp94:** glucose-regulated protein 94; **(GM)130:** the Golgi membrane marker cis-Golgi matrix protein; **GPⅢα:** glycoproteinⅢα.
- **hADMSC:** human adipose-derived mesenchymal stem/stromal cells; **hAMSCs:**-Nrf2 human adipose derived mesenchymal stromal cell high expressed Nrf2; **hBMMSCs:** human amniotic epithelial cells; **hBMMSCs:** human amniotic mesenchymal stem cells; **hBMMSCs-miR-135 OE:** miR-135-overexpressing human amniotic mesenchymal stem cell; **hAMSC-miR-135 KD:** miR-135-knockdown human amniotic mesenchymal stem cell; **HAPC5:** hydroxyapatite/chitosan composite hydrogels; **hBMMSCs:** human bone marrow derived MSCs; **hBMMSCs:** human decidua-derived MSCs; **hDPSCs:** human dental pulp stem cells (DPSCs); **hEDSCs:** human endometrial stem cell; **hEfSCs:** human epidermal stem cells; **hFDMSCs:** human fetal dermal mesenchymal stem cells; **HFL1:** human lung fibroblasts; **hGMSCs:** human...
sEV administration and dosage regimen

Dose

The administered sEV dose differed widely. sEV amount was approximated as protein amount in most studies, ranging from 2 µg to 5 mg (n = 45, 66.2%). In 7 studies (10.3%), dose was reported as number of particles, ranging from 2×10¹⁰ to 2×10¹² particles (n = 7, 10.3%). However, only one study explicitly took into account the size of the animal, reporting sEV dose as protein per animal weight (5 mg/kg) [85], and amount was not reported at all in 15 studies (22.1%).

Dose-response was assessed in one trial with three doses of 25, 50, and 100 µg/ml of PBS [91] and in five studies (7.4%) with low and high doses [44, 52, 82, 92, 93]. In these studies, wound healing was reported to be positively associated with dose.

Administration route

Local injection was the most prevalent approach (n = 47, 69.1%): subcutaneous (n = 32), intradermal (n = 3), and other (n = 12). sEV-loaded hydrogels were injected into the wound in seven studies [44, 70-74, 78]. sEVs were topically applied in 17 studies (25%), either mixed with PBS (n = 2) or embedded in hydrogels or other scaffolds (n = 13). Intravenous (n = 3, 4.4%) and intraperitoneal (n = 1) routes were less common (Figure 3D). One study compared the influence of subcutaneous and intravenous administration, reporting superiority of intravenous administration [94].

Dosing frequency and intervention duration

The majority of studies (n = 51, 75%) involved a single dose. Of the multi-dose studies (n = 17, 25%) (Table 2), two compared repeated-dose vs single-dose administration, concluding that repeated administration of low doses outperformed a single high dose [44, 82]. The intervention period was diverse ranging mostly from 8 to 28 days (Table 2).

Immunno-biocompatibility

Human sEVs were administered to immuno-competent animals in 57 studies (83.8%) (Figure 3C). Allogeneic sEVs (from the same species) were used in 11 studies (16.2%), whereas autologous sEVs (from the same subject) were investigated in only one study [42]. Direct comparisons of the efficacy and immune response to autologous, allogeneic, or xenogeneic sEVs were inadequately considered in the included studies in this review, with only a single study comparing the therapeutic efficacy of sEVs from xenogeneic and allogeneic sources [51], and another comparing autologous sEVs with allogeneic sEVs [42]. No difference in efficacy was found between xenogeneic and allogeneic sources [51]. Autologous sEVs were reported to be more effective and viable in treated tissues than allogeneic sEVs, even though the latter had a sufficient therapeutic effect when compared with placebo [42]. More studies are needed to verify these findings and investigate the mechanism behind.

Labelling and tracking of sEVs in vivo

Only six studies (8.8%) reported tracking of transplanted sEVs [42, 44, 82, 86, 87, 94]. In these studies, sEVs were pre-labeled with lipophilic fluorescent dyes, namely PKH26 (n = 3), PKH67 (n = 1), DiR (n = 1), and lipid conjugated Cy7-dipalmitoylphosphatidylethanolamine (DPPE). All but one of these studies [82] administered a single dose of sEVs. A wide span of time points (1 hour to 21 days) was investigated. sEVs were tracked in vivo in four studies [44, 86, 87, 94], ex vivo (post-mortem) in one study [42], and in vitro and ex vivo in another study [82]. None of these studies examined the biodistribution of sEVs to organs other than the skin tissue around the wound area. See Table 4 for detailed findings about sEV bioavailability.

Quality assessment

We sought to evaluate the quality of both methodology and reporting. Methodological biases may skew the outcomes of studies, resulting in misleading estimates of therapeutic efficacy and flawed inferences. Poor reporting impedes experiment evaluation and reproducibility. We thus evaluated several methodological aspects and compliance with established guidelines.
| Ref. | Animal model | Sample Size | Wound model | seV intervention | Dose | Frequency | Route of administration | Vehicle | Follow-up period | Dose Response curve? | Comparator |
|------|--------------|-------------|-------------|-----------------|------|-----------|------------------------|---------|------------------|----------------------|------------|
| [52] | B6. Lepr<sup>db</sup> mice; Gender matched; 11 to 12 wks old; Genetically type 2 diabetic | 5-7/G (3Gs) | Full-thickness excisional dorsal diabetic wounds; 6mm | Human G0 stimulated fibrocyte derived-exosomes | 5 or 50 µg exosome in 80 µl PBS | Once | SC injection and topical | PBS | 21 days | No | 200 µl of PBS |
| [50] | Rats; STZ induced diabetes | 6/G (4Gs) | Full-thickness excisional ischemic leg diabetic wound; 10mm | LPS-hUC-MSC-exo | 60 µg in 0.5 ml PBS | Once | Injected into wound edge | PBS | 14 days | No | 1) Untreated normal group; 2) Untreated diabetic group; 3) Diabetic + naive hUC-MSC-exo |
| [45] | Adult female SD rats; 220±20 g | 6/G (5Gs) | Full-thickness dorsal, deep second-degree burn wound; 18 mm | 1) hUC-MSC-exo or, 2) HFL1-exo | 200 µg exosome (hUC-MSC-exo or HFL1-exo) in 200 µl PBS | Once | SC injection | PBS | 14 days | No | 1) Untreated normal group; 2) Untreated diabetic group; 3) Diabetic + naive hUC-MSC-exo |
| [98] | Adult male SD rat; 250-300 g | 3Gs (NR) | Full-thickness excisional wound; 18 mm | hu-iPSC-MSCs-exo | 160 µg hu-iPSC-MSC-exo | Once | SC injection | PBS | 14 days | No | 1) Untreated normal group; 2) Untreated diabetic group; 3) Diabetic + naive hUC-MSC-exo |
| [73] | ICR mice and nude mice (BALB/c-n); Adult, male | NR | Full-thickness dorsal skin wound (excisional); 1.5 cm | hUC-MSC-exo | 100 µg/ml of PBS mixed with hydrogel | Once | In hydrogel (1:1 ratio, (Hydrogels, Matrix, Sigma)) | PBS | 25 days | No | 1) PBS; 2) HeK-293T-exosome (100 mg/ml); 3) UEP5 |
| [94] | Adult Balb/c mice; Male; 6-8wks old | 4Gs (NR) | Full-thickness excisional dorsal and inguinal skin wounds; 1.5 cm | hADMSC-exo | 200 µg exosome in 200 µL PBS | Once | SC injection or I.V. | PBS | 21 days | No | 1) Untreated normal group; 2) Untreated diabetic group; 3) Diabetic + naive hUC-MSC-exo |
| [60] | SD rats; Male; 300-350g; STZ induced diabetes | NR | Full-thickness excisional dorsal diabetic wounds; 18mm | Unclear | Once | Topical | HAPCS | PBS | 14 days | No | 1) Untreated; 2) HAPCS without exosome |
| [62] | Male, SD rats; 300-350 g; STZ induced diabetes | NR | Full-thickness dorsal excisional wounds; 18mm | Unclear (used 1.2ml in hydrogel preparation) | Once | Topical | Chitosan hydrogel | PBS | 14 days | No | 1) Chitosan hydrogel+ PBS; 2) Untreated control |
| [93] | SD rat, male, adult; 250-300 g; STZ induced diabetes | 3Gs (6 wounds/ G) | Full-thickness excisional wound; 15mm | hUCBC-EPC-exo | 2×10<sup>5</sup> in 200 µl PBS | Once | SC injection | PBS | 14 days | No | 200 µl PBS (SC injection) |
| [105] | Wistar rats, Male, 220 | 24 rats (2 G) | Excisional wound-splitting model; 5mm | hADMSC-exo | Total EVs in gel prep: (1.9×10<sup>6</sup> vesicles) | Applied daily | Topical with HEC | In a 1: 1 ratio with HEC gel (1%) | 21 days | No | Plain HEC gel (1%) |
| [80] | SD rats, Male, 300-400g, 12 wks old, STZ induced diabetes | 36 (4G, 9/G) | Full-thickness excisional diabetic dorsal skin wounds; 1.5cm | hPRP-Exo | NR (but explained how it was calculated) | Unclear | Topical | SAH | 14 days | No | 1) No treatment; 2) SAH only; 3) PRP+SAH |
| [76] | Male, SD rats; STZ and diet induced diabetes | 24 (3Gs, 8/G) | A full-thickness excisional dorsal diabetic wound model; 10mm | hGMSC-exo | 150 µg exo | Once | Topical | PBS+CS hydrogel | 2 weeks | No | PBS+CS hydrogel; 2) PBS only |
| [109] | Balb/c mice; 6-8 weeks old | 3Gs, 6/G | Full-thickness excisional dorsal diabetic wound model; 1.5cm<sup>2</sup> in 200 µg in 200 µl PBS | hADMSC-exo | I.V. | PBS | 21 days | No | 1) PBS (200 µl); 2) CM-Exo (200µl) |
| [91] | SD rats, Male, 250-300g | 6 rats (4 wounds/r at) | Full-thickness excisional dorsal wounds; 1 cm × 1 cm | hAECs-exo | 25 µg/mL or 50 µg/mL or 100 µg/mL | Once | SC injection | PBS | 21 days | Yes | 100 µl PBS (SC injection) |
| [84] | C57BL/6 mice; Female, 8 months old, 25-30g, STZ | 24 (8/G, 3Gs) | Full-thickness excisional dorsal skin wound (excisional); hUSC<sup>shDMBT1</sup>-exo | 200 µg hUSC<sup>shDMBT1</sup>-exo in 100 µl PBS | Once | SC injection | PBS | 12 days | No | (1) 100 µl PBS; (2) 200 µg hUSC<sup>shDMBT1</sup>-exo in 100 µl PBS |
| Ref. | Animal model | Sample Size | Wound model | sEV intervention | Dose | Frequency | Route of administration | Vehicle | Follow-up period | Dose Response curve? | Comparator |
|------|--------------|-------------|-------------|-----------------|------|-----------|-------------------------|---------|-----------------|----------------------|------------|
| [87] | C57BL/6 mice; Male, 12 wks old, 26-30g | 20 mice/2gs | Full-thickness excisional dorsal skin wound; 12mm | hUCBP-exo | 200 µg in 100 µL PBS | Once | SC injection | In PBS | 8 days | No | 2) 100 µL PBS SC injection |
| [97] | C57BLKs/J-Leprdb (db/db) mice; 9-wks old, Male, adult, Genetically diabetic, 41.0–45.5 g | NR | Full-thickness excisional wound-splinting model; Diabetic, 8mm | Human iPSCs-exo | 4 µg in 20 µL PBS | Once | SC injection | In PBS | 28 days | No | 1) PBS; 2) M-Exo |
| [63] | SD rats; Female, 150-200g, 4-6 weeks, STZ induced diabetes | NR | Round full-thickness excisional DFU at the dorsum of hind feet wounds; 5-mm | PB-EPChA DMSCs-exo or PB-EPChA DMSCs-Nrt2-exo | NR | Once | Injection | NR | 15 days | No | 1) PBS; 2) PB-EPCs |
| [96] | Inbred C57BL/6 mice; Male, 5-7 wks old, STZ induced diabetes | (9 Gs, 6/G at each time point) | Full-thickness diabetic dorsal skin wound; 8mm | hMerrSC-Exo | 10 µg hMenSC-EVs in 100 µL of PBS | Once | I.D. | PBS | 14 days | No | (1) PBS (control group, 100 µl); (2) hMenSCs (cell group, 1 × 10⁶ cells in 100µl PBS) |
| [54] | SD rats; Male, 250-300g, STZ induced diabetes | 3 Gs, NR | Full-thickness diabetic dorsal skin wound (excisional); 20mm | DFO-hBMSCs Exo | 100 µg DFO-hBMSCs Exo in 100 µL PBS | Once | SC injection | PBS | 14 days | No | 1) 100 µg hBMMScs Exo in 100 µL PBS; 2) 100 µL PBS |
| [44] | 1) C57BL/6 wild-type; 2) Db/db mice, diabetic II, genetic model; 3) C57BL/6, diabetic I, STZ-induced; Male, 20-30 g, 8-10 weeks old | 13 Gs (2 set of exp.) | Full-thickness excisional dorsal skin wounds; 6mm; Diabetic II, or nondiabetic | hUCBMNCs-EVs | A) sEV dosage exp: 0.4, 2 µg/wound; B) sEV + LTHAG exp: 2 µg/wound | Single dose or Bi-daily doses | 1) Topical; 2) Injection | 10 days | No | A-sEV dosage exp: 1) PBS, 2) PDGFbb/4µg/cm²; B-sEV+LTHAG exp: 1) Gel only+light, 2) Gel+sEVs only, 3) sEV+Gel on top+light |
| [92] | SD rats; STZ induced diabetes (type1) | NR (n = 3 in figures) | Full-thickness excisional dorsal diabetic wound; 1.5 cm | Low concentration RAW 264.7-exo; 2) High concentration RAW 264.7-exo; 3) High concentration RAW 264.7-exo + LPS Macque-Fibr iliPSCs-exo | 1) (100 µg/mL); 2) (1 mg/mL); 3) 10 µg/mL exo + LPS (10 µg/mL) | Once | SC injection | NR | 14 days | No | 1) 1ml PBS |
| [42] | Adult male macaques | 4 animals | 24 skin punch full-thickness dorsal excisional wounds/animal; 5-mm | Mouse-Leukocyte-TBC1D3-exo | 50 µg exosomes | Once | Topical | NR | 14 days | No | 4.6 × 10⁴ iPSCs (autologous or allogeneic) in 20µl |
| [86] | Adult male C57Bl/6 mice; 8-10 weeks | 3Gs, 6/G | Full-thickness excisional wound-splinting model; 4mm | Mouse-Leukocyte-TBC1D3-exo | 2x10⁶ EVs in 25 µl of PBS | Once | Topical | PBS | 13 days | No | 1) PBS; 2) EVs obtained from vector control cells |
| [81] | Adult male Wistar | 12 (3Gs) | A full-thickness excisional wound model; 1.5 cm | Rat-ADMSC-exo | 300 µl Alg-exo hydrogel | Once | Topical | Alg hydrogel | 14 days | No | 1) 300 µl Alg hydrogel; 2) Untreated control |
| [82] | Adult, SD rats weight 240 ± 26 g | 10 (n = 9-10 wounds) | Full-thickness excisional dorsal wound model; 0.19 ± 0.03 cm² | sOMEC-cExo (Sheets of oral mucosa epithelial cells) | Exp1: 7.6 µg (day 0 and day 1); Exp2: 12.5 µg on day 0 | Once | Topical | Unclear | 17 days | No | 1-PBS (n = 6 wounds) 2-noncond exo (from auto-serum supplemented medium) |
| [53] | Male, SD rats | 4/G | Skin punch | 4 types of | Exp1: EVs from | Once | NR | NR | 8 days | No | 1-Saline, |
| Ref. | Animal model | Sample Size | Wound model | sEV intervention | Dose | Frequency | Route of administration | Vehicle | Follow-up period | Dose Response curve? | Comparator |
|------|--------------|-------------|-------------|-----------------|------|-----------|------------------------|---------|-----------------|---------------------|------------|
| [82] | Eight week old | Full-thickness dorsal excisional wound; 8mm | hUCB-MSCs- EVs (10% O2, 40 U thrombin, 1 μg LPS, or 50 μM IL-6(G)) | (5×10^6) of hUCB-MSCs | 10 μg of: 1-free exosomes or, 2-loaded in FHE-exo hydrogel | Once injection | FHE hydrogel | 21 days | No | 2-Naive EVs: Exp1: EVs from (5×10^6) of hUCB-MSCs; Exp2: 20μg/10 μl of EVs 1-Saline; 2- FHE hydrogel alone |
| [83] | Male, ICR mice; 30g, STZ induced diabetes | 8 weeks | Full-thickness dorsal diabetic wound; 8mm | Mouse-ADMSC-exo | 10 μg of: 1-free exosomes or, 2-loaded in FHE-exo hydrogel | Once injection | FEP scaffold | 21 days | No | 1- Untreated 2- FEP only |
| [84] | Male, ICR mice; 8 weeks old, STZ induced diabetes, Type 1 diabetes | 8-10 wk old | Full-thickness dorsal diabetic wound; 10mm | FDMSC-exo | 200 μg FDMSC-exosomes in 200 μl PBS | Once | SC injection | PBS | 14 days | No | 200 μl PBS (SC injection) |
| [85] | Female (BKS-Dock Leprem 2C,479, db/db); Genetically diabetic mice wounds | 40 (5 at each timepoint) | Full-thickness excisional diabetic wound; 16 mm | hdMSC-exo | 5.22 × 10^11 particles /ml in 100 μl PBS | At day 7, 14, 21, and 28 | SC injection | PBS | 28 days | No | 100 μl PBS (SC injection) |
| [86] | Kunning, male mice; 9-12 wks, 200 ± 30g | 60 (4G, 15/G) | Full-thickness excisional diabetic wound; 12 mm | hUC-MSC-EVs | 200 μg in 100 μl PBS | Once | SC injection | PBS | 8 days | No | 1) 200 μl PBS (SC injection); 2) hUC-MSCs-EVs-inhibitor-NC; 3) hUC-MSCs-EVs-miR-27b-inhibitor |
| [87] | SD rats; 3G, 3/G | Full-thickness excisional diabetic wound; 15 mm | rat-sEV-AT or p-sEV-AT | 600 μg in 100 μlPBS +100 μl PBS | Every week (3x) | Topical (dropping) | 1/1 PVA+PBS | 21 days | No | 1/1 PVA+PBS (200 μl) |
| [88] | SD rats; 8 wk old, female; 200 g | Full-thickness excisional diabetic wound; 15 mm | hEPSC-exos | 200 μg/100 μl of EPSC-Exos dissolved in PBS and hydrogel-1:1 | Every weeks (4x) | SC injection | Hydrogel (Hydro-text) | 28 days | No | 1/PBS (200 μl); 2) EGF+ hydrogel (200 μl) |
| [89] | SD rats, adult; 200 ± 50 g | 25 (5/G, 6G) | Full-thickness excisional diabetic wound; 1.5 cm × 1.5cm | NR | Once | Topical (coated) | Type I collagen coat | 15 days | No | 1) Saline; 2) HeK 293T-exo |
| [90] | C57BL/6J mice; Female, 9 weeks | 6/G | Full-thickness excisional diabetic wound; 5 mm | HS-5 exos | 15 μg or 1.5 × 10^3 vesicles | 3x (day 0, 2, 4) | L.D. | NR | 5 days | No | 1) SELL (1.5 × 1011 vesicles); 2) PBS |
| [91] | C57BL/6J mice; 8 weeks | 6G | Full-thickness excisional diabetic wound; 6mm | 1) hBM-MSC-TSG6-OE | 100 μg/100 μl | Once | SC injection | NR | 35 days | No | 1) no wound ctrl; 2) wound + Saline; 3) wound hBM-MSC exo-Lenti-Crl; 4) wound hBM-MSC-Lenti-shTSG6-exo; 5) Wound hBM-MSC-exo-Lenti-ShCtrl |
| [92] | C57BL/6J mice; Male, 5 wks; 20.88 ± 1.94 g; STZ induced diabetes | 3Gs, 12/G | Full-thickness excisional foot diabetic wound (DFU); 10 mm | Mouse myeloid-MS-C-exo vector; 2) MSC-exo OE H119 | NR | Once injection | NR | 13 days | No | 1) Untreated control (12) |
| [93] | Wistar rats; 6 wks, male | 4Gs, 9/G | Full skin thickness dorsal burn by diode laser | 1) naïve hUC-MSCs-exo group in 100 μl PBS; 2) hUC-MSCs-exo + NPs; 3) hUC-MSCs-exo + NPs + | 1) 100 μg Exos in 100 μl PBS; 2) 100 μg Exo + NPs in 100 μl PBS; 3) 100 μg Exo + NPs in 100 μl PBS | Once | I.V. | PBS | 5 weeks | No | 1) PBS group (100 μl PBS) |

https://www.thno.org
| Ref. | Animal model | Sample Size | Wound model | sEV intervention | Dose | Frequency | Route of administration | Vehicle | Follow-up period | Dose Response curve? | Comparator |
|------|--------------|-------------|-------------|-----------------|------|-----------|------------------------|---------|----------------|----------------------|------------|
| [48] | SD rats; Female, 6 weeks, 100 ± 5 g | 15 / 4G | Photaged skin induced by ultraviolet B, wavelength 290-320 nm, dose of 7.8 J/cm² | MAG group hADMSC-exo | 25 g/mL in 100 μL PBS | Once | SC injection | PBS | 28 days | No | (1) 100 μL PBS |
| [47] | SD rats; Male, 200-240 g, Deep second-degree skin burn induced rats | NR | Deep second-degree skin burns; 20 mm | hUC-MSC-ExAng-2 and hUC-MSC-Ex | 1 mg in 200 μL | Once | SC injection | PBS | 13 days | No | 1) PBS 200 μl 1mg in 200 μl of: 1) hUC-MSC-ExGF; 3) hUC-MSC-Ex-shCitr; 4) hUC-MSC-Ex-shAng-2 |
| [55] | SD rats; 8 weeks old, Male, 250 ± 10 g, Diabetic/STZ induced model | 54/3G | Full-thickness dermal skin wound; 20-mm | hBM-MSCs-melanotinin-exo | NR | Once | SC injection | PBS | 14 days | No | 1) PBS (Control), 2) hBM-MSCs-Exo |
| [101] | Kunming mice; 6-8 weeks old, Male, 18-22 g | 25 (5/G) | Two full-thickness excisional skin wounds; 12-mm | hADMSC-<EVs | 200 μg in 100 mL of PBS | Once | SC injection | PBS | 8 days | No | 1)100μL PBS; 2) miR-486-5p antagonist; 3) antagonim NC (Concomitent injection of miR-486-5p antagonist or antagonim NC) |
| [65] | SD rats; Male, 150-200 g, 5-week-old, STZ induced diabetes | 30/5Gs | Full-thickness diabetic dorsal skin wound; 15 mm | hADMSCs-miR-21-5p-exo | NR | Three times | Topical and covered with gel | 200 μL PBS | 15 days | No | (1) Control; (2) Free miR-21; (3) Naive Exo; (4) hADMSCs-miR-21-5p-exo-NC |
| [88] | C57BL/6 mice; 6-8 weeks old, Male | 30/5Gs | Full-thickness excisional skin wound; 10-mm | baaliva-exos | Saliva-Exos (100 μg in 100 μL PBS) | 200 μL of corresponding hydrogels | Twice (day 3 and 7) | Topical hydrogels | 14 days | No | 1) paraffin gauze; 2) Chitosan-glycerol |
| [77] | BALB/c mice; 8 weeks old, Male, 27 to 32g | 15/3Gs | Full-thickness excisional wound, circular; 7-mm | Chitosan-glycerol-hENSC-exo | Once | SC injection | PBS | 14 days | No | 1) PBS (100 μL); 2) saliva (100 μL) |
| [85] | SPF Balb/c mice; 5-8 weeks old | 9 (3G) | Full-thickness dorsal skin wound (excisional); 1 cm² | mAPCs-Exo | 5 mg/kg | 8x | L.P. | PBS | 10 days | No | 1) PBS; 2) Vms-/APC-Exo |
| [58] | Wild-type (WT) neonatal and adult C57BL/6 mice; 5-7 g, 14 days old | 3Gs, 9/G | Full-thickness excisional dorsal skin wounds; 1cm | hBM-MSCs-NS-exo; 2) hBM-MSCs-AS-exo | 100 μg in 100 μL PBS | Once | L.D. | PBS | 14 days | No | 100 μL PBS |
| [56] | SD rats; 8 weeks, male, STZ induced diabetes | 4Gs | Full-thickness skin wounds | PTHrP2- HUVEC- exo | NR | Once | SC injection | PBS | 14 days | No | Untreated HUVEC derived exosome |
| [68] | C57BL mice (male); STZ induced diabetes | 18 (6/G, 3Gs) | Full-thickness excisional wound at dorsal leg; 4mm | 1) Naive ADMSC-exo 2) mmu_circ_000250; ADMSC-exo | 200 μg exo in 100 μL PBS | Once | SC injection | PBS | 15 days | No | 100 μL of PBS |
| [61] | Balb/c mice; 18-25 g | NM | Full-thickness midline excisional wound, 10-mm | Mouse melanoma B16F10 cell-exosomes 1-WT+PD-L1, 2-WT+IFN-γ 1) hPMSC-exo in PBS; 2) hPMSC-exo in hydrogel | 10 μg of exosome in 200 μL of PF-127 hydrogel | Once daily from day 3 until day 7 | Topical thermo-responsive PF-127 hydrogel | 7 days | No | 1) Negative group was treated with 20% PF-127 alone (Ctrl); 2) 20% PF-127 containing hFGF cytokine |
| [78] | C57BLKS-Lepidib mice; Male, 6-8 weeks, Congenital diabetes | 60 (15/G, 4Gs) | Full thickness excisional dorsal, above the tail, diabetic wound; 7mm | Total concentration 2 x 10³ mL⁻¹ in hydrogel or 100 μL PBS | Once | Injection | MC-CS hydrogel or PBS | 15 days | No | 1) 100 μL PBS; 2) MC-CS hydrogel only |
| [103] | Mice, 4-week-old, STZ induced diabetes | 48/G (3Gs) | Full thickness excisional midline dorsal; Size of 1 x 1 cm² | hPEC-EV (100 μg/mL) | Every 3 days for a period of 14 days | Injection | PBS | 14 days | No | 1) 100 μL PBS every 3 days for 14 days (injection); 2) 100 μL of 50 μg/mL NC every 3 days for 14 days |

https://www.thno.org
| Ref. | Animal model (Species/strain/age) | Sample Size | Wound model (Size/shape/condition) | sEV intervention | Dose | Frequency | Route of administration | Vehicle | Follow-up period | Dose Response curve? | Comparator |
|------|----------------------------------|-------------|----------------------------------|----------------|------|----------|----------------------|--------|----------------|-------------------|------------|
| [69] | Male db/db mice (C57BL/6 Jt); 12 weeks; leptin receptor-deficient diabetes | 40 mice (n = 3 in figure) | Two full thickness dorsal wounds; 8mm | 1) DMSO + hAMSC-exos; 1) LY294002 + hAMSC-exos | 1) 10% DMSO + 200 µl hAMSC-exos (1000 µg/ml); 2) LY294002 + 200 µl hAMSC-exos (1000 µg/ml) | Once | SC injection | PBS | 18 days | No | (injection) 1) 10% DMSO + 200 µl PBS |
| [69] | SD rats, Male, 300–400 g; Six-week-old | 24 rats (3G, 8/G) | A full-thickness excisional dorsal skin wound; 20 x 20 mm | 1) hBMMSC-exos; 1) hAMSC-exos; 2) FeO4 NPs-SMF-hBMMSC-exos | 100 µg in 100 µl PBS | Once | SC injection | PBS | 14 days | No | 100 µL PBS |
| [191] | C57BL/6J mice; Male, 6 weeks, 20–30 g | 5G, 6/G | Full-thickness dorsal skin wound (excisional); 10 mm | 1) DFLU-peripheral blood-exo; 2) NFU-peripheral blood-exo; 3) DFLU-Exos/AntagomirR-15a-3p | 200 µg exos in 100 µl PBS; 3) 2OD Antiagomir + 200 µg exos | 6 times | SC injection | PBS | 14 days | No | (1) 100 µl PBS; (2) AntagomirR-15a-3p |
| [107] | BALb/c mice; Adult female, 5 weeks, 170–200 g | NR | Full-thickness dorsal skin wound (excisional; square); 1 cm² | hADMSCs-exos | hADMSCs-exos | Once | SC injection | PBS | 14 days | No | (1) PBS; (2) hADMSCs (1x10⁶) |
| [107] | SD rats; Male, 210±25 g, 10 weeks, STZ induced diabetes | 24 (G) | Two symmetrical; Full-thickness diabetic dorsal skin wound (excisional); 10 mm | 1) hUCMSC-exo in PF-127 Hydrogel; 2) hUCMSC-exo in PBS | 100 µg Exos in 100 µl PF-127 or PBS | Every 3 days | Injected topically | PBS | 14 days | No | (1) 100 µl PF-127 only; (2) 100 µl PBS |
| [57] | SD rats; Male, 250 ± 20 g, 8 weeks, STZ induced diabetes | NR | Circular full-thickness diabetic dorsal skin wound (excisional); 2 cm | hBMSC-miR-126-exo | hBMSC-miR-126-exo | Once | Injection | PBS | 14 days | No | 1 µg/ml PBS |
| [64] | C57BL/6J mice; 8-week-old, 20–25 g | 24 (G, 8/G) | Full thickness dorsal excisional skin wound | 100 µg Exo in 100 µl PBS | 100 µg Exo in 100 µl PBS | Every 3 days | Injection | PBS | 14 days | No | (1) 100 µl PBS; (2) 200 µg Exo-NC in 100 µl PBS |
| [75] | SD rats; 280–320 g, Male | 18 (6/G) | Full-thickness dorsal skin wound | 100 µg Exo in 100 µl PBS | 100 µg Exo in 100 µl PBS | Once | Injection | PBS | 14 days | No | (1) 100 µl PBS; (2) 500 µg Exo-NC in 100 µl PBS |
| [99] | Balb/C mice; Male, 20–25 g | 60 (6G, 10/G) | Full thickness dorsal excisional wound; 0.8 cm x 0.8 cm | hUC-MSC-exos | hUC-MSC-exos | Once | Injection | PBS | 14 days | No | 1 µg/ml PBS |
| [104] | C57BL/6J mice; 8 weeks, 20–25 g | 30 (10/G, 3G) | Full-thickness dorsal excisional skin wound | 1 h-bDPSCs-EVs; 2) hDPSCs-EVs | 200 µg in 100 µl PBS | Once | SC injection | PBS | 14 days | No | 1 µg/ml PBS |
| [43] | New Zealand Rabbit; Female, 2.5–3.0 kg | 16 (8/G) | Hypertrophic scar model excisional; 8-mm-wound on the ventral side of both ears | 1) hADMSC-exos; 2) EV-free medium | 1) Unclear (0.1 ml EVs in PBS) | 4 times (on day 0, 7, 14, 21) | Injection (base and edge of wound) | PBS | 28 days | No | 0.1 ml of PBS |
| [192] | Balb/C mice, 20–25 g | 15 (5G, 5/G) | Full-thickness dorsal excisional skin wound; 1 cm in | 1) hADMSC-exos-NC; 2) mir-19b inhibitor-hADMSC-exos | 100 µg exosomes in 100 ml PBS | Once | SC injection | PBS | 8 days | No | 100 µL PBS |
| [49] | C57BL/6J mice; male, 6 weeks, Induced skin | 6/G (from results) | Skin pressure ulcers, 12mm | 1) hUSC-EVs only; 2) hUSC | hUSC | Once | Topical | HAAM/PBS | 21 days | No | 1) HAAM only (aged mice); 2) PBS (aged mice); |
Quality of reporting

Quality of reporting was generally low. Most of the reviewed studies did not report pre-processing details such as donor number, age, and gender. For EV production, the number, seeding density, and passage number of EV-secreting cells were poorly reported, along with cell viability at harvest. EV production, the number, seeding density, and passage number of EV-secreting cells were poorly reported, along with cell viability at harvest.

Risk of bias assessment

We used the SYRCLE’s ROB tool [95] to assess the risk of bias in animal experiments (Figure 6). Overall, there was an unclear risk of bias for most of the elements investigated. Randomization of animals was reported in 44 studies (64.7%) but without disclosing the randomization method. 24 studies (35.3%) did not report randomization. While 42 studies (61.8%) reported comparable baseline characteristics between control and experimental groups, judgment was not possible in 26 studies (38.2%) due to insufficient reporting of certain animal characteristics, particularly age, which is a determinant factor in wound healing.

None of the studies clarified if allocation was concealed, or if animals were randomly housed. Blinding while performing the experiments was reported for only two studies [96, 97]. Six studies conducted random outcome assessment (mostly
angiogenesis experiments) [43, 65, 69, 84, 88, 98]. We identified a high risk of attrition bias in six studies (8.8%) [46, 55, 75, 76, 84, 99], low risk in 17 (25%), and an uncertain risk in the remaining 45 (66.2%). Blinding while assessing the outcomes was reported for seven studies (10.3%). Low risk was captured for all studies in relation to the selective reporting item, based on what was reported in the methods, although none of these studies reported publishing an *a priori* protocol to verify this judgment. The summary of the risk of bias assessment is shown in Figure 6.

Adherence to ISCT criteria for MSC characterization

To ensure comparability of studies of mesenchymal stromal cells (MSCs), the International Society for Cell and Gene Therapy (ISCT) has proposed minimal criteria to characterize and define these cells [40]. Specifically, cells should: 1) show ability to adhere to plastic; 2) be positive for surface markers CD105, CD73, and CD90, and negative for CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR; and 3) show *in vitro* multi-lineage differentiation capacity into osteogenic, adipogenic, 

---

**Figure 6.** Risk of bias assessment of the 68 reviewed studies based on SYRCLE's ROB tool represented by RevMan 5.4.1. (1) Randomization (selection bias); (2) Random sequence generation (selection bias); (3) Baseline characteristics (selection bias); (4) Allocation concealment; (5) Random housing (performance bias); (6) Blinding of personnel (performance bias); (7) Random outcome assessment (detection bias); (8) Blinding of outcome assessment (detection bias); (9) Incomplete outcome data (attrition bias); (10) Selective reporting (reporting bias). A domain concerning the declaration of the randomization method was added (domain 1), while the domain of "other sources of bias" was not covered in this review. Symbols used: ▪: low risk; ☐: unclear risk; ◼: high risk.
and chondrogenic lineages under specific culture-differentiating conditions. Among the 68 included studies, 43 (63%) used MSC-derived sEVs. However, just over half of the MSC studies (n = 23) characterized cells as recommended by ISCT. 16 studies (23.5%) did not report any MSC characterization; in nine, MSCs were said to have been obtained commercially or from other institutes. One study investigated only two ISCT criteria, namely MSC adherence and surface antigen expression, and three focused exclusively on one ISCT criterion, namely surface antigen expression.

Adherence to MISEV2018 for sEV characterization, purity, and nomenclature

sEV characterization

To verify the identity of the isolated preparations, MISEV2018 indicates that EVs should be characterized by 1) concentration (such as protein and particle count); 2) at least two positive EV protein markers (including at least one transmembrane and one cytosolic marker), plus at least one source-appropriate negative, non-EV protein marker; and 3) two complementary single-vesicle analysis techniques to assess morphology and biophysical properties such as counts and size distribution [14]. Of the 68 studies analyzed here, only 14 (20.6%) satisfied the above criteria [49, 52-55, 69, 82, 83, 88, 90, 96, 100-102].

sEV preparation purity estimation

MISEV2018 also suggests reporting protein:particle, lipid:particle, or lipid:protein ratios as surrogates of EV purity. Only two studies (2.9%) quantitatively estimated sEV purity according to MISEV2018, reporting particle:protein ratio [44, 83]. Additionally, only 17 studies (25%) checked for the presence of negative/depleted (non-EV) markers that indicate the presence of non-EV contaminants.

sEV nomenclature

Since cells release EVs of varying sizes via different biogenesis pathways, and in the absence of specific, universal markers to distinguish EV subtypes, MISEV2018 recommends the term “extracellular vesicles” [14]. MISEV2018 also encourages that EVs be further described by physical properties (such as size), biochemical makeup, source cell, or culture condition. Historical and variously defined terms such as exosome and microvesicle are discouraged unless biogenesis can be proven. Here, we included studies that investigated the therapeutic potential of “small” extracellular vesicles (30-200nm) in wound healing and skin regeneration. 56 studies (82.4%) used the term “exosome” to describe the preparation without presenting clear justification for use of this term. This included 78% (39/50) of the studies published in 2019 onwards, following the MISEV2018 release. 12 studies (17.6%) used the term “extracellular vesicles” [43, 44, 49, 51, 53, 86, 100-105], 11 of which were published in 2019 or later. Of these, four followed MISEV2018 nomenclature by size identification and specified that they were small extracellular vesicles [44, 49, 51, 100], while the remaining studies described them by the cell of origin and culture condition.

Reporting to EV-TRACK

MISEV2018 highly encourages submitting methodological details to EV-TRACK, a crowdsourcing tool developed to enable reproducibility and understanding methodology and experimental outcomes [14, 106]. An “EV-METRIC” is assigned to each submitted study based on the proportion of required methodology details that are submitted. Here, only one study (1.5%) reported submitting details to the EV-TRACK knowledgebase [82].

Outcomes

Wound healing

61 studies (89.7%) investigated wound closure (Table 3). 60 studies reported that sEVs significantly accelerated wound healing at least one time point (p < 0.05 and as low as 0.001), while a single study found this effect to be not statistically significant when compared with experimental placebo-control and liposomes [83]. While one study detected substantial enhancements at an early stage of the wound healing process but not at the endpoint [105], others observed these enhancements exclusively at [47, 93] or near the endpoint [55, 69, 72, 91, 96, 100, 107]. Several studies reported improvement at all time points, ranging from day 2 to day 21 post wounding [44, 52, 57, 60, 80, 87, 88, 103]. Surprisingly, reporting of precise complete wound closure time was frequently overlooked, as only 12 studies reported wound closure timepoints. Total closure of diabetic wounds was reported on day 14 [62, 72, 92] and day19 [97]. Diabetic wounds were observed to be “almost closed” on day 14 [68, 76, 80, 103] and day 18 [79]. Meanwhile, complete non-diabetic wound closure was noted on day 8 [53], day 14 [49, 104, 105, 107], day 21 [74, 91], and day 25 [73], and “almost closed” on day 10 [61, 85] and day 14 [75, 77, 81], indicating no major differences between diabetic and non-diabetic wound closure time in the examined studies.
| Ref. | Human GF stimulated-Fibrocyte derived Exos | Primary outcome measures | Main results | Secondary outcome measures | Conclusion |
|------|---------------------------------------------|--------------------------|--------------|---------------------------|------------|
| [52] | 1-Wound healing rate; 2-Protein expression of re-epithelialization markers | 1-Sig" dose-dependent acceleration of wound closure; 2-Sig" dose-dependent rise in COL1, α-SMA, and CK14 (day 14) | 1-Adverse effect; 2-Angiogenesis | NS/NS; Sig" dose-dependent rise in MECA32 (day 7) | Exosome derived from fibrocyte may accelerate diabetic wound healing in a dose-dependent manner. |
| [50] | LPS-hUC-MSC-exo | Wound closure rate was enhanced by LPS-hUCMSc-exo treatment. | 1-Adverse effect; 2-Angiogenesis; 3-Inflammation | 1- NR/ NS; 2- More capillaries in LPS-hUC-MSC-exo group; 3- Reduced inflammatory cell infiltration and higher M2 than M1 at day 3. | LPS-hUCMSC-exo can promote wound healing by modulating inflammation in diabetes rat model. |
| [45] | hUC-MSC-exos or HFL1-exo | Wound closure rate was enhanced by LPS-hUCMSc-exo treatment. | 1-Adverse effect | 1- NR/ NS | hUC-MSC-exos improved wound healing and cell proliferation in second degree skin burn model in rats. |
| [98] | hu-iPSCs-MSC-exos | Wound closure rate was enhanced by LPS-hUCMSc-exo treatment. | 1-Adverse effect | 1- NR/ NS; 2- hiPSCs-MSC-exo treated wounds had a similar sig" increase in cell numbers and PCNA compared with HFL1-exo, HFL1 and untreated control; 2- Reduced inflammatory cell infiltration and higher M2 than M1 at day 3. | hiPSCs-MSCs-exos show potential in promoting angiogenesis and WH in rat model. |
| [73] | hUCMSC-Exo+ hydrogel | Wound closure rate was enhanced by LPS-hUCMSc-exo treatment. | 1-Adverse effect | 1- NS/ NR | hUCMSC-Exo can induce wound healing and also decrease scarring and myofibroblast development |
| [94] | hADMSC-Exo | Wound closure rate was enhanced by LPS-hUCMSc-exo treatment. | 1-Adverse effect | 1- NR/ NS | hADMSC-Exo promoted wound healing and collagen deposition and maturation. L.V administration of hADMSC-Exo seems superior to S.I in healing process suggesting exosome homing to wound area. |
| [60] | HAP-CS-SMSCs-126-exos | Wound closure rate was enhanced by LPS-hUCMSc-exo treatment. | 1-Adverse effect | 1- HAP-CS-SMSCs-126-Exos and HAP-CS sig* accelerated WH at day 4, 7, 14; 2- Reduced inflammatory cell infiltration and higher M2 than M1 at day 3. | HAPCS-SMSCs-126-Exos has the potential to accelerate healing process of diabetic wounds. |
| [62] | Human SMSCs-126-exo | Wound closure rate was enhanced by LPS-hUCMSc-exo treatment. | 1-Adverse effect | 1- No death or abnormality; 2- Human SMSCs-126-exo Chitosan hydrogel promoted the greatest vessel density and vessel maturation compared with Chitosan hydrogel helped the controlled release of SMSCs-126-Exos and improved wound healing in diabetes rat. | HAPCS-SMSCs-126-Exos had the greatest effect. |

**Table 3. Safety and efficacy findings of the selected studies**
| Ref. | sEV type | Primary outcome measures | Main results | Secondary outcome measures | Main results | Conclusion |
|------|----------|--------------------------|--------------|---------------------------|--------------|------------|
| [93] | hUCB-EPC-exos | 1-Wound size reduction rate; 2-Re-epithelialization And scar formation (width); 3-Collagen maturity MT. | 2-Human SMSCs-126-exo-Chitosan hydrogel had a sig* longer neoeplithelium compared with hydrogel only and untreated controls. 3-Human SMSCs-126-exo-Chitosan hydrogel had sig* promoted collagen deposition, maturation, and alignment. The granulation tissue was the thickest. | 1-Adverse effect; 2-Angiogenesis -Microfil perfusion and micro-CT -IF: CD31 and α-SMA | 1-Adverse effect; 2-HUCB-EPC-exos treated wounds had the greatest number of newly formed and mature blood vessel and the highest expression of α-SMA, CD31; 1 × 10^11 sig* > 2 × 10^10 exosomes* > PBS. | Exosome treatment promoted WH, and the increased dose had further enhanced exosome efficacy in promoting angiogenesis and WH in diabetes rat model. |
| [105] | hADMSC-EVs+HEC | 1-Wound diameter | hADMSC-EVs+HEC sig* accelerated wound closure at day 7 and 14, but was equivalent to control at day 21 | 1-Adverse effect; 2-Angiogenesis | -NS/NR | Topical application of a gel containing MSC EVs promoted wound healing in an animal model. |
| [80] | hPRP-exo | 1-Rate of wound closure; 2-Neoeplithelium formation; 3-Collagen deposition | 1-PRP-exo sig* accelerated wound closure (3, 7, 14 days), but showed no difference with PRP-only treated wounds at day 14; 2-Neo-epithelium was sig* longer in PRP-treated wounds compared to controls (including PRP only group) at day 14; 3- Massive deposition of woven collagen fibers in PRP-exo treated wounds compared to controls (including PRP only group). | 1-Adverse effect; 2-Angiogenesis -Microfil perfusion and micro-CT -IF: CD31 and α-SMA and blood vessel density | 1-No adverse effect detected; 2-Sig* high number of blood vessels in PRP-exo treated wounds compared to controls (including PRP only group); -Sig* high number of blood vessels and mature blood vessels in wounds treated with PRP-exo. | Exosomes secreted by PRP may mediate PRP-stimulated angiogenesis and accelerate diabetic wound healing. |
| [76] | hGMSC-exo | 1-Wound closure rate; 2- Neo-epithelium length; 3-Collagen deposition and maturation: MT | 1-hGMSC-exo-CS hydrogel sig* promoted wound closure compared with hydrogel and PBS group 2-hGMSC-exo-CS hydrogel had sig* longer neoeplithelium compared with hydrogel and PBS group 3- Massively increased number of blood vessels and mature blood vessels in PRP-exo treated wounds compared to controls (including PRP only group). | 1-Adverse effect; 2-Angiogenesis -Microfil perfusion and micro-CT -IF: CD31 and α-SMA and blood vessel density | 1-11 × 10^11 > 3 × 10^10 | The mixture of the exosomes and hydrogel may effectively enhance the skin wound healing of diabetes rat wounds. |
| [109] | hADMSC-exo | 1-Scar width and scar depth (H&E); 2-Collagen deposition: -PSR staining -IHC IHC, WB, qRT-PCR: Col I, Col III. 3- Fibroblast differentiation to myofibroblast: -IHC, WB, qRT-PCR of TGF β1, TGF β2. -IF, WB, qRT-PCR: α-SMA. | 1-Sig* Less scar width and depth in hADMSC-exo compared with PBS and the CM-Exo groups. 2- hADMSC-exo showed well-arranged collagen fibers comparable to native tissue. Sig* Lower density of Collagen fibers compared to controls. | 1-Adverse effect | 1-1 × 10^11 sig* > 2 × 10^10 exosomes* > PBS. | hADMSC-exo stimulated ECM regeneration and reduced scar formation. |
| [91] | hAEC-exos | 1-Wound size reduction rate; 2-Re-epithelialization and scar formation; 3-Collagen deposition and organization: MT, IHC | 1-Sig* dose-dependent acceleration of wound closure with hAEC-exos treatment (50 and 100 µg/ml) at day 14; 2- Remarkable dose-dependent re-epithelialization hAEC-exos treatment groups. Complete re-epithelialization with less scar formation at day 14 with 100 µg/ml hAEC-exos. 3- Collagen fibers appear well organized in hAEC-exos treatment groups | 1-Adverse effect | 1-1 × 10^11 sig* > 2 × 10^10 exosomes* > PBS. | Exosome derived from amniotic epithelial cells may accelerate wound healing in a dose dependent manner. |
| [84] | USCExo#DMBT1 #1-Exos | 1-Rate of wound closure; 2-Re-epithelialization (H&E); 3-Scar width (H&E); 4-Collagen maturity (MT); | 1-USCExo #4-DMBT1 Exos sig* accelerated wound closure compared with PBS and shDMBT1 exo group (sig at day 14 only); 2-USCExo #4-DMBT1 Exos sig* increased rate of re-epithelialization at day 12; 3-USCExo #4-DMBT1 Exos sig* reduced scar | 1-Adverse effect; 2-Angiogenesis -IF: CD31 and blood vessel density. | 1-NS/NR; 2-USCExo #4-DMBT1 Exos significantly increased blood vessel formation (p < 0.05) day 12 | -USC-Exos is effective in promoting diabetic wound healing. -DMBT1 seems to mediate USC-Exos' wound healing and |
| Ref. | sEV type | Primary outcome measures | Main results | Secondary outcome measures | Conclusion |
|------|----------|--------------------------|--------------|---------------------------|------------|
| [63] | hADMSCs-exos or hADMSCs-Nrf2-exos | 1- % Wound closure; 2-Collagen deposition: MT. | 1- Both hADMSCs-exos and hADMSC-Nrf2-exos sig* promoted wound closure compared with PBS and PBS; 2- Sig* Reduced fibrosis by hADMSCs-exos and hADMSC-Nrf2-exos showed. | 1- Adverse effect; 2- Angiogenesis; IF: CD31 and blood vessel density. | Adipose derived stem cell-sEVs could potentially promote wound healing in DFU animal model. Overexpressing Nrf2 could further potentiate sEVs therapeutic impact. hMenSC derived sEVs significantly promoted healing of diabetic wounds. |
| [96] | hMenSC-EVs | 1- % Wound closure (day 0, 4, 7, 12, and 14). 2- Re-epithelialization (H&E). 3- Epithelial thickness (mm). 4- Size of scar tissue (width, depth, area). 5- Collagen deposition MT, qRT-PCR. | 1- hMenSC-EVs sig* increased wound closure only at day 12, 14 (was not sig at day 4, 8). 2- hMenSC-EVs enhanced re-epithelialization. Difference was sig* with hMenSC group only at day 4, while effect was equivalent to hMenSC at days 7, 14. 3- Both EVs and hMenSCs increased epithelial thickness, but only hMenSCs showed a sig, effect compared with PBS. 4- EVs and hMenSCs similarly reduced scar size sig*. 5- hMenSCs-EVs improved collagen deposition compared with hMenSCs and PBS (40%, 40%, 20%). Coll-Coll3 ratio was higher in the EV group compared with controls at Day 7, it reduced at Day 14. | 1- Adverse effect; 2- Angiogenesis; IF: CD31, α-SMA and blood vessel density. | hMenSC derived sEVs significantly promoted healing of diabetic wounds. |
| [54] | hBMSCs-DFO-Exo | 1- Rate of wound closure; 2- Scar width (H&E); 3- Collagen maturity (MT). | 1- Wound closure was sig* accelerated with Exo and DFO-Exo at day 7 and 14 with DFO-Exo showed better effect. 2- Both Exo and DFO-Exo sig* lowered scar formation, but DFO-Exo showed a sig effect compared with Exo. 3- Wavy collagen fibers more abundant in DFO-Exo-treated wounds. | 1- Adverse effect; 2- Angiogenesis; microvessel perfusion and micro-CT -IHC: CD31 and α-SMA. | BMSCs preconditioned with DFO improve the proangiogenic capacity of sEVs and promote skin wound healing in diabetes mice. |
| [44] | hUCBMNC-sEVs | 1- Wound healing rate; 2- Re-epithelialization (H&E). 3- IF: keratin 14, keratin 5 expression. | 1- Wound healing was sig* enhanced when small doses of EVs (0.02 µg, total 0.4 µg/wound) applied bidaily for 10 days compared with single dose application. Wound healing was sig* highest because of the controlled release of sEVs from LTHAG; 2- Epidermal regrowth was the highest in sEVs+ LTHAG+light; 3- Keratin 14 was highly expressed in cells of sEVs+ LTHAG+light, while keratin 5 expression was similar to control (gel+light only). | 1- Adverse effect; 2- Angiogenesis; microvessel perfusion and micro-CT -IHC: CD31 and α-SMA. | Dosage regimen does influence the efficacy of sEVs. Small frequent doses showed better outcome than an equivalent single dose. Controlled release LTHAG showed superior effect on healing, regeneration, and new vessel formation in diabetic I, II, and non-diabetic wounds. |
| [92] | RAW 264.7-exo | 1- Wound size reduction rate; 2- Collagen deposition and maturation: MT. | 1- Wound closure rate was significantly higher in sEV groups (100 µg/ml and 1 mg/ml) compared with PBS group at day 7, 14, and 21. At day 7, wounds closed by 18%, 64%, 81% when treated with PBS, 100 µg sEVs, 1 mg/ml sEVs respectively. Completely closed at day 14 (for EVs) but 1- Adverse effect; 2- Angiogenesis; -IHC: CD31; 3- Inflammation. | 1- NS. 2- Increased blood vessel density and CD31 expression in sEV treated groups within 7 days of treatment. 3- Lower infiltrating immune cell count (neutrophils and | Macrophage derived sEVs promoted wound closure, collagen deposition and maturation, angiogenesis and |
| Ref. | sEV type | Primary outcome measures | Main results | Secondary outcome measures | Main results | Conclusion |
|------|----------|--------------------------|--------------|---------------------------|--------------|------------|
| [42] | Macque-Fibro-ipSCs-exo | 1-Wound closure rate; 2-Epithelial thickness (mm); 3-Collagen deposition: MT. | 1-Both Auto-iPSCs-exo and Allo-iPSCs-exo sig* accelerated wound closure compared with EPC and PBS; · Auto-iPSCs-exo showed better efficacy. · No sig* difference between Auto-iPSCs and Auto-iPSCs-exo; and no sig* difference between Allo-iPSCs vs Allo-iPSCs-exo; | 1-Adverse effect; 2-Angiogenesis IF: CD31 and blood vessel density. | 1-Auto and allo iPSCs, and their exosomes, did not trigger immune rejection; 2-Both Auto-iPSCs-exo and Allo-iPSCs-exo sig* promoted vessel formation. | -Both allogenic and autologous iPSC-derived exosomes promoted wound healing with no immune rejection. | `-Auto-iPSCs-exo showed better performance. |
| [86] | Mouse-leukocyte-Mouse. | 1-% Wound closure | TBCID3-exo failed to promote wound closure while control EVs sig* accelerated wound healing | 1-Adverse effect | 1-NR/NS | Transduction of source cells with TBCID3, which is involved in vesicle trafficking, hampered the stimulatory effect of EVs in wound healing. | |
| [81] | Rat-ADMSC-exo | 1-% Wound closure; 2-Epithelial thickness (mm); 3-Collagen deposition: MT. | 1- Alg-EXO hydrogel sig* reduced wound size compared with Alg-hydrogel (day 7, 14). 2- Alg-EXO hydrogel showed the highest epithelial thickness. 3-Both Alg-EXO hydrogel and Alg-hydrogel promoted collagen deposition compared with untreated control. | 1-Adverse effect | 1-NR/NS | Oral mucosal sheet derived EVs significantly promoted wound healing. Lower doses but frequent treatment application appears to have better efficacy than a single higher dose. | |
| [82] | shOMEC-cExo | 1) Wound size area; 2) Re-epithelialization; 3) Collagen (Picrosirius staining). | 1-Sig difference in wound healing capacity compared to non-exo control (day 6 and 17). With one application of 12.5 g was less beneficial than 2 applications of 7.6 g. 2) Reduction of the granulation tissue. At the 17-day, the hypertrophic epithelium detected in all groups was decreased to a close to normal size layer. 3) Normal collagen localization and deposition. | 1-Adverse effect | 1-NR/NS | Thrombin preconditioning showed improvement in sEV efficacy in wound healing. | |
| [53] | hUCB-MSCs-EVs | 1-Wound closure rate | 1- Thrombin preconditioned EVs group had sig* higher rate of WH compared with the other groups (hypoxia, LPS, H2O2, saline naïve EVs). | 1-Adverse effect; 2-Inflammation. | 1-NR/NS | Thrombin preconditioning showed improvement in sEV efficacy in wound healing. | |
| [70] | Mouse-ADMSC-exo | 1- Wound closure rate; 2-Re-epithelialization; H&E; IHC: cyto kinase. 3-Collagen deposition and maturation: MT. | 1- ADMSC-exo + FHE hydrogel showed a sig* accelerated wound healing. ADMSC-exo + FHE hydrogel > Free exo > FHE hydrogel > Saline; 2- ADMSC-exo + FHE hydrogel showed the best outcome with visible skin appendages and cyto kinase at day 21. ADMSC-exo + FHE hydrogel > Free exo > FHE hydrogel > Saline; 3- ADMSC-exo + FHE hydrogel had the most sig* amount of well-organized collagen fibres and highest collagen 1/III. | 1-Adverse effect; 2-Angiogenesis IF: α-SMA and blood vessel density | 1-NR/NS | Incorporating ADMSC-exo with FHE hydrogel along with the pH-responsive release of exo had a synergistic effect in promoting wound healing in diabetic mice. | |
| [71] | Mouse-ADMSC-exo | 1-Wound closure rate; 2- Re-epithelialization H&E; 3-Collagen deposition: MT; Immunostaining Coll, Col III; 4-Cytokeratin and Ki67. | 1- At day 3, FEP-exo and exo groups had similar enhancing effect on WCR. At day 7 FEP-exo had the highest effect; 2- Abundant and thickened granulation tissue with skin appendages in FEP-exo group FEP-exo > exo > FEP > control. 3- FEP-exo group showed sig* highest collagen deposition at days 7, 14; FEP-exo > exo > FEP > control; and increasing trend of Coll and CollIII expression at days 7, 14. 4- FEP-exo group showed sig* highest Cytokeratin and Ki67 expression. | 1-Adverse effect; 2-Angiogenesis IF: α-SMA and blood vessel density. | 1-NR/NS | Loading ADMSC-exo to FHE hydrogel along with the pH-responsive release of exosome improved exosome efficacy in promoting wound regeneration and angiogenesis in diabetic mice. | |
| [108] | FDMSC-exos | 1-Wound closure rate; 2- Re-epithelialization H&E; | 1- FDMSC-exo sig* accelerated WH at day 7 and 14; 2- FDMSC-exo group had more cells and collagen deposition as well as thicker | 1-Adverse effect | 1-NR/NS | FDMSC-exos can promote wound healing by stimulating re-epithelialization, |
| Ref. | sEV type | Primary outcome measures | Main results | Secondary outcome measures | Main results | Conclusion |
|------|----------|--------------------------|--------------|-----------------------------|--------------|------------|
| [100] | hUC-MSCs-EVs | 1) Wound size reduction; 2) Scar; 3) Collagen deposition and organization MT; 4) Epithelial thickness. | 1) Both rat-sEV-AT and p-sEV-AT promoted wound closure. | 1) NR/NS | Suppression of wound healing in diabetic mouse model. |
| [102] | hUC-MSCs-EVs or hUC-MSCs-EVs-inhibitor-NC | 1) Wound size reduction rate; 2) Re-epithelialization; 3) Collagen deposition and organization MT. | 1) Both rat-sEV-AT and p-sEV-AT promoted wound closure. | 1) NR/NS | Allogenic and xenogenic EVs derived from adipose tissue exhibited similar efficiency in promoting wound healing in rat model, indicating EVs from different species might possess similar therapeutic properties. |
| [103] | hAMSCs-exo | 1) Wound size reduction; 2) Scar; 3) Collagen deposition and organization MT. | 1) hAMSC-exo-miR-135a OE promoted wound closure. | 1) NR/NS | Exosomes derived from epidermal stem cells could remarkably accelerate wound closure stimulate angiogenesis and suppress scar formation through suppression of TGF-β1 and downstream genes. |
| [104] | hAMSC-exo | 1) Wound size reduction; 2) Scar; 3) Collagen deposition and organization MT. | 1) hAMSC-exo-miR-135a OE promoted wound closure. | 1) NR/NS | Exosomes derived from adipose tissue exhibited similar efﬁciency in promoting wound healing in rat model, indicating EVs from different species might possess similar therapeutic properties. |
| [105] | hAMSC-exo | 1) Wound size reduction; 2) Scar; 3) Collagen deposition and organization MT. | 1) hAMSC-exo-miR-135a OE promoted wound closure. | 1) NR/NS | Exosomes derived from adipose tissue exhibited similar efﬁciency in promoting wound healing in rat model, indicating EVs from different species might possess similar therapeutic properties. |
| [106] | hAMSC-exo | 1) Wound size reduction; 2) Scar; 3) Collagen deposition and organization MT. | 1) hAMSC-exo-miR-135a OE promoted wound closure. | 1) NR/NS | Exosomes derived from adipose tissue exhibited similar efﬁciency in promoting wound healing in rat model, indicating EVs from different species might possess similar therapeutic properties. |
| [107] | hAMSC-exo | 1) Wound size reduction; 2) Scar; 3) Collagen deposition and organization MT. | 1) hAMSC-exo-miR-135a OE promoted wound closure. | 1) NR/NS | Exosomes derived from adipose tissue exhibited similar efﬁciency in promoting wound healing in rat model, indicating EVs from different species might possess similar therapeutic properties. |
| [108] | hAMSC-exo | 1) Wound size reduction; 2) Scar; 3) Collagen deposition and organization MT. | 1) hAMSC-exo-miR-135a OE promoted wound closure. | 1) NR/NS | Exosomes derived from adipose tissue exhibited similar efﬁciency in promoting wound healing in rat model, indicating EVs from different species might possess similar therapeutic properties. |
| Ref. | Primary outcome measures | Main results | Secondary outcome measures | Main results | Conclusion |
|------|--------------------------|--------------|----------------------------|--------------|------------|
| [59] | hBMMSC-TSG6-OE exo | 1) Scar formation Assessment; 2) Collagen deposition MT; 3) RT-qPCR, TGFβ1, collagen I, collagen III, α-SMA, p-SMAD2/3/4/5 and p-SMAD3/4/5/7 | 1) hBMMSC-TSG6-OE exo sig* reduced scar formation, recovered cell polarity, increased TSG6 expression compared to knocked down TSG6-exo and other controls. 2) hBMMSC-TSG6-OE exo sig* lowered collagen deposition in scar (64.4%) compared to naïve hBMMSC-exo (47.3%). Neutralizing TSG-6 in exo reversed this effect and increased collagen deposition in the scar. 3) hBMMSC-TSG6-OE exo sig* lowered TGFβ1, collagen I, collagen III, α-SMA, p-SMAD2/3/4/5 and p-SMAD3/4/5/7 | 1) Adverse effect; 2) Inflammatory markers. | 1) Degeneration, necrosis, and fibrosis were evaluated. 2) hBMMSC-TSG6-OE exo sig* lowered inflammatory markers: MCP-1, TNF-α, IL1β, IL6. | Transfection of hBMMSC-exo to overexpress TSG6 improved the pro-healing capacity of exosomes and reduced inflammation and scar formation in animal wound model. |
| [67] | 1) MSC-exo vector; 2) MSC-exo OE H19 vs untreated control | 1) Wound closure %; 2) Re-epithelialization | 1) MSC-exo oe-H19 significantly accelerated wound healing rate. 2) Exo treatment produced significantly thicker granulation tissue, expression of collagen I (p < 0.01). | 1) Adverse events; 2) Angiogenesis; 3) Inflammation. | 1) TUNEL assay showed apoptosis was suppressed. 2) Sig increased VEGF, TGF-β1, α-SMA levels. 3) MSC-exo OE H19 suppressed IL-1β and TNF-α, and increased IL-10 expression. | Exosomes derived from Fe3O4 NP-loaded MSCs along with magnetic guidance has enhanced homing, retention and efficacy in burn wounds. |
| [46] | hUC-MSCs-exo vs hUC-MSCs-exo+Fe3O4 NPs; hUC-MSCs-exo+Fe3O4 NPs+MAG | 1) Wound closure%; 2) Re-epithelialization%; 3) Wound edge length (mm); 4) Collagen deposition MT. | 1) At week 5, The Exo and Exo + NP groups showed similar sig* accelerated closure rate, enhanced collagen deposition, re-epithelialization, reduced wound edge length. While Exo + NPs + MAG had the greatest sig* effect of all. 2) At week 5 CK19 expression was sig* greater in the Exo + NPs, and Exo + NPs + MAG than in the control. | 1) Adverse effect; 2) Angiogenesis; IF-CD31 and α-SMA. | 1) NR/NS; 2) At week 5, The Exo and Exo + NP groups showed greater average vessel density and number of mature vessels than the control. While Exo + NPs + MAG had the greatest effect of all. | hADSC derived exosomes treatment potentially improved photodamaged skin, promoted proliferation, restored epidermis and dermis thickness and improved collagen type I production. |
| [48] | hADSC-exo | 1) Epidermal and Dermal thickness (H&E); 2) Nucleus Proliferation in Stratum Basale Cells of the Epidermis; 3) Type I Collagen, Type III Collagen, MMP-1, and MMP-3 mRNA in the Dermis (RT-PCR); 4) Protein Expression of Type I Collagen, Type III Collagen, MMP-1, and MMP-3 mRNA in the Dermis (WB). | 1) hADSC-exo showed a reduced thickness of the epidermis and increased in the dermal thickness of the photosaged skin at day 7, 14, and 28. 2) hADSC-exo sig* reduced the nuclei in a proliferating state in the stratum basale. 3) hADSC-exo upregulated the relative gene expression of type I collagen mRNA and downregulated the expression of type III collagen, MMP-1, and MMP-3. 4) hADSC-exo upregulated the relative protein expression of type I collagen protein and downregulated the expression of type III collagen, MMP-1, and MMP-3. | 1) Adverse effect | 1) NR | hADSC derived exosomes treatment potentially improved photodamaged skin, promoted proliferation, restored epidermis and dermis thickness and improved collagen type I production. |
| [47] | hUC-MSC-ExAng−2 | 1) Wound healing rate; 2) Epidermis and appendages regeneration | 1) hucMSC-Exo showed a sig* faster wound closure at 13 days compared to controls (EX-GFP, PBS). 2) hucMSC-Exo group had a better regenerated epidermis and a small number of appendages. | 1) Adverse effect; 2) Angiogenesis CD31-specific staining IHC (qualitative). | 1) NR; 2) hUC-MSC-ExAng−2-treated group exhibited stronger CD31 expression, and more blood vessels. - Knocked down Exo: hUC-MSC-Ex-shAng−2 had attenuated CD31 expression. | Overexpression of angiopoietin-2 in hucMSC-Exo enhanced angiogenesis, accelerated cutaneous wound healing, and epidermis regeneration in a rat model of deep second-degree burn injury. On the other hand, knockdown of angiopoietin-2 attenuated exosome therapeutic effects. |
| [55] | MT-hBMMSC-Exo | 1) Wound closure rate; 2) neopithelium length rate (H&E); 3) Collagen deposition-Masson staining, RT-PCR. | 1) MT-Exo sig* reduced wound size compared to other groups at days 7, 14 (PBS and naïve exo). 2) MT-Exo sig* increased neopithelium formation compared to others (days 7, 14). 3) MT-Exo sig* upregulated collagen-related genes Collagen I and III, and increased thickness (days 7, 14). | 1) Adverse effect; 2) Angiogenesis: IF-CD31 expression, 3) Neo-vascularization: Microfiber density, 4) Inflammation: (air pouch model). | 1) NR; 2) MT-Exo increased CD31/α-SMA expression 3) MT-Exo developed sig* higher number of new blood vessels. 4) MT-Exo reduced CCR7 positive cells, and increased CD206 cells (M2: M1). | hBMMCs derived MT-Exo potentially healed diabetic wound by promoting re-epithelialization, wound closure, angiogenesis and increased M2 to M1 polarization activating PTE1/AKT pathway in vivo. |
| [101] | hADMSC-EVs | 1) Wound healing rate; 2) Collagen deposition-MT; 3) Re-epithelialization (H&E); | 1) hASC-EVs reduced wound size rate was sig* higher than controls. 2) hADMSC-EVs formed more collagen fibre than control. 3) hADMSC-EVs promoted wound re-epithelialization. | 1) Adverse effect; 2) Angiogenesis: IF-CD31 & α-SMA expression. | 1) NR; 2) hADMSC-EVs injected skin stained more with CD31 & α-SMA. | hADMSC-EVs accelerated cutaneous wound healing and enhanced angiogenesis in vivo model. |
| [65] | miR-21-5p-exo | 1) Wound closure rate; 1) miR-21-5p-exo-treated diabetic wounds, 1) Adverse effect; 1) NS/NR | 1) ASC-exos with miR-21 | | | |
| Ref. | EV type | Primary outcome measures | Main results | Secondary outcome measures | Main results | Conclusion |
|------|---------|--------------------------|--------------|---------------------------|--------------|------------|
|      | 2-Re-epithelialization (H&E); 3- Collagen deposition (Masson staining). | the unclosed rate was 71, 21, and 8% on days 5, 10, and 15 and higher than control. miR-21-5p-exo reached highest re-epithelialization percentage of 98.4%. Compared to controls miR-21 (62.6%), naïve exo (75.4%), (NC) (74.3%) and control group (52.7%). miR-21-5p-exo significantly increased collagen deposition. | 2-Angiogenesis; IF: CD31+ a-SMA+; and vessel density. 3- Inflammation. | 2- miR-21-5p-exo increased the density of blood vessels higher than controls. 3- At day 15, there were less inflammatory cells in miR-21-5p-exo than in controls. | accelerating diabetic wound healing by increasing re-epithelialization, collagen remodelling, angiogenesis, and vessel maturation in vivo. |
|      | hsa saliva-Exos | 1- Wound diameter; 2- Wound healing rate. | 1- The saliva and saliva-Exos groups had a higher rate of wound healing than the control exo > saliva > PBS. At days 3, 5, 7, 10, 14. 2- Saliva-Exos showed smaller scar width was smaller in the saliva-Exos group than in the control group Exo > saliva > PBS. | 1- Adverse effect; 2- Angiogenesis; IF expression of CD31 and neo-vascularization. | 1- NS/NS; 2- Higher number of CD31-positive cells saliva-Exos sig* showed higher neo-vascularization at the wound. | Saliva exosomes accelerated in vivo wound healing and angiogenesis. |
|      | Ch-glycerol-EXO | 1- Wound healing rate; 2- Re-epithelialization (H&E); 3- Collagen deposition-Masson staining and appendages. | 1- Ch-glycerol-EXO sig* reduced wound size than other group at day 7. Both hydrogels completely healed at day 14 but not NC. 2- Ch-glycerol-EXO sig* sig* increased epithelial thickness. 3- Ch-glycerol-EXO produced more collagen and skin appendages. | 1- Adverse effect; 2- Angiogenesis; IF expression of CD31 and neo-vascularization. 3- Inflammation. | 1- No signs of infection; 2- Ch-glycerol-EXO increased vessel density and increased expression of CD 31. | Ch-glycerol combined with exosomes potentiated wound healing and promoted tissue regeneration in in vivo model. |
|      | mAPCs, Vim-/APC-Exo | 1- wound closure rate; 2- RNA isolation and qPCR analysis. | 1- WT-APC-Exo recovered faster with reduced scar compared to Vim-/-APC-Exo and PBS groups. 2- WT-APC-Exos sig* increased TGFβ and collagen I compared to the control group or Vim-/-APC-Exo group. | 1- Adverse effect; 2- Angiogenesis; 3- Inflammation. | 1- NS/NS; 2- NS; 3- WT-APC-Exo sig* lowered inflammation and immune cell infiltration compared to Vim-/-APC-Exo and control. 4- WT-APC-Exos downregulated pro-inflammatory cytokines IL-6 and TNF-α and suppressed IL-10. Vim-/-exosomes have no effect in these cytokine productions. | Exosomal vimentin shortens the healing time and reduces scar formation thus enhances wound healing. |
|      | MSCNS-Exo; 2- MSCAS-Exo | 1- Wound diameter; 2- Wound healing rate; 3- Collagen deposition-Masson staining; 4- Re-epithelialization (H&E). | 1- NS-Exo educated MSCs (MSCNS-Exo) healed the fastest among the three groups. 2- MSCNS-Exo formed better epithelial and appendages. 3- Collagen deposition is higher in MSCNS-Exo compared to AS-Exo educated MSCs (MSCNS-Exo). 4- Increased Ki614. Less alpha sma that indicate myofibroblast and contraction of the wound. | 1- Adverse effect; 2- Angiogenesis; IF expression of CD31. | 1- NR; No effect on body weight; 2- MSCNS-Exo showed better CD31 expression MSCNS-Exo group not significant; *p < 0.05. | -Exosomes released by educated MSCs could promote angiogenesis. -Exosomes released by neonatal-endo-educated-MSCs showed better performance than MSC-endo educated with adult exo. |
|      | PTHrP-2 pre-treated HUVEC derived exosomes vs untreated HUVEC derived exosomes. | 1- Wound closure %; 2- Collagen deposition MT. | 1) Sig* improved wound closure rate in PTHrP-2-2-HUVEC-exo. 2) I, 2, and 14 days post wounding PTHrP-2-2-HUVEC-Exo group showed greatly enhanced re-epithelialization, and collagen organization. | 1- Adverse effect; 2- Angiogenesis; IF: CD31; CD31 expression. | 1- NR/NS; 2- 14 days post wounding PTHrP-2-2-HUVEC-Exos group showed greatly enhanced angiogenesis. | Pretreatment of HUVEC with PTHrP-2 has improved exosome efficacy in promoting healing and angiogenesis in rat diabetic wound model. |
|      | 1) Naive ADMSC-exo; 2) mmu_circ_0000250; ADMSC-exo. | 1- Wound closure%. | 1) mmu_circ_0000250 exosome group had a sig* accelerated wound closure, wound closed at day 14. | 1- Adverse effects; 2- Angiogenesis; IF: CD31. | 1- No signs of infection; 2- Tunel staining showed that mmu_circ_000025 exosomes significantly reduced apoptosis of skin tissue relative to control. 2-mmucirc_0000250 exosome treated group showed sig* enhanced neovascularization. | Exosomes with a high concentration of mmu_circ_0000250 showed improved therapeutic outcomes via enhancing wound closure, angiogenesis and reduced apoptosis and autophagy activation, in diabetic wound model. Exosomal PD-L1 improves tissue repair and regeneration. |
|      | Mouse melanoma B16F10 cell line derived exosomes. WT+IFN-γ and WT+PD-L1 With pI=127 hydrogel. | 1- Wound closure %; 2- HIC: Ki67, α-SMA, vimentin. | 1) WT+ IFN-γ and WT+PD-L1 groups exosome group had a sig* accelerated, re-epithelialization and wound closure equivalent to the positive BFGF group. Wound almost closed at day 10 while negative control had a large scar. 2- PD-L1 group showed sig* better expression indicating better proliferation, migration, and maturation. | 1- Adverse effect; 2- Inflammation. | 1- No abnormalities with spleen, lymph nodes and animal weight. 2- Less infiltrated immune cells at day 7, and reduced IL6, TNF-α, granzyme B levels in EV groups. | Loading exosomes into self-healing improved hydrogels functionality by improved wound |
|      | 2) hPMScs exosomes in MC-CS hydrogel. | 1- Wound reduction rate; 2- Re-epithelialization (H&E) and appendage formation; 3- Collagen deposition | 1- Exo-hydrogel group accelerated wound closure sig* at day15 compared with exosome only, hydrogel only and PBS groups. 2- At days 5, 10, and 15, Exo-hydrogel | 1- Adverse effects; 2- Angiogenesis; IF: CD31; α-SMA; -VEGF expression. | 1- (Apoptosis): Bcl-2 levels increased (day 10) while BAX levels decreased (days 5, 10) by EXO-hydrogel group, indicating inhibition of | Loading exosomes into self-healing improved hydrogels functionality by improved wound |
| Ref. | sEV type | Primary outcome measures | Main results | Secondary outcome measures | Main results | Conclusion |
|------|-----------|--------------------------|--------------|----------------------------|--------------|------------|
| [103] | hPEC-EVs | 1-Wound reduction rate; 2-Re-epithelialization; 3-Collagen deposition (MT). | hUCMSC-exos group performed sig* better in terms of tissue thickness compared to exosome only, hydrogel only and PBS groups. Appearance of hair follicles. 3-MC-CS-Exo-hydrogel group had more well-organized collagen fibers. | 1- Adverse effects: apoptosis; 2-Angiogenesis: IF; CD31; CD34; 3-Anti-inflammatory effect. | 1- No adverse reaction -hPEC-EVs inhibited premature senescence. 2- Improved neo-vascularization with Sig* more CD34- and CD31-positive cells in hPEC-EVs group compared to control. 3- hPEC-EVs group enhanced percentage of type II macrophages (CD163+) to type I macrophages (CD86+). | closure rate, re-epithelialization, collagen maturation and appendage formation, and reduced apoptosis. hPEC-EVs enhanced wound closure, improved re-epithelialization with improved epithelial thickness, collagen deposition, angiogenesis, and anti-inflammation in diabetic mice model. |
| [89] | hAMSC-exos | 1-Wound reduction; 2-Collagen deposition (MT) picrosirius red; 3-HIF: Col 1A1, COL3A1. | hUCMSC-exos group had a sig* accelerated wound closure (days 8, 12, 14) and reduced wound size relative to the DMSO + PBS. LY29402 hAMSC-exos had sig *decreased wound closure rate. 2-hAMSC-exos group had an increased collagen deposition that was well-organized and resemble native tissue. LY294002+hAECs-Exos group was in between. 3- hAMSC-exos group had a sig* increase in COL1A1 and COL3A1 expression. This was not observed in LY29402+hAECs-Exos group. | 1- Adverse effects; 2-Angiogenesis: IF, HIF; CD31. | 1- NR/NS; 2- hAMSC-exos group had a sig* higher capillary density of the (565±10.9/hpf) relative to PBS group (225±17.4/hpf, p < 0.003). LY294002 + hAMSC-exos (35.67±2.87/hpf) was lower. | hAMSC-exos have shown to remarkably accelerate wound closure, collagen deposition, neovascularization in diabetic wounds. -Blocking PI3K-AKT-mTOR activity with LY294002 suppressed hAMSC-exos therapeutic benefits which highlight the importance of this pathway. |
| [69] | SMF-FeO4 NPs-hBMMSC-exos and native hBMMSC-exos | 1-Wound reduction; 2- Re-epithelialization, scar width; 3-Collagen deposition and maturation MT | 1- SMF-FeO4 NPs- hBMMSC-exos showed the greatest wound closure rate at days 4, 7, 10 and 14 after wound creation. 2- SMF-FeO4 NPs- hBMMSC-exos significantly enhanced re-epithelialization with lowest scar width, increased formation of appendages. 3- SMF-FeO4 NPs- hBMMSC-exos promoted largest collagen deposition at day 14. | 1- Adverse effects; 2-Angiogenesis: IF, HIF; CD31. | 1- NR/NS; 2- Sig* enhanced neovascularization SMF-FeO4 NPs- hBMMSC-exos marked by increased CD31 expression. | Loading hBMMSC-exos with SMF-FeO4 nanoparticles potentiated their pro-regenerative efficacy of EVs. |
| [191] | DFU-exo | 1-Rate of wound closure | 1- Closure rate was significantly higher in DFU-Exo-AntagomiR-15a-3p compared DFU Exos. | 1- Adverse effects; 2-Angiogenesis: IF, HIF; Assess the blood perfusion. | 1- Unclear; 2- CD31 was lower in DFU-Exo treated wounds and enhanced in Exos-AntagomiR-15a-3p. | Inhibition of mir-15a-3p in exosome isolated from DFU patients, improved wound healing and angiogenesis. |
| [107] | hADMSC-exos | 1-Rate of wound closure | 1- hADMSC-exos accelerated wound closure. Day 7: cell-exo* > pbs Day 14: all healed but PBS group had large scar tissue. | 1- Adverse effect. | 1- NS/NR. | mir-21 is highly expressed in AD-exos and can significantly accelerate the wound healing process and enhance the migration and proliferation. |
| [72] | hUCMSC-Exo in PF-127 hydrogel | 1- Rate of wound closure; 2- Ki67; 3- Re-epithelialization (H&E). | 1- hUCMSC-exos- PF-127 treatment resulted in a significantly accelerated wound closure rate at days 7, 14 (almost healed at day 14) compared with hydrogel only and PBS groups. 2- Ki67 highly expressed in hUCMSC-Exo-PF-127 compared to exosome only, PF-127 only or PBS hUCMSC-exos- PF-127 > (exo = Pf-127 = pbs). 3- Re-epithelialization was more pronounced in hUCMSC-Exo- PF-127 group, with appendages formation. | 1- Adverse effect; 2-Angiogenesis: HIF; CD31. | 1- NR/NS; 2- Increased expression of CD31, hUCMSC-exos- PF-127 and exo only group. - Significant increase in hUCMSC-exos- PF-127 group and exo only group. - Increased expression of VEGF and TGFβ-1. | PF-127 hUCMSC-exos improved wound healing rate, re-epithelialization, and skin appendage formation in diabetic wound model. |
| [57] | 1)ATV-hBMMS C- Exo; 2) hBMMS C- Exo. | 1-Rate of wound closure; 2- Wound length; 3- Re-epithelialization; 4-Collagen deposition (MT). | 1- sig* accelerated wound closure was observed in the Exos groups (ATV and native); ATV-Exo > native Exo > PBS at day 3, 7, and 14. 2- sig* lower wound length in ATV-Exo compared to native exo or pbs group; ATV-Exo* > native Exo > PBS. 3- Better re-epithelialization and neoeplithelium length. 4- Well-organized and more deposition of collagen fibers in the ATV-Exos group. | 1- Adverse effect; 2-Angiogenesis: IF, a-SMA, Microfil perfusion assay; 3-Inflammation. | 1- Did not affect renal or liver functions (creatinine, BUN, ALT, AST). No edema or sensitivity. 2- Exo treated groups had better vessel area and number ATV-Exo* > native Exo* > PBS, higher CD31, a-SMA (7 to day 14 were sig*). 3- At day 14, considerable infiltration of inflammatory | ATV preconditioning of hBMMSC enhanced exosomes regenerative capabilities in diabetes rats and facilitated wound closure, re-epithelialization and angiogenesis. |
### Summary of the outcomes of small extracellular vesicle intervention for treatment of wounds in animal models.

**Abbreviations:** CM-Ev: exosome-free conditioned medium; FDMSCs: fetal dermal mesenchymal stem cells; FHE hydrogel: pluronic F127 (F127) + oxidized hyaluronic acid (OHA) + EPL; ECM: extracellular matrix; EGF: epidermal growth factor; H&E: haematoxylin and eosin stain; hADMSC: human adipose-derived mesenchymal stem/stromal cells; hAMSC-Nrf2: human adipose derived mesenchymal stem cells high expressed Nrf2; hAECs: human amniotic epithelial cells; hBMMSCs: human bone marrow derived mesenchymal stem cells; hDPSC: human dental pulp stem cells; hEPSC: human epidermal stem cells; hGMSCs: human gingival mesenchymal stem cells; hUSCs: human umbilical cord derived mesenchymal stem cells; HUVECs: human umbilical vein endothelial cells; iCAMS: interleukin-6, and MMP-13. F127; hUC-MSCs-Exo: exosomes isolated from human umbilical cord mesenchymal stem cells; hUSCs: human umbilical cord derived mesenchymal stem cells; H&E: haematoxylin and eosin stain; hUSCs-Exo: exosomes isolated from human umbilical cord derived mesenchymal stem cells; HUVECs: human umbilical vein endothelial cells; hADMSC: human adipose derived mesenchymal stem cells; hAMSC: human amnion mesenchymal stem cells; hBMMSCs: human bone marrow derived mesenchymal stem cells; hEPSC: human epidermal stem cells; hGMSCs: human gingival mesenchymal stem cells; hDPSC: human dental pulp stem cells; hAMSC-exo-miR-135 OE: miR-135-overexpressing human mesenchymal stem cell exosome; hAMSC-exo-miR-135 KD: miR-135-knocked down human mesenchymal stem cell exosome; hAMSC-exo: exosomes isolated from human umbilical cord derived mesenchymal stem cells; 1) hUSCs: human umbilical cord derived mesenchymal stem cells. HUVECs GelMA Exos promoted re-epithelialization, collagen deposition and angiogenesis thus accelerated wound healing.

| Ref. | sEV type | Primary outcome measures | Main results | Secondary outcome measures | Main results | Conclusion |
|------|----------|--------------------------|--------------|-----------------------------|--------------|------------|
| [64] | hBMMSCs-miR-miR-126-Exo | 1-Rate of wound closure; 2-Scar width (H&E). | 1- hBMMSCs-miR-miR-126-Exo accelerated wound closure, compared with Control group; miRNA-126 exo > naive Exo > PBS. 2- hBMMSCs-miR-exo-126 sig* reduced scar formation. | 1-Adverse events; 2-Angiogenesis (IHC). | cells was still noticed in control groups. | Exo-miR-126 is a potential agent to promote angiogenesis, and wound healing. |
| [75] | HUVECs GelMAExos | 1-Rate of wound closure; 2- Re-epithelialization (H&E); 3- Collagen deposition (MT), WB (Coll, CollIII). | 1- HUVECs GelMAExos sig* accelerated wound closure, compared with Control group, & GelMA group. 2- HUVECs Exos loaded in GelMA could significantly enhance re-epithelialization. 3- At day 14, HUVECs GelMA-Exos sig* improved collagen organization and deposition. WB showed sig* higher Col I and Col III. | 1-Adverse events; 2-Angiogenesis (IHC); CD31. | 1- NR; 2- Significant higher volume and density of newly formed blood vessel in GelMA-Exos group. | HUVECs GelMA Exos promoted re-epithelialization, collagen deposition and angiogenesis thus accelerated wound healing. |
| [99] | hUC-MSCs-Exos | 1-Rate of wound closure; 2- Re-epithelialization (H&E); 3- Epidermal regeneration (CK10 (IHC)); 4- Scar assessment (α-SMA). | 1- hUC-MSCs-Exos sig* increased wound closure (days 7, 14). 2- hUC-MSCs-Exo injection sig* enhanced re-epithelialization hUC-MSC-Exo and hUC-MSC had sig* effect (days 7, 14). 3- hUC-MSCs-Exos elevated CK10, indicating epidermal regeneration. 4- hUC-MSCs-Exos decreased α-SMA at day 14 indicating reduced scarring. | 1- Adverse effect; 2- Angiogenesis (IHC); CD31. | 1- NR; 2- Promoted new blood vessels formation in the wound area; -Sig* upregulated CD31. | hUC-MSC-Exo injection effectively promoted rapid wound closure, re-epithelialization, formation of blood vessels; and reduced fibrosis and scar formation. |
| [104] | 1- h-hDPSC-EVs; 2- P-hDPSC-EVs | 1-Rate of wound closure; 2- Scar width (H&E). | 1- P-hEVs accelerated cutaneous wound healing in mice; P-hEVs > H-EVs > PBS. 2- P-hEVs-treated wounds had a lower level of scar formation; P-hEVs > H-EVs > PBS. | 1- Adverse effect; 2- Angiogenesis (IHC); CD31. | 1- No signs of distress; 2- Increased VEGF and CD31 in P- EV group indicating higher vessel formation; P-EVs > H-EVs > PBS. | P-EVs outperformed H-EVs in terms of promoting wound closure, re-epithelialization, vascularization, and scar reduction. |
| [43] | hADMSC-EVs only; 2- h-uAMSC-EVs-HAAM. | 1- Scar height (H&E); 2- Collagen 1 and myofibroblast aggregation formation; α-SMA expression (WB, MT). | 1- hADMSC-EVs significantly reduced hypertrophic scars and less SEL. hADMSC-EVs* > (EV-free medium = PBS) 2- hADMSC-EVs reduced myofibroblast aggregation and collagen I deposition. More well-organized collagen I. | 1- Adverse effects | 1- NR | suppression of miR-19b in exosomes repressed the therapeutic benefits of the exosomes. |
| [192] | hADMSC-Exos; 2- miR-19b inhibitor- hADMSC-exos | 1- Rate of wound closure; 2- Granulation. | 1- Both hADMSC-Exos and miR-19b inhibitor- hADMSC-Exos showed accelerated wound healing but with reduced regenerative capability of the miR-19b inhibitor exo. 2- Thicker granulation tissue in hADMSC-exos group and TGF-βI expression. | 1- Adverse effect; 2- Inflammation. | 1- NR; 2- Less infiltration of inflammatory cells and decreased expression of the inflammatory factor CCL1. | Suppression of mir-19b in exosomes repressed the therapeutic benefits of the exosomes. |
| [49] | 1) hUSCs-EVs only; 2) h-uAMSCs-EVs-HAAM. | 1- Rate of wound closure; 2- Scar; 3- Collagen maturity (MT). | 1- hUSCs-EVs-HAAM treated group showed a sig* accelerated wound closure compared to all groups, followed by hUSCs-EVs only group (day 3, 7, 14). 2- Sig* diminished scar formation compared with control young mice. 3- Improved collagen deposition. | 1- Adverse effect; 2- Inflammation. | 1- NR; 2- Reduced expression of IL-1, IL-6, and MMP-13. | HAM further enhanced regenerative effect of hUSCs-EVs and was able to ameliorate cellular senescence and enhance healing in aged mice. |
| [90] | 1- S-MSC-exosomes; 2- Naive-MSC-exosome. | 1- Wound closure. | 1- Native-MSC-exosome group had Sig* reduced wound size compared with PBS (day 3, 6, 9) and accelerated closure. Naive > Senescent > PBS. | 1- NS; 2- Positive expression in native, and S-MSC groups but not PBS group Naive > Senescent > PBS. | EVs isolated from senescent cells had impaired functionality compared with native EVs, highlighting the importance of aging status of parent cells in source selection. |
| [79] | 1- hADMSC-exo- PVA-Alg nanohydrogel. | 1- Wound closure; 2- Collagen deposition (MT). | 1- Wound almost closed at day 18; Accelerated wound closure with exo-NHp > exo* > NH = negCTRL. 2- Improved collagen deposition, and organization. | 1- Adverse effects; 2- Angiogenesis. | 1- NS; 2- Exo hydrogel group scored sig* higher CD31, α-SMA expression (Q) and consequently, the amount of mature blood vessels. exo-NH > exo* > NH only and increased VEGF levels. | EVs encapsulation in PVA-Alg nanohydrogel outperformed EV only group in accelerating wound healing in diabetes rat model. |
cells; hMenSCs: human menstrual blood-derived mesenchymal stem cells; HS-5: HPV-16 E6/E7 transformed human bone marrow mesenchymal stromal cell; hPEC-EV: Human plasma endothelial cells-derived-extracellular vesicles; hPRP: human platelet rich plasma; hUCB-MSCs: human umbilical cord blood-derived mesenchymal progenitor cells; hUCB: human umbilical cord blood plasma; hUCB-MSCs: human umbilical cord blood-derived MSCs; hUCBMNCs: human umbilical cord blood mononuclear cells; hUC-MSCs-EVs-inhibitor-NC: hUC-MSCs transfected miR-27b-inhibitor negative control-EVs; IF: immunofluorescence; I.V.: intravenous; iPSCs: induced pluripotent stem cells; I.F.: immunofluorescence; LPS-hUC-MSC-exo: Lps induced human umbilical cord derived MSCs; LHAG: hyaluronic acid light-triggerable hydrogel; MC-CS hyrogel: self-healing methylcellulose-chitosan hydrogel; MECA32 mouse specific microvessel marker; MT-Masson’s trichrome staining; microcomputed tomography; NH: nanohydrogel; NP: nanoparticle; Nrf2: nuclear factor-E2-related factor2; NS: not studied, NR: not reported; p-sEV-AT: porcine adipose tissue derived EVs; PTHrP-2: parathyroid hormone related peptide; PB-EPC: peripheral blood derived endothelial progenitor cells; PBS: phosphate buffered saline; PCR: polymerase chain reaction; PSR: picrosirius red staining; (Q): analysed quantitatively; rat-sEV-AT: rat adipose tissue derived EVs; S.E.: S-MSC-exosomes; exosomes isolated from H2O2 induced-senescent MSCs; Scar elevation index; SELL: synthetic exosome-like liposomes; shOMECs-cExo: sheets of human oral mucosa epithelial cells derived exosomes from conditioned media; Sig*: significance; S-NC: immunoprecipitation-supernatant-negative; SMF-Fe3O4 NPs- hBMMSC-exos: human bone marrow MSCs exposed to Static Magnetic Field and Fe3O4 nanoparticles; S.I: subcutaneous injection; MT-hBMMSC-Exo: melatonin stimulated human bone marrow MSC-derived exosomes; UEFS: umbilical cord-derived mesenchymal stem cell exosome-free supernatant; USC-EVs: urine derived stem cell extracellular vesicles; VEGF a: vascular endothelial growth factor A; WCR: wound closure rate.

Re-epithelialization

Of the 38 studies (56%) that evaluated re-epithelialization, 37 indicated improvements as a result of sEV intervention. These studies also noted enhanced granulation, culminating in well-formed tissue that resembled the native tissue in thickness and cellularity. Several studies demonstrated that sEV-treated wound beds had significantly enhanced cellularity [45, 84], which gradually reduced towards the end of the study [96]. Higher levels of proliferation and CXCR4 [100], as well as lower p21 expression [99], PCNA [45, 46, 100, 108], Ki67 [61, 71, 72, 74, 84], showed a spike followed by a gradual decline [63, 94]. Similarly, mRNA expression of collagen type 1 and III expression varied among studies [48, 74, 96, 109, 102, 104, 109] . Several studies reported hypertrophic or keloid scar formation in treated tissues [43], or area [96], showing a significant reduction in the measured index versus controls. No study reported hypertrrophic or keloid scar formation in sEV-treated groups. In addition, collagen type I/collagen type III ratios were examined to assess fibrosis. One study noted higher collagen type I to collagen type III ratios in EV-treated tissues [45], but three observed the reverse [74, 96, 109]. Several studies examined α-smooth muscle actin (α-SMA) levels to evaluate myofibroblasts in treated tissues [43, 58, 73, 74, 109]. α-SMA was significantly reduced, suggesting that sEVs suppressed myofibroblast aggregation in wounds. Reduced levels of proteolytic enzymes, i.e., MMP-9 [92], MMP-13 [49], MMP-1 and MMP3 [48], were also reported, while levels of transforming growth factor-β (TGF-β) varied among studies [67, 72, 74, 85, 109].

Collagen deposition

The extent of scarring in tissues that received sEVs was assessed in 22 studies (32%), all of which concluded that sEVs effectively minimized scar formation. Scars were evaluated quantitatively by measuring the width [54, 64, 69, 84, 87, 88, 93, 96, 98, 100, 102, 104, 109], depth [96, 109], length [73], height [43], or area [96], showing a significant reduction in the measured index versus controls. No study reported hypertrophic or keloid scar formation in sEV-treated groups. In addition, collagen type I/collagen type III ratios were examined to assess fibrosis. One study noted higher collagen type I to collagen type III ratios in EV-treated tissues [45], but three observed the reverse [74, 96, 109]. Several studies examined α-smooth muscle actin (α-SMA) levels to evaluate myofibroblasts in treated tissues [43, 58, 73, 74, 109]. α-SMA was significantly reduced, suggesting that sEVs suppressed myofibroblast aggregation in wounds. Reduced levels of proteolytic enzymes, i.e., MMP-9 [92], MMP-13 [49], MMP-1 and MMP3 [48], were also reported, while levels of transforming growth factor-β (TGF-β) varied among studies [67, 72, 74, 85, 109].
Angiogenesis

45 studies (66%) examined vascularization of newly formed tissues, reporting a significant improvement in both diabetic and non-diabetic wounds that was associated with sEV treatment. These studies detected a rise in new vessel density, quantified by positive markers like CD31 (n = 35), α-SMA (n = 18), CD34 (n = 4), and Meca32 (n = 2). 12 investigations identified mature blood vessels as those positive for both CD31 and α-SMA, with substantial enhancement approaching the study endpoint. Several studies also showed upregulated vascular endothelial growth factor (VEGF) [67, 72, 78, 79, 96, 104]. Marker detection techniques included immunohistochemistry (n = 20), immunofluorescence (n = 25), and Western blotting (n = 3). Techniques to assess neovascularization were microfilm perfusion and micro-CT scanning (n = 9) and small animal doppler detection (n = 1). Hettitch et al. observed an enhanced vascularization localized to the wound margins where sEVs were injected, implying a possible enhanced local impact near the injection site [83].

Inflammation

A limited number of studies (n = 16, 23.5%) assessed inflammation. Overall, sEVs exerted an anti-inflammatory effect via different mechanisms. sEVs promoted the transition of macrophages from M1 (pro-inflammatory) to M2 (anti-inflammatory) phenotypes, as evidenced by a higher M2/M1 ratio [50, 55, 96], increased expression of arginase (ARG) to inducible nitric oxide synthase (iNOS) [96], and CD206 to CCR7-positive cells [55]. Decreased infiltration of inflammatory cells, predominantly macrophages and neutrophils [50, 65-67, 72, 85, 92], was observed in sEV-treated groups, with no noticeable presence of these cells towards the endpoints of two studies [65, 92]. In contrast, inflammatory cells were abundant in control groups. These findings were in line with downregulated expression profiles of pro-inflammatory mediators such as tumor necrosis factor (TNF-α) [53, 59, 61, 67, 85, 92], IL (interleukin)-6 [53, 59, 61, 85, 92], IL-1 [49, 59, 67], MCP-1 [59], Toll-like receptor 4 and p-P65 activation and without light [67, 85] and PTEN [55, 67] as well as activation of p-STAT3 and p-AKT [50]. Both MSC-derived sEVs (n = 9) and non-MSC-derived sEVs (n = 7) showed immunomodulatory effects.

Adverse events

No harmful events were reported by any study. 12 studies (17.6%) presented information related to adverse events. 12 studies (17.6%) presented information related to adverse events.
adverse event evaluation, four of them having pre-specified in advance that the potential for harm would be investigated [57, 59, 61, 96]. Yu et al noticed no erythema, edema, or irritation in skin tissues receiving sEV local injections, and no increase in renal injury markers (creatinine and BUN) or liver function indicators (ALT and AST) [57]. Su et al. evaluated CD4+ and CD8+ T cell counts in the spleen and lymph nodes proximal to the treated sites in mice and found no difference between treatment with unmodified EVs and a negative control, although they observed a slight decrease of CD8+ T cells in the lymph of animals treated with EVs overexpressing PD-L1 [61]. One study monitored overall well-being and behavior of mice [96], whereas another checked for indicators of degeneration and necrosis [59]. However, neither study reported the outcome. Three studies assessed apoptosis in treated skin tissues using TUNEL assay [67, 68] or by evaluating Bcl-2 and iBax levels [78], all of which showed a reduction in apoptosis. Four studies made generic statements that no negative effects or discomfort [60, 62, 80, 104] or no impact on body weight [58, 82] were detected. Lastly, one study reported that allogeneic iPSC-derived sEVs did not endow recipient cells with pluripotency or elicit immune rejection following repeated doses over 14 days of treatment [42].

The effect of modifications on the “characteristics” and “therapeutic outcomes” of sEVs

Preconditioning

Nine studies employed different pre-conditioning regimens as elaborated earlier (Section 2.4.2.a). Six (8.8%) found that preconditioning improved efficacy by promoting wound closure, re-epithelialization, collagen deposition, and angiogenesis [50, 53-57]. One study found that MSC-derived sEVs were more potent when parent MSCs were preconditioned with neonatal serum sEVs versus adult serum sEVs [58]. Additionally, effects of preconditioning on sEV size distribution, cargo components, marker expression, concentration, and release profiles were examined, suggesting that preconditioning modified sEV cargo composition but not size distribution [50, 53]. Priming cells with PDGF-BB, TGF-β1, FGF2 [52], LPS [50, 53], thrombin, H2O2, hypoxia with 1-10% O2 [53], and PTHrP-2 [56] appeared to increase sEV release, whereas treatment with melatonin [55] and ATV [57] did not. Most studies reported that preconditioning did not alter sEV marker profiles [50, 54, 55, 57]. However, Geiger et al. showed that the immunogenic surface markers MHC class I, MHC class II, CD80, and CD86 were deficient in growth factor-stimulated fibrocyte-sEVs compared with their unstimulated counterparts [52]. Also, Sung et al. detected an increase in mitochondrial cytochrome C expression in sEVs from H2O2 and hypoxia-primed cells, but not in LPS, naïve, and thrombin groups [53]. In that study, a comparison of the different preconditioning agents revealed a superior effect of thrombin, highlighting the importance of optimizing preconditioning regimens.

Genetic modification

11 studies (16.2%) examined the impact of genetic manipulation of producing cells on the in vivo activity of released sEVs. Manipulation of parent cells affected the cargo of released sEVs. Five studies revealed a proangiogenic role of the engineered components, including miR-126-3p [60, 62], miR-126* [64], Nrf-2 [63], and angiopoietin-2 [47]. Other studies established the involvement of manipulated proteins and non-coding RNAs, notably TSG-6 [59], PD-L1 [61], and IncRNA H19 [67], in inflammation regulation or autophagy activation [68]. Upon comparison with sEVs from naïve cells, overexpression of Nrf-2 [63], angiopoietin-2 [47], miR-126* [64], TSG-6 [59], PD-L1 [61], IncRNA H19 [67], and mmu_circ_000250 [68] conferred accelerated wound closure efficacy to sEVs [47, 61, 63-68], enhanced re-epithelialization [47, 61, 65, 66] and/or angiogenesis [47, 63-65, 67, 68], or suppressed inflammation [59, 61, 65, 67] and scar formation [59, 64]. Importantly, none of these studies reported adverse effects.

Nanoparticle loading

Superparamagnetic iron oxide nanoparticles (Fe3O4-NPs) were reported to be efficiently loaded into parent cells and sEVs [46, 69]. Accumulation of membrane-encapsulated nanoparticles was demonstrated in the cytoplasm [46, 69] and nucleus [69] of sEV-producing cells. The use of nanoparticles and static magnetic fields significantly enhanced the beneficial impact of sEVs when administered locally [69]. Analyzing sEV content revealed an abundance of miRNA content, predominantly miR-21-5p, and/or angiogenesis [47, 63-65, 67, 68], or suppressed inflammation [59, 61, 65, 67] and/or scar formation. Importantly, none of these studies reported adverse effects.

* The arm was not specified.

Incorporation of sEVs into biomaterial scaffolds

20 studies examined the efficiency of sEV-
functionalized biomaterial scaffolds on wound healing. sEV-loaded scaffolds demonstrated superior therapeutic potential compared with either sEVs or scaffolds alone. A considerable improvement in wound closure (n = 20), new blood vessel formation (n = 14), re-epithelialization (n = 16), and collagen deposition (n = 17) was reported. 16 studies compared gel-only with gel-sEV preparations, while only three studies included sEV-only preparations, demonstrating superior effectiveness of gel-sEV preparations. Interestingly, Henriques-Antunes et al. indicated that light-triggered hydrogel-sEV preparations significantly outperformed preparations of hydrogel-sEV alone [44]. In addition, hydrogels enriched with sEVs were as potent as hydrogels loaded with bFGF in promoting wound healing [61].

A head-to-head comparison with source and conditioned media (secretome)

Few studies attempted to compare the performance of enriched sEV preparations in promoting skin healing and regeneration with that of their source and conditioned medium, i.e., the total secretome. Interestingly, seven studies compared sEV efficacy with that of their source (menstrual blood-MSCs, platelet-rich plasma (PRP), iPSCs, saliva, hADMSCs, and hucMSCs) [42, 45, 80, 88, 96, 99, 107]. Four studies detected an overall equivalent effect of sEVs and their source cells on wound closure, re-epithelialization, and collagen deposition [42, 45, 99, 107]. However, Dalirfardouei et al., observed that sEVs were superior at inducing wound closure rate, neovascularization, and M1 to M2 polarization [96]. Similarly, PRP and saliva-derived sEVs appeared to outperform PRP and saliva respectively in promoting wound closure, angiogenesis, and neo-epithelialization [80, 88]. Just two studies examined the efficacy of sEVs versus conditioned medium. While unfractonated conditioned medium was found to have a similar beneficial effect on wound closure as sEVs, with enhancement of angiogenesis and epidermis thickness [99], EV-depleted conditioned medium had an impact inferior to sEVs but comparable to that of a control [99, 109].

Meta-Analysis

26 studies were eligible for meta-analysis of wound closure outcome, involving 174 animals from 12 diabetes and 14 non-diabetes model studies. An overall significant enhancement of wound closure rate was scored for wounds treated with sEVs (SMD = 4.25, 95% CI: 3.39 to 5.11, p < 0.00001) in comparison with control (Figure 7). The heterogeneity index was relatively high (I² = 72), reflecting the variability in sEV source, preparation, and dosage regimen. Similarly, subgroup meta-analyses in diabetic and non-diabetic groups demonstrated that sEV therapy was significantly more effective than control in accelerating wound closure in both models (SMD = 4.72, 95% CI: 3.25 to 6.18, p < 0.00001; SMD = 3.94, 95% CI: 2.87 to 5.00, p < 0.00001 in diabetes and non-diabetes models, respectively). Heterogeneity was likewise high in subgroups regardless of the disease model (I² = 74%, and 71% in diabetes and non-diabetes models, respectively).

Among all included studies, 22 assessed scar formation, of which 13 studies used scar width (in μm) as the scar assessment metric for examining the influence of sEV interventions. Of the 13 studies that used this metric, nine studies reported sample size and were included in the meta-analysis (a total of 60 animals; two studies used diabetes models, and seven used non-diabetes models). Overall, sEV therapy resulted in a substantial decrease in scar width compared with controls (SMD = -5.85, 95% CI: -7.98 to -3.73, p < 0.00001). However, when subgroup analysis was performed, the difference in scar width between the control and experimental groups in diabetes studies was insignificant (SMD = -12.78, 95% CI: -33.75 to 8.19, p = 0.23). Indeed, the results of only two studies (11 animals) are insufficient to draw conclusions from a meta-analysis, particularly given the high heterogeneity index (I² = 92%). In comparison, sEVs significantly inhibited scar development in the non-diabetic group (SMD = -5.69, 95% CI: -7.79 to -3.58, p < 0.00001). Overall heterogeneity of the effect was high (I² = 77%) (Figure 8).

Nine studies assessing blood vessel density (number of blood vessels/mm²) to evaluate the effect of sEV transplantation on angiogenesis were eligible for meta-analysis (44 animals), and subgroup analysis (5 diabetes model studies of 30 animals; 4 non-diabetes model studies of 14 animals) was thus performed. A meta-analysis revealed an overall significant impact of sEVs in supporting blood vessel development (SMD = 5.03, 95% CI: 3.17 to 6.88, p < 0.00001). The heterogeneity index was moderate (I² = 60%). In subgroup analysis, both diabetic and non-diabetic subgroups demonstrated a significant positive effect of sEV treatment compared with control (SMD = 5.42, 95% CI: 2.97 to 7.88, p < 0.0001; and SMD = 4.94, 95% CI: 1.26 to 8.63, p = 0.008; in diabetes and non-diabetes models, respectively) (Figure 9). Heterogeneity indices in the two groups were moderate (I² = 66% and 64%, in the diabetic and non-diabetic groups, respectively).
### Figure 7.
Forest plot of mean difference of wound closure rate of 26 studies following sEV interventions in diabetic or non-diabetic skin wound models in comparison to placebo controls. The diamond represents the pooled SMD. sEV interventions were effective in promoting wound closure, (pooled SMD = 4.25, 95% CI: 3.39 to 5.11, \( p < 0.00001 \)).

### Figure 8.
Forest plot of mean difference of scar width (in µm) of nine studies following sEV interventions in diabetic and non-diabetic wound models in comparison to placebo controls. The diamond represents the pooled SMD. sEV interventions were effective in inhibiting scar formation, (pooled SMD = -5.69, 95% CI: -7.79 to -3.58, \( p < 0.00001 \)).
Figure 9. Forest plot of mean difference of blood vessel density (number of blood vessels/mm²) of nine studies following sEV interventions in diabetic and non-diabetic wound models in comparison to placebo controls. The diamond represents the pooled SMD. sEV interventions were effective in promoting new blood vessel formation, (pooled SMD = 5.03, 95% CI: 3.17 to 6.88, p < 0.00001).

We also performed meta-analyses of the wound closure rate outcome for studies that 1) characterized their EV preparation as required by MISEV2018 (section 2.7.4.a) and 2) disclosed the number of animals used in the experiments. A total of ten studies were considered eligible by these criteria (4 studies of 21 diabetic animals and 6 studies of 50 non-diabetic animals). We performed a sensitivity analysis that resulted in excluding one study [82], which produced considerable heterogeneity in the meta-analysis. Thus, only nine studies were included in the meta-analysis (4 studies of 21 diabetic animals and 5 studies of 40 non-diabetic animals) (Figure 10). Consistent with our earlier findings, sEV intervention had a substantially favorable influence on wound closure across all studies (SMD = 3.50, 95% CI: 2.61 to 4.38, p < 0.00001) and in subgroup analyses (SMD = 3.13, 95% CI: 1.49 to 4.78, p < 0.00002; SMD = 3.80, 95% CI: 2.85 to 4.76, p < 0.00001) for diabetes and non-diabetes animal models, respectively (Figure 10A). The sEV interventions, on the other hand, had a more homogeneous effect, as demonstrated by the lower I² statistics in each subgroup (I² = 48, and 22%, respectively) as well as in the overall meta-analysis (I² = 41%), in contrast to the higher heterogeneity observed in the overall analysis of wound closure that also included studies that did not comply with MISEV2018 (Figure 7). The funnel plots for the four meta-analyses showed no evidence of publication bias (Figure 11).

Discussion

We have systematically reviewed the available evidence on therapeutic efficacy and safety of sEVs in wound healing and skin regeneration using animal models. We summarize recent research in this area and critically appraise the quality of the included studies, with an emphasis on methodology, reporting quality, and compliance with related guidelines. By doing so, we inform the scientific community of the main findings and the quality of evidence provided by the current literature. We detected a recent exponential surge in publications exploring sEV therapeutic potential in wound healing and skin regeneration, highlighting growing interest and enthusiasm towards sEV research in this area. 68 studies met our inclusion criteria, exploring a diverse spectrum of sEVs: not only from MSCs, but also from other cell types, as well as from complex tissues and biofluids. Although separated EV preparations contain mixed populations of sEVs, and not only exosomes (of endosomal origin), the bulk of the analyzed studies continued to describe their preparations as “exosomes,” to which they related the observed functionality. In absence of techniques capable of identifying EVs from distinct intracellular origin [110], it is likely that these particles were instead a broader population of sEVs [14, 26]. Throughout this discussion we will highlight unresolved issues and address several crucial questions, beginning with this central, fundamental question:

Was sEV intervention therapeutically effective?

Overall, our systematic review and meta-analysis concluded that sEV intervention had
significant efficacy in promoting skin regeneration in diabetic and non-diabetic animal models. This finding agrees with earlier systematic reviews that examined the therapeutic efficacy of MSC-derived sEVs in wound healing in general [111] and diabetic wound healing in particular [112]. Based on our analysis, sEV intervention targets multiple features of the intricate healing process, resulting in enhanced regeneration and suppressed fibrosis.

As prior research established that deficient vascularization is a key contributor to the chronicity of diabetic lesions [113], it was remarkable to observe the proangiogenic effect of sEVs on diabetic wounds, which was on par with the effect on non-diabetic wounds. This was supported by our meta-analysis findings that quantitatively revealed that there was no substantial difference between diabetic and non-diabetic models. Diabetic lesions usually exhibit diminished levels of VEGF, which contributes to compromised angiogenesis [114]. sEV interventions boosted blood vessel regeneration and maturation with increased expression of VEGF.

![Figure 10. A) Forest plot of mean difference of wound closure rate in diabetic and non-diabetic wound models of studies that characterized sEV based on MISEV 2018. The diamond represents the pooled SMD. A) sEV interventions were effective in promoting wound closure, (pooled SMD = 2.61 to 4.38, p < 0.00001). B) A sensitivity analysis resulted in excluding one study [82], causing considerable heterogeneity in the meta-analysis (Figure 10A, without the study, and Figure 10B with the study, I2 = 41% vs 79%).](https://www.thno.org)
Only a few studies addressed the immunomodulatory effects of sEVs. Nonetheless, those studies provided evidence for sEV modulation of the inflammatory milieu, favoring the transcriptional transition of pro-inflammatory M1 to anti-inflammatory M2 macrophages and reduction of immune cell infiltration. This is crucial for the inflammatory phase to resolve and the subsequent proliferative phase to commence, as persistent inflammation is a typical feature of non-healing wounds [115]. Accordingly, sEVs reduced the production of pro-inflammatory mediators such as TNFα, IL-1, and Toll-like receptor 4 (TLR4), whilst elevating levels of anti-inflammatory counterparts such as IL-10. It is worth noting that this immunomodulatory activity was not limited to MSC-derived sEVs. More studies are needed to explore the potential and mechanisms of sEV interventions on inflammation in this context.

Furthermore, sEVs promoted re-epithelialization by enhancing skin cell proliferation and extracellular matrix secretion. sEVs fostered deposition of collagen, especially collagen type I, the major structural protein of the skin, and supported collagen maturation and organization. Although collagen production is critical for efficient wound closure, excessive production may lead to tissue fibrosis and scarring [116]. In ideal healing scenarios, collagen production increases during the proliferation stage, then decreases and matures during the remodeling stage. Nonetheless, our evaluation of the reports on collagen expression levels and ratios of collagen type I/III at later phases of healing revealed discrepancies among studies, demanding further investigation. Even so, by examining scar formation macroscopically and histologically, a number of studies noted a considerable reduction in scar indices following sEV application, supporting the anti-scarring role of sEVs. Myofibroblasts, which are key contributors in collagen deposition and wound contraction [117], were reported to be suppressed, and there was no evidence of fibrosis or hypertrophic scar development. Most studies had relatively short follow-up periods (14- or 21-days post-wounding), though, limiting their ability to thoroughly assess collagen and scar development and maturation in healing tissues. It is estimated that scars in rodent models mature within 70 days of injury [118]. Hence, it is necessary that relevant endpoints be defined and validated for future studies evaluating sEV usefulness in minimizing scarring and promoting tissue maturation. We observed that the protein marker α-smooth muscle actin (α-SMA) was used both to examine myofibroblast abundance and to mark blood vessel formation, revealing suppressed levels in the former and elevated levels in the latter. This creates some uncertainty over the actual expression of this marker in response to sEVs. Further examination of the utility of α-SMA as a differential marker may be needed.

Apparantly, sEV modulation of the different
healing mechanisms improved wound closure and tissue regeneration, with no differences in closure times for diabetic and non-diabetic wounds. sEVs likely improved the wound microenvironment, eventually encouraging tissue repair [118]. However, some studies found wound closure acceleration throughout the follow-up period, and others only during the early or late stages of healing. This could be due to heterogeneity of sEV sources, preparation methods, and delivery strategies, necessitating additional head-to-head comparisons. Given the challenges of restoration of appendages in adult skin [119, 120], it was remarkable that sEVs supported the regrowth of hair follicles and sebaceous and sweat glands, indicating high-quality skin repair.

Comparisons with other treatment modalities were very limited. Interestingly, one study reported superior reparative activity of sEVs compared with the FDA-approved PDGF-BB therapy [44]. Also, comparisons of sEV preparations with their cell sources demonstrated comparable, if not superior, efficacy in stimulating skin repair and regeneration. Such comparisons are necessary to establish the relative value of sEVs over cells. Theoretically, cells may be more beneficial than EVs: although EVs have a “set message” that may not further respond to the microenvironment, cells might perceive signals from the milieu and respond by releasing various factors, including EVs. Thus, observations of sEV efficacy versus cells are crucial to establishing comparative value. Efficacy could be due in part to EVs being less immunogenic and carrying a unique payload that may be delivered in trace levels, yet exert a profound impact [121].

To summarize, our in-depth analysis of the various aspects of wound healing and skin regeneration indicates the usefulness of sEVs as regenerative agents to promote skin repair. In the context of diabetic wounds, the evidence reviewed demonstrated that sEV interventions may overcome the barriers to lesion repair. Nevertheless, longer durations of examination may be required to effectively establish the influence on tissue maturation.

While some studies evaluated native sEV efficacy, others modified EV content and functionality, bringing us to the following question:

**Could modifying sEVs influence their therapeutic efficacy?**

Modifying cells to improve their therapeutic qualities has been extensively investigated in recent years, with encouraging results. Several studies examined if manipulation of EV-producing cells by a variety of strategies translated into improved therapeutic functionalities of released sEVs in wound healing and skin regeneration. Endogenous loading of sEVs was achieved by physical loading with nanoparticles or genetic modification to overexpress certain proteins or nucleic acids. However, efficiency of loading and quantitation of cargo were seldom assessed. Furthermore, priming cells with assorted physiological and pharmacological cues showed a differential influence on the release profile, payloads, and hence downstream functionality of released sEVs [53], emphasizing the need for careful protocol and agent selection. Culturing MSCs with sEVs from neonatal versus adult sources resulted in more potent regenerative potential of released EVs [58], showing the importance of stimulant selection in sEV production. Notably, sEVs derived from modified cells had improved healing properties compared with their non-modified counterparts at all levels (re-epithelialization, proliferation, angiogenesis, collagen deposition, and maturation). It was not clear, however, if these modifications affected the stability, half-life, targeting (tropism), or internalization of these sEVs in injured tissues. On the other hand, encasing sEVs with biomaterials boosted their efficacy, possibly due to an enhanced release profile or other properties.

Indeed, the capability to manipulate EVs has sparked interest in creating “designer EVs” as a means to achieve desirable properties compared with native EV forms, including using them as drug delivery vehicles [29]. Besides manipulating parent cells (i.e., endogenous loading) as described by most studies here, manipulating sEVs post isolation is also possible. Such exogenous loading has been attempted passively [122] and actively (e.g., by sonication [123]), with varying success rates and loading efficiencies. In an exhaustive review aimed at developing a preliminary set of guidelines to standardize reporting of exogenous EV loading, Rankin-Turner et al. were surprised at the paucity of research into fundamental parameters such as incubation time and temperature, along with the variability and inconsistency in strategies [124]. They stressed the need for optimizing loading procedures, which we also fully endorse.

In the midst of numerous studies aimed at improving sEV function, none reviewed here explored altering the sEV surface to enhance targeting, retention, or delivery, or to prevent non-target uptake to prolong EV half-life. For example, conjugating EVs with polyethylene glycol (PEG) might enhance stability in the circulation and reduce build-up in the liver [125], most probably by masking scavenger receptors. Likewise, EV CD47 extends half-life by signaling macrophages, “do not eat me” [126]. EV surface modification has been done...
by chemical modification (CLICK chemistry and enzymatic conjugation) [127] and membrane cloaking [128]. These strategies may be worth investigating in the future to increase sEV stability and targetability in skin tissues.

Translational challenges to sEV therapy development

Despite encouraging findings, we have identified translational challenges that must be addressed before moving forward with human clinical trials.

Source

What is the ideal source of sEVs? In our review, sEVs were derived from tissues, biofluids, and cultured cells (Figure 4), but research comparing the efficacy of different preparations is lacking. Only a single study compared the efficacy of human umbilical cord-derived MSCs with human lung fibroblasts (HFL1), concluding that MSC-EV preparations were more potent in enhancing skin regeneration [45] and suggesting source-dependent variation in activity. This emphasizes the need for evidence-based source selection. No studies examined the effect of 3D culture or bioreactors as scalable culture approaches for generating sEV skin therapeutics. Additionally, production of biological therapeutics requires verification of source identity. We examined compliance with ISCT guidelines for minimal identification of MSCs [40], finding that the criteria were met by just over half of the MSC-EV studies. To exclude heterogeneous and non-MSC cell populations, these criteria are important [129, 130], and ongoing efforts to develop standardized EV potency assays are crucial [130].

Depletion of exogenous EVs

In vitro, serum-derived EVs from culture medium additives may contaminate EV isolates. These EVs might not negatively affect the potency of therapeutic EVs, but their removal may be necessary to ensure reproducibility. Also, contamination with xenogeneic EVs (e.g., from FBS) could complicate translation. Almost half of the studies included in this systematic review collected sEVs from serum-free media. While this is a good strategy to minimize contaminating EVs, switching to a serum-free condition might starve and stress the cells [131], modifying EV release profile and biological properties [132]. Depleting FBS of EVs before supplementation, primarily using ultracentrifugation, can also alter the activity of cultivated cells [133], although gradual transitioning can help [129]. However, depletion is rarely complete. Driedonks et al. revealed that various depletion strategies had a varying influence on the concentration and types of fetal calf serum RNA contaminants in medium and that optimizing purification techniques can result in lower contaminant levels [134]. While a minimum of 18 hours of ultracentrifugation was recommended to remove bovine EVs [135], depletion of only 70 minutes to three hours was reported in studies we examined. Additionally, contaminants can be present even in serum-free and so-called “chemically defined” media [136]. Because some of the reviewed studies did not disclose their depletion protocols, we cannot fully assess the degree of purity of EV preparations. Indeed, MISEV2018 asserts the importance of specifying the precise source, procedures, and reference for depleted components, as well as the significance of verifying the “EV-free” status (or otherwise) of all supplements [14].

Separation and purification

Separating a specific EV subpopulation effectively while eliminating non-EV impurities may be one of the biggest technical hurdles in developing EV therapeutics [137, 138]. Since “the process is the product” [139], different preparation procedures, even starting with the same source, might yield a diverse mixture of co-isolates and sEV subsets [140] with varying attributes such as size and biogenic origin. Thus, different separation techniques could lead to functional and physical differences [140]. While it is still not clear how the different sEV subgroups with varying roles (e.g. disposal vs. signaling) and origin (endosome vs. plasma membrane) interact to influence the final healing outcomes [141], contaminants, on the other hand, were found to affect the therapeutic effect of EV preparations [142]. Interestingly, it cannot be excluded that so-called contaminants might even contribute to desirable effects.

In part for this reason, MISEV2018 does not recommend a specific separation strategy, and combining multiple strategies may improve on single technique approaches. If the goal is to attribute all therapeutic effects to EVs only, high purity preparations should be obtained [14]. Multiple pre-processing steps are needed to isolate EVs from complex biofluid or tissue sources, and thus specific protocols must be tailored to the particular source to remove contaminants before EV separation [143]. The studies we reviewed used diverse separation procedures. Heterogeneity in the separation methods reflects a lack of standardization, hampering comparability and possibly delaying clinical translation [141]. Classical methods like the various protocols of ultracentrifugation still predominate, even though this technique may result in aggregation.
[144] or functional [140] of EVs and has limited scalability [145]. Precipitation-based concentration kits were also popular among the analyzed studies despite high protein contamination [146] and debatable usefulness [129, 146]. Liangsupree et al. found a trend towards size exclusion chromatography (SEC) in recent years [147], but we did not observe this trend for the field that we reviewed. We also did not see uses of size-based separation techniques such as tangential flow filtration (TFF), SEC, or asymmetrical flow field-flow fractionation, or affinity-based technologies. Nonetheless, there was an increased reliance on method combinations and washes to improve purity.

Separation methods for sEV therapeutics should be selected for their scalability, automation potential, ability to optimize the purity and recovery of target sEVs [147], and translatability. Given the parallels between EVs and viruses, established virus purification techniques could be useful for separation and purification of EVs on a large-scale [145]. Concerningly, none of the research reviewed here reported producing GMP-compliant sEVs, mirroring a recent systematic review of EV therapies for lung conditions [148]. Unfortunately, high cost is not a valid excuse for lack of GMP compliance, as EVs will otherwise not be usable in the clinic.

Characterization

Given the inherent difficulties of standardizing sEV source and separation techniques, quantitative identity measures are required for improved post-separation sEV identification, quality control, and comparability. Characterization covers three aspects: identity, integrity, and purity [14]. MISEV2018 guidelines recommend that, at a minimum, the concentration of EV preparations (such as protein and particle count) and EV markers (proteins expected to be enriched or depleted in EVs) should be determined. Of these markers: (1) at least two EV-protein specific markers (referred to as positive or enriched markers) must be detected to confirm EV isolation: one that is an integral membrane or membrane-anchored protein, signifying the presence of the lipid bilayer, and another that is an established cytosolic protein, implying the presence of enclosed cytoplasmic content and not just membrane fragments; and (2) at least a negative or depleted protein marker including source-related protein contaminants (such as albumin in EV plasma or uromodulin in EV urine samples), subcellular compartments, or cell death artifacts. Moreover, MISEV2018 suggests two complementary single vesicle analysis approaches to visualize and evaluate EV biophysical features. Here, preparations were mostly evaluated for protein concentration, particle count, morphology, and EV protein markers, employing multiple techniques; but just a few satisfied all MISEV2018 characterization criteria. To determine size distribution, nanoparticle tracking analysis (NTA) was the most-used method. Since our inclusion criteria stipulated that studies of sEVs with a size distribution beyond 30-200 nm were to be excluded, the studies that were included fell within this range. As different sizing platforms may have varying detection limits resulting in diverse outputs, employing multiple orthogonal technologies may be useful [149].

Although NTA was used to measure particle concentration, most studies reported protein concentration, but not particle concentration, usually by colorimetric assays like BCA. However, data on total protein yield were mostly lacking. Total protein assays do not distinguish EV and non-EV proteins, i.e., sEV preparation purity [150]. As a result, the MISEV2018 guidelines advocate assessing protein-to-particle, lipid-to-particle, or lipid-to-protein ratios to indicate sample purity, as well as negative or depleted markers. Since ratios and negative markers were rarely documented in the reviewed research, the purity of the tested preparations cannot be assessed. It is important to note that co-isolated impurities should not be confused with the extravesicular cargo or loosely-associated factors [17], which may contribute to EV bioactivity [151-153], although the distinction between the two is still being defined [17].

Interestingly, our meta-analysis revealed a lower heterogeneity index for the wound closure rate outcome for the studies that adhered to MISEV2018. However, the reviewed articles emphasized “positive” EV markers, particularly tetraspanins (CD63, CD9, and CD81), over cytosolic markers (TSG101, Alix, and HSP70). While tetraspanins may be functional [154], their involvement in sEV-mediated skin wound healing is still largely unknown. Western blot was the preferred approach in these studies due to its utility for bulk analysis and protein marker identification, but it is less helpful to analyze EV subpopulations or to understand marker allocation within positive subpopulations [150]. Single-particle approaches like flow cytometry were less popular here. Morphology was assessed mainly by TEM. Collectively, these findings are consistent with previous reports, in that these analysis techniques remain the most favorable by the EV community [155]; however, expanded approaches are needed to understand the contributions of EV subtypes and non-EV components.

Encouragingly, opportunities for advancement abound. Despite the unique signature of lipids in EVs,
they were rarely characterized in the covered studies. The current state of knowledge on the structure and function of EV lipids is still rudimentary [156]. EV lipids may play a part in mediating EV bioactivity [157], including during senescence induction [158]. Here, only a single study identified sEV lipids as key players in the mechanism of sEV-mediated stimulation of wound regeneration [83], highlighting the need for more investigation. Similarly, standardized reference materials are needed to facilitate benchmarking. Nanoparticles and EVs are being engineered or recombinantly synthesized to allow calibration, validation, and quality control [150]. As EV research advances, characterization technologies are also being applied in novel ways to EVs: for example, ion-mobility spectrometry (IMS), Raman spectroscopy (RS), and nano-flow cytometry (Nano-FCM) [159].

**Dosage regimen**

Optimization of dosing (method of delivery, amount per administration, frequency, interval between doses, and duration of the intervention [160]) is crucial to achieve full therapeutic potential while mitigating off-target effects. For wound healing and skin regeneration, the optimal sEV dosage regimen has yet to be established.

**Methods of administration**

In most studies we reviewed, sEVs were directly infused to the wound site, primarily via injection, and to a lesser extent by direct application after incorporation into biomaterial scaffolds. Local delivery of sEVs has several advantages, circumventing phagocyte and circulatory clearance (primarily in the liver and spleen [126]) while increasing bioavailability in target tissues and reducing the required therapeutic dose. sEVs were found to exhibit tropism for specific organs (lung, liver, kidney, spleen) when delivered to the systemic circulation [161], but the single study that compared sEV intravenous (IV) with subcutaneous (SC) administration produced an unexpected finding: IV-administered sEVs promoted skin regeneration more effectively than SC-administered equivalents, homing to the wound bed starting from day one of treatment [94]. While prior studies suggested preferential affinity of sEVs for injured tissues [162], the reason for the observed variation in therapeutic impact between IV and SC requires additional investigation.

Non-healing lesions requiring protracted therapy may have limited clinical translatablebility because of patient compliance. Incorporating sEVs into biomaterial scaffolds might reduce the frequency of application and enable delivery of sEVs in a targeted and concentrated manner. Here, hydrogels (both synthetic and natural) were the most preferred biomaterials. In these biomaterials, EVs are shielded against rapid clearance and destruction in the hostile wound environment, prolonging their duration of release and bioavailability [44]. Hydrogel dressings are typically used to rehydrate the injured tissues, insulate against infections, and provide a temporary framework for host cells to penetrate and adhere to before being replaced by native ECM [163], or for their antibacterial qualities [164]. Combining these qualities with the proangiogenic, pro-regenerative, anti-inflammatory, and anti-scarring features of sEVs was beneficial. Several studies in this review utilized “smart” biomaterials: temperature, light, and pH-responsive, enabling spatially and temporally orchestrated release of sEVs. Light-triggerable hydrogels loaded with sEVs accelerated wound closure better than non-triggered hydrogels or even several doses of sEVs, underscoring the critical role of the controlled release system in boosting healing kinetics [44]. Advances in 3D bioprinting will enable scaffolds to be tailored to each patient's unique demands. It is critical, however, to investigate the possible interaction of biomaterials with sEVs, and their effect on the functionality and physical attributes of the vesicles.

**Dose and frequency**

To date, there are no guidelines for EV dose selection. Here, experimental doses ranged from 2 to 5000 µg of protein. In most studies, dose selection was unclear and did not account for wound size, condition, type of injury, skin type, animal weight, or route of administration. Since protein levels are influenced by purity, dosage estimation may also be unduly influenced by impurities, which were mostly unreported. Dose-response studies were also lacking, and dose was based only on in vitro experiments in 2D in some studies, although the dose needed in vivo to present the therapeutic benefits may differ substantially from that projected in vitro [16]. Two studies concluded that sequential administration of small doses was superior to a single administration of a larger dose [44, 82]. Furthermore, sustained release from a light-responsive biomaterial scaffold outperformed high-dose and sequential administration regimens [CITE]. Both head-to-head comparisons and quantifiable measures of potency and quantity of biotherapeutic molecules in EVs are needed to establish dosage [165].

**Labeling and tracking of sEVs**

Despite the importance of in vivo stability, only six studies tracked transplanted sEVs (Table 4). In
these studies, sEVs were found to be localized to the wound bed and were detected in the cytoplasm of skin tissue cells. However, the wide range of follow-up time points and duration hampered comparability and conclusions about how long a single sEV dose remained detectable in tissue. While one study observed that sEV signals lasted up to 21 days (IV delivery) [94], another noted that they disappeared after only five days [87]. Sjöqvist et al. reported a loss of signal four days after injection due to interference by hair growth and scab formation; however, the signal could be detected later after extraction of tissue (ex vivo) [82]. Another study noted that the drop in sEV detection signal was less pronounced for light-triggered hydrogels than for free sEVs, pointing, as previously highlighted, to the potential of sustained-release systems in prolonging sEV bioavailability.

Accelerated clearance of systemically introduced sEVs after repeated administration has been reported in the literature, probably due to development of immune responses [166]. Further investigation is needed to determine if this happens in skin tissues. Additionally, the depth to which sEVs penetrated damaged tissues was not investigated. When Zhang et al. assessed the potential of sEVs to permeate an ex vivo model of intact human skin, they noticed that sEVs could not penetrate beyond the stratum corneum of the epidermis, proposing it as a possible area of activity [167]. However, sEVs would plausibly penetrate deeper in skin injury versus intact skin because of barrier disruption. This should be tested in skin injury.

Beyond general dose and tracking questions, we believe that upcoming studies should address fundamental questions including: 1) What proportion of sEVs are internalized by cells? What are the target cells? Is internalization required to exert the therapeutic effect? How about surface ligand-receptor interactions? Does uptake of sEVs necessarily mean functional delivery of payloads (membrane-membrane fusion)? Are sEVs similarly internalized by different types of cells in the skin, or do they show different tropisms? What is the influence of cell source or various preparation techniques on sEV uptake and tissue distribution?

Importantly, sEVs were predominantly labeled with fluorescent lipophilic dyes in the analyzed studies. These dyes sequester into the lipid areas of the phospholipid membranes and are highly photostable [168]. As this is a widespread approach for in vivo tracking of labeled cells with negligible alteration of functional and mechanical properties of cells [168], this approach may not be preferable for tracking sEVs due to the lack of specificity. Unfortunately, lipid dyes also label cellular membranes [168], and some have been found to have low EV staining efficiency [169], bind to non-vesicular impurities such lipoproteins and soluble proteins [170], or aggregate into nano-sized micelles that can be confused with sEVs [130, 169]. They could also leak from EVs and persist in tissues, greatly outlasting the labeled EVs in vivo due to long half-life, causing misinterpretation of EV fate in vivo [171]. This lack of specific labels makes tracking EVs a challenging task. New labeling techniques with improved performance are emerging, such as radiolabeling [172] and magnetic labeling [173], yet all with pros and cons, mandating use of complementary technologies for a better understanding of EV distribution in tissues [130].

Relevance of animal models and external validity aspects

The studies here investigated rodent models for sEV efficacy (97% of studies), including diabetic and non-diabetic mice and rats. Type 1 diabetes was predominantly modeled, while type 2 diabetes, the most prevalent of the two, was underrepresented. Similarly, full-thickness excisional wounds were assessed more frequently than other lesions, such as diabetic foot ulcers, pressure ulcers, incisional or partial thickness wounds, and burns.

Although rodent models have been crucial in the initial stages of new drug screening and testing, inherent structural and physiological differences between rodent and human skin have spurred heated arguments on the translational relevance of these models [174]. Indeed, 90-95% of drugs that show promise in pre-clinical trials fail to translate to the clinic [175]. Despite similarities in portraying the four overlapping phases of wound healing, variances in life expectancy, the number of skin layers and thickness, and healing mechanism (e.g., contraction-based) are among the many factors that might undermine clinical applicability [174]. Furthermore, the extent to which existing diabetes models accurately represent chronic, non-healing wounds remains an open subject [3]. For example, in the reviewed studies, diabetic wounds in control groups were capable of independent healing. Also, relevant non-healing wound scenarios such as infected wounds or aged-animal wounds were understudied. Collectively, these concerns challenge the “external validity” of the studies, that is, the degree to which the outcomes can be generalized to human disease [176].

Since each strategy has limitations, we recommend a combination of approaches. Apart from rodent models, which have already demonstrated
significant success in promoting cutaneous regeneration, larger animal models such as swine and non-human primates might be important to study. Together, evidence from diverse species might better predict human response [177]. Supporting data from emerging approaches that aim to achieve the 3R principles (replacement, reduction, refinement) for animal experiments are also valuable. This includes evidence from technologies such as microfluidic tissues-on-a-chip that involve multiple system interactions and enable real-time mechanistic readouts [178]. Other approaches include in silico experiments, artificial intelligence, and machine learning [179]. Additionally, more representation of lesions such as burns and diabetic ulcers is needed. Consistent evaluation of the testing system's predictability and applicability is critical for determining the effectiveness of each approach.

Internal validity aspects

Successful translation requires not only external, but also "internal validity" [176]: the rigor with which experiments are designed, conducted, and reported [176]. Inadequate reporting impedes assessing experiment validity and is a common issue in preclinical research [180]. In some domains, the scientific community has developed guidelines and checklists of a minimum set of items to be documented in comprehensive and transparent reporting, such as the MISEV2018 recommendations [14], EV-TRACK, and the MSC-EV criteria mentioned previously. Compliance with these guidelines has been correlated with enhanced reporting, experimental design, and conduct [181, 182]. Here, we observed that incomplete reporting affected many aspects of research design and methodology. For instance, there was an overall poor reporting of pre-processing and EV source, the number and age of animals, how sample size was determined, and of numerical data for means or variation measures for the outcomes. In some cases, experiments were reported that were not covered in the method section. Only a single study submitted procedures to EV-TRACK [82]. This incomplete reporting limited our ability to examine key elements that are identified by the SYRCLE’s ROB tool as plausible sources of bias in animal experiments [95]. As a result, we concluded an unclear risk of bias for most of the elements (Figure 6), presenting reasonable grounds for concern about the true level of bias in the included studies. Failing to handle internal validity threats is likely a key contributor to overestimated effect sizes in preclinical research [183]. Adoption and documentation of better reporting measures would help to mitigate or identify bias and increase confidence in the evidence and quality of the experiments [184]. The non-mandatory nature of the reporting guidelines may explain their low uptake in published studies. While authors should strive to provide detailed experiment reports, journals and funding agencies are the gatekeepers and should endorse compliance with reporting guidelines [180].

Is sEV intervention a safe option in skin regeneration therapy?

The possibility of adverse reactions to sEV therapy received scant attention, although the few studies that examined this possibility detected no serious adverse effects. Interestingly, no reports indicated immune rejection even of allogeneic or xenogeneic preparations, which constituted the majority of the tested preparations. Of note, Lu et al. observed a mild immune response to allogeneic iPSCs but not to their sEVs, although allogeneic sEV viability in treated tissues was inferior to that of their autologous counterparts [42]. These findings collectively are in line with prior research supporting sEV safety in treating various conditions [20]. Although hundreds of animal studies and clinical trials have demonstrated the biosafety profile of sEVs, safety assessment is integral to any novel therapeutic product development. As emphasized earlier, each EV preparation is a unique product due to the heterogeneous components involved in its manufacture [139]. In the absence of guidelines by regulatory bodies to assess the associated risks, verification of each product’s safety is necessary [29]. This entails evaluating the potential risks associated with each stage, from source selection to delivery to patients [185].

Given that sEVs are messengers for their parent cells, caution is needed in source selection. While MSCs have an established general safety profile [20, 129], sEV therapies are derived from various sources, not just from MSCs. Some of these sources have unclear safety profiles. Earlier studies in the literature showed examples of immune responses to immune cell-derived-EVs, for instance, when delivered to patients [186]. Additionally, immortalized cell lines and cancer cells may pass along oncogenic components through EVs [141, 187]. EV-associated extravesicular cargo [17] such as protein coronae may also elicit immune responses, which should be considered [188].

As discussed earlier, adverse effects associated with manipulation of source cells or EVs should also be assessed. For instance, extending EV half-life might have the potential to induce fibrosis. Additionally, the risks associated with recurring sEV administration, overdosing, and off-target interactions merit further
examination. An improved understanding of sEV biodistribution and bioavailability in treated tissues will surely aid in deciphering these interactions [141]. It is also imperative that regulatory approval is obtained before the initiation of clinical trials and application in clinics to confirm safety and efficacy [29]. Unlicensed “exosome”-containing products that might result in devastating consequences for patients led the FDA to issue a “Public Safety Notification on Exosome Products” [189], stressing the need for regulatory approval to ensure safety and efficacy before initiating clinical trials and application in clinics [29].

Concluding remarks and future prospects

Providing effective therapeutic options to promote skin regeneration is a key goal that has yet to be met, placing a continual burden on public health. This health burden is projected to continue to grow as diabetic and elderly populations expand. sEV therapy is proposed as a promising biological therapeutic approach that is able to potentiate skin regeneration. In this review, we have systematically examined studies evaluating sEV potential to induce wound healing and skin regeneration. We critically analyzed findings, reporting, and methodology and discussed strengths, pitfalls, and challenges. Collectively, our critical review of the available preclinical evidence supports the therapeutic efficacy and safety of sEVs in cutaneous wound healing and skin regeneration across all outcomes (wound closure, angiogenesis, anti-inflammatory, re-epithelialization, scarring reduction, collagen production), regardless of cell source, production protocol, or disease model. Modifying sEV cargo appears to potentiate therapeutic functionality, resulting in better healing compared with unmodified sEVs. Moreover, biomaterial scaffolds could offer a promising tool for targeted sEV delivery.

However, these exciting findings should be interpreted with caution for several reasons. First, most studies have unclear risk of bias, and insufficient reporting hampered our ability to make an informed judgment. Second, the absence of purity assessment makes it difficult to attribute the observed efficacy to sEVs versus co-isolates. Third, the animal models used may not be faithful representatives of human disease, although this is a general limitation of animal testing and not unique to sEVs. Lastly, heterogeneity in sEV production, sources, characterization, and dosage regimens challenge direct comparisons.

We believe that adherence to established guidelines such as MISEV2018 will facilitate the conduct of rigorous research and enhance its validity. The high failure rate in translating preclinical discoveries to the clinic represents a waste of time, effort, and resources. Therefore, applying rigor and analyzing risks from the early stages of development will largely contribute to greater translatability and success stories. As a result, we urge researchers to follow best reporting practices, including a detailed description of their rigorous work in order to enable reproducibility, comparability, and evaluation of the studies’ evidence. Submission to EV-TRACK is a great approach to enhance transparency and may also serve as a guide for authors regarding which items should be reported. To account for the shortcomings of confining research to rodent models, we propose examining a variety of models, including non-rodent and non-animal models. We further recommend that the follow-up period be extended to adequately assess the effect of sEVs on the healed skin maturation and scarring, as well as the immunological response. Future research should cover other skin lesions as well, such as burns, ulcers, incisional ischemic lesions, and more representative models of diabetic type 2 and non-healing wounds.

Moreover, there are several unresolved issues that warrant future research. These include establishing the optimal sEV source with the minimal possible risks and greatest therapeutic efficacy as well as identifying the components responsible for the ascribed functions. In this regard, the evaluation and reporting of the preparations' purity should not be overlooked and should be regularly identified. Furthermore, more research is needed to establish the basis for dosage regimen selection to achieve the best outcome; and to evaluate the in vivo pharmacokinetics and pharmacodynamics of sEVs in skin tissues. Since the evaluation of possible unwanted effects has received less attention, it is critical for future research to conduct a full review of the safety aspects associated with sEV therapy of skin lesions. Comprehensive characterization is key in evaluating the role of EV cargo safety. Indeed, the variability of sEV production processes, sources, and characterization presents a challenge, however, the development of quality controls and suitable reference materials might provide the foundation for standardization, allowing for lab-to-lab comparability. Nonetheless, the current expansion of novel and intriguing approaches is encouraging. Also, personalized sEV skin therapy products might be the future direction as each skin type, condition, and defect may have different therapeutic demands.

The future for sEV skin therapies seems bright if we learn the right lessons. Along the way, decades of experience with enveloped viruses and synthetic nanoparticles, which have many similarities with sEVs, have much to teach the EV field, particularly
regarding the former’s large-scale production and purification and the latter’s delivery. Safety and efficacy evaluation of biologics (such as cell therapy) may also serve as reference models for EV therapy. However, clinical applications should not be hastened prior to clinical trials and regulatory permissions, as this will put patients at risk and may jeopardize the field. Although the road to the clinic is still paved with obstacles, sEV therapy holds tremendous potential as a biological cell-free therapeutic modality capable of promoting wound healing and skin regeneration. Collaborative efforts are needed to realize this potential and successfully translate it into practice.

**Methodology**

**Literature search strategy**

The protocol of this study was developed a priori, peer-reviewed, registered, and published in the International Prospective Register of Systematic Reviews (PROSPERO; protocol ID: CRD42020159994). The current review covers only the in vivo part of the intended study. The search was initiated by forming a query (i.e., keywords) sourced from a number of related published studies and the Medical Subject Headings (MeSH) Database. The formed query was further checked by experts in the field (J.X.L., M.A.A., J.B.F.). Three bibliographic databases containing peer-reviewed journals were searched, namely, Web of Science (Science Citation Index Expanded), Scopus, and PubMed. Where applicable, filters were applied to include only original research publications, that were written in English and had the search terms in the title and abstract. No restriction on the date was applied. All returned articles were pooled from the three databases to EndNote, and duplicates were removed. Initially, the search covered studies that were published until 11th November 2019. Later, the search was updated to include related studies published from 11th November 2019 to 1st March 2021, obtained through an activated search-alert that was set earlier. Study selection was carried out at two stages by two reviewers independently (M.E.A., J.X.L.). Disagreements were resolved by discussion and by consulting the third and fourth reviewers (M.A.A. and J.B.F.). The first search stage involved screening titles and abstracts of retrieved studies, while the second stage was based on reviewing the full text of articles according to the predefined exclusion and inclusion criteria. The search query was adjusted as needed to function with each respective database. Keywords used were as follows:

| Database         | Query                                                                 |
|------------------|----------------------------------------------------------------------|
| **Web of Science** | TS=(“skin regeneration” OR “skin rejuvenation” OR “wound healing” OR “skin repair”) OR “extracellular vesicle*” OR nanovesicle*) AND TS=(“skin regeneration” OR “skin rejuvenation” OR “wound healing” OR “skin repair”) AND LANGUAGE: (English) AND DOCUMENT TYPES: (Article). |
| **PubMed**       | ((exosome* OR extracellular vesicle* OR nanovesicle* AND (English[lang]))) AND (wound healing OR skin repair OR skin regeneration OR skin rejuvenation AND (English[lang])) |
| **Scopus**       | TITLE-ABS-KEY ((exosome* OR “extracellular vesicle*” OR nanovesicle*) AND (“skin regeneration” OR “skin rejuvenation” OR “wound healing” OR “skin repair”)) AND DOCTYPE( ar ). |

**Eligibility criteria**

For the qualitative synthesis of studies, at the first stage we included only those articles that were 1) peer-reviewed original research articles; 2) written in English; 3) evaluated exosome/sEV therapeutic roles in wound healing and skin regeneration; and 4) conducted in mammalian animal models. Human trials were not covered in this review. We excluded studies that 1) were not original research, such as reviews, letters, commentaries, and conference proceedings, as well as those that were non-peer-reviewed (including preprints); 2) were written in languages other than English; 3) were unrelated to sEV applications in wound healing; and 4) were on non-mammalian animal models.

At the second stage of search, only studies that had 1) controlled interventional design; 2) examined at least one sEV positive marker (of the markers recommended in MISEV2018 [14]); 3) experimentally confirmed the size of isolated sEVs (30-200nm); 4) investigated wound healing and skin regeneration either macroscopically or microscopically, qualitatively or quantitatively; and 5) of which full text could be accessed either online or after request from the authors. There were no restrictions on sEV source, source cell manipulation, scaffold or vehicle use, or control type. We excluded studies that: 1) did not establish sEV identity by determining the size; 2) did not establish sEV identity using at least one EV positive protein marker; 3) did not assess wound healing or skin regeneration macroscopically or microscopically, qualitatively or quantitatively; 4) were not controlled; 5) did not include the pre-specified primary outcomes or reported insufficient data on the outcomes; or 6) their full text could not be retrieved despite contacting the authors.

**Data extraction and synthesis**

Data were extracted by two independent groups of reviewers (M.E.A and C.Y.N. as well as U.V. and R.S.) and arranged in a pre-designed data extraction.
form prepared by the reviewers. Disagreements were resolved by discussion and by consulting the third and fourth reviewers (J.X.L. and M.A.A.). Data were extracted from texts, tables, figures, supplementary materials and references cited for methods. These included intervention design, dosage (amount), dosing frequency, route of administration, doseresponse assessment, biocompatibility, vehicles, and comparators; characteristics of the animal models used, including species/strain, gender, age, body weight, disease model, wound model, size, and location; as well as the number of animals per group. Data on the EV source cells were also collected including cell type, modification type, if any, cell passage at extraction. Also, data on exogenous EV depletion regimens, methods of sEV separation, and characterization. In addition, any data on labeling and tracking of sEVs after administration were also collected. The primary outcomes extracted from studies were quantitative and qualitative data related to wound healing process evaluation, including wound closure rate; re-epithelialization; collagen deposition and maturation; angiogenesis; and scar assessment. The secondary outcome data extracted were qualitative data related to any reported adverse effects and inflammation. Additionally, general study characteristics such as authors, year, and country of corresponding author/s were obtained.

Quality and risk of bias assessment

The Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE’s) risk of bias tool was used to assess each study’s risk of bias [95]. This tool comprises a ten item-checklist: (1) random sequence generation, (2) baseline characteristics, and (3) allocation concealment, to evaluate selection bias; (4) random housing and (5) researcher blinding, to evaluate performance bias; (6) random outcome assessment, and (7) blinding of outcome assessment, to evaluate detection bias; (8) incomplete outcome data, to evaluate attrition bias; (9) selective reporting, to evaluate reporting bias; and (10) other source(s) of bias, if any. We modified the tool to include another item, declaration of the randomization method, but we excluded point (10) and thus did not check for other sources of bias.

We further assessed sample size calculation, quality of reporting, adherence to MISEV2018 characterization criteria, nomenclature, purity assessment, and EV-TRACK submission [106]. We also evaluated the adherence to ISCT minimal criteria to characterize mesenchymal stem cells (MSCs), where applicable. We evaluated the animal and disease models used to examine the external validity of the studies.

Meta-Analysis

The studies identified through our comprehensive search were checked for eligibility for a meta-analysis. We performed meta-analysis for three outcomes: wound closure rate, scar reduction, and angiogenesis, using Review Manager 5.4.1 (Cochrane) [190], comparing naïve sEVs (unmodified) with placebo controls. Meta-analysis was performed only when three studies or more reported the same outcome using the same scale. We retrieved means, standard deviations, or standard error of the mean as stated in the studies and emailed the authors to obtain missing data (including sample size), where necessary. We extracted data from figures in studies where numerical data were not available using an online application (WebPlotDigitizer, https://apps.automeris.io/wpd/). We excluded from the meta-analysis the studies for which the sample size was not provided even after contacting the authors. Statistical mean differences (SMD) and pooled size effects were estimated using random effects model, taking into account the diversity in sEV preparation, source, and wound size. Statistical heterogeneity (a measure of the heterogeneity of intervention effects across studies) was measured using I² index. A subgroup analysis of naïve sEVs versus placebo control was performed to assess if the effect of sEVs varied between diabetes and non-diabetes models. Additionally, we conducted another meta-analysis of wound closure rates for studies that reported characterization using MISEV2018 criteria, with subgroup analysis of diabetes and non-diabetes models. Statistical significance was considered when p < 0.05. To note, outcomes of studies that were not included in the meta-analysis were described qualitatively.

Abbreviations

EV: extracellular vesicle; sEV: small extracellular vesicle; MSC: mesenchymal stem/stromal cells; NTA: nanoparticle tracking analysis; UF: ultrafiltration; UC: ultracentrifugation; SYRCLE’s ROB tool: The Systematic Review Centre for Laboratory Animal Experimentation risk of bias tool.

Acknowledgements

This work was supported by research grants from the Universiti Kebangsaan Malaysia (GUP-2021-033) and Faculty of Medicine, Universiti Kebangsaan Malaysia (FF-2021-096). The Organization for Women in Science for The Developing World (OWSD) and The Swedish International Development Cooperation Agency (Sida) are appreciated for the PhD fellowship awarded to Maimonah E. Al-Masawa to support her studies. The graphical abstract was created with
Author contributions
Conception and design of the systematic review and meta-analysis: J.X.L, M.E.A, and M.A.A.; writing the manuscript: M.E.A.; screening and filtering the articles: M.E.A. and J.X.L.; consultation in selection stage: M.A.A., JB.F; data extraction and synthesis: M.E.A,C.Y.N., U.V., and R.S.; graphical abstract: C.Y.N. and M.E.A.; consultation, critical revisions, editing and final approval of the manuscript: J.X.L, K.W.W, M.A.A, AMH.N, JB.F.; and N.G.

Competing Interests
The authors have declared that no competing interest exists.

References
1. Subramaniam T, Fauzi MB, Lokanathan Y, Law JX. The role of calcium in wound healing. Int J Mol Sci. 2021; 22: 6848.
2. Rittié L. Cellular mechanisms of skin repair in humans and other mammals. J Cell Commun Signal. 2016; 10: 103-20.
3. Barakat M, DiPietro LA, Chen L. Limited treatment options for diabetic wounds: barriers to clinical translation despite therapeutic success in murine models. Adv Wound Care (New Rochelle). 2021; 10: 436-60.
4. Law JX, Chowdhury SR, Aminuddin BS, Ruszymah BHI. Role of plasma-derived fibrin on keratinocyte and fibroblast wound healing. Cell Tissue Bank. 2017; 18: 585-95.
5. Oliveira A, Simões S, Ascenso A, Reis CP. Therapeutic advances in wound healing. J Dermatolog Treat. 2020: 1-21.
6. Souto EB, Ribeiro AF, Ferreira MI, Teixeira MC, Shimojo AAM, Soriano JL, et al. New nanotechnologies for the treatment and repair of skin burns infections. Int J Mol Sci. 2020; 21: 393.
7. Fong C, Ibrahim A, Bulstrode NW, Ferretti P. An overview of the therapeutic potential of regenerative medicine in cutaneous wound healing. Int Wound J. 2017; 14: 450-9.
8. Doersch KM, DelleFritto DJ, Newell-Rogers MK. The contribution of interleukin-2 to effective wound healing. Exp Biol Med (Maywood). 2017; 242: 384-96.
9. Barrientos S, Brem H, Stojadinovic O, Tomic-Canic M. Clinical application of growth factors and cytokines in wound healing. Wound Repair Regen. 2014; 22: 569-78.
10. Spampinato SF, Caruso GI, De Pasquale R, Sortino MA, Merlo S. The treatment of impaired wound healing in diabetes: looking among old drugs. Pharmaceuticals (Basel). 2020; 13: 60.
11. Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol. 2014; 29: 116-25.
12. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of miRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2004; 6: 545-9.
13. Foo JB, Looi QH, How CW, Lee SH, Al-Masawa ME, Chong PP, et al. Mesenchymal stem cell-derived exosomes and microRNAs in cartilage regeneration: biogenesis, efficacy, miRNA enrichment and delivery. Pharmaceuticals (Basel). 2021; 14: 1093.
14. Théry C, Wittwer KW, Aikawa E, Alcazar MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018; 7: 1535750.
15. Tkach M, Kowal J, Théry C. Why the need and how to approach the functional diversity of extracellular vesicles. Philos Trans R Soc Lond B Biol Sci. 2018; 373: 20160479.
16. Noren Hooten N, Yañez-Mó M, DeRita R, Russell A, Quessenberry P, Ramatnam B, et al. Filting the bullseye: are extracellular vesicles targeted on their target? J Extracell Vesicles. 2020; 10: e205292.
17. Palviainen M, Saravast M, Varga Z, Kitka D, Neuvonen M, Puhka M, et al. Extracellular vesicles from human plasma and serum are carriers of extravascular cargo—Implications for biomarker discovery. PLoS One. 2020; 15: e0236439.
18. Noren Hooten N, Evans MK. Extracellular vesicles as signaling mediators in type 2 diabetes mellitus. Am J Physiol Cell Physiol. 2020; 318: C1189-C99.
19. Yates AG, Pink RC, Erdbrügger U, Sijlrandre PBM, Dellar EB, Pantazopoulos P, et al. In sickness and in health: the functional role of extracellular vesicles in physiology and pathology in vivo. J Extracell Vesicles. 2022; 11: e12151.
20. Griebel B, Kordelas L, Böger V. Clinical potential of mesenchymal stem/stromal cell-derived extracellular vesicles. Stem Cell Investig. 2017; 4: 84-.
21. Lai RC, Chen TS, Lim SK. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med. 2011; 6: 481-92.
22. Sawalani R, Fonseka P, Chitti SV, Mathivanan S. Milk-derived extracellular vesicles in inter-organism, cross-species communication and drug delivery. Proteomes. 2020; 8: 11.
23. Atkin-Smith GK, Tixeira R, Paone S, Mathivanan S, Collins C, Lien M, et al. A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure. Nat Commun. 2015; 6: 7439.
24. Cocucci E, Meldolesi J. Exosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015; 25: 364-72.
25. Mathieu M, Névo N, Jouve M, Valenzuela JL, Mauritn M, Verweij FJ, et al. Specificities of exosome versus small exosome secretion revealed by live intracellular tracking of CD63 and CD9. Nat Commun. 2021; 12: 4389.
26. Wittwer KW, Théry C. Extracellular Vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature. J Extracell Vesicles. 2019; 8: 1648167.
27. Ng CY, Chai JY, Foo JB, Mohamad Yahaya NH, Yang Y, Ng MH, et al. Potential of exosomes as cell-free therapy in articular cartilage regeneration: a review. Int J Nanomedicine. 2021; 16: 6749-81.
28. Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doepner TR, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014; 28: 970-3.
29. Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021; 16: 748-59.
30. Xu L, Faruqui FN, Lim YM, Lim KY, Lian-Or R, Walters AA, et al. Exosome-mediated RNAi of PAK4 prolongs survival of pancreatic cancer mouse model after loco-regional treatment. Biomaterials. 2021; 264: 120369.
31. Jiang L, Driedonks T, Lowman M, Jong WSP, van den Berg van Saparoea HB, Dhakal S, et al. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2. bioRxiv. 2021; 2021.06.28.450181.
32. Cheng S, Kong Q, Hu X, Zhang C, Xian Y. An ultrafast strain displacement signal amplification-assisted synchronous fluorescence assay for surface proteins of small extracellular vesicle analysis and cancer identification. Anal Chem. 2022; 94: 1085-91.
33. Cheng L, Hill AF. Therapeutically harnessing extracellular vesicles. Nat Rev Drug Discov. 2022.
34. Narauskaite D, Vydmantaitė G, Ruseikaitė J, Sampath R, Rudaiytė A, Šatalytė G, et al. Extracellular vesicles in skin wound healing. Pharmaceuticals (Basel). 2021; 14: 811.
35. Lee JH, Jung H, Song I, Goh MS, You G, Mok H. Activated platelet-derived vesicles for efficient hemorrhagic activity. Macromol Biosci. 2020; 20: 1900338.
36. del Conde I, Shrimpton CN, Thigirajapen P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005; 105: 1604-11.
37. Kolonics F, Kajdaci F, Farkas VJ, Veres DS, Khamari D, Kittel Á, et al. Neutrophils produce proinflammatory or anti-inflammatory extracellular vesicles depending on the environmental conditions. J Leukoc Biol. 2021; 109: 793-806.
38. Gangadaran P, Rajendran RL, Oh JM, Hong CM, Jeong SY, Lee S-W, et al. Extracellular vesicle-derived from macropage promote angiogenesis in vitro and accelerate new vasculature formation in vivo. Exp Cell Res. 2020; 394: 112146.
39. Arif S, Larochelle S, Moulin VJ. PLG-F1 contained in normal wound myofibroblast-derived microvesicles stimulated collagen production by dermal fibroblasts. J Cell Commun Signal. 2020; 14: 427-38.
40. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006; 8: 315-7.
41. Gopalakrishnan S, Gurunskumar P. Systematic reviews and meta-analysis: understanding the best evidence in primary healthcare. J Family Med Prim Care. 2013; 2: 9-14.
42. Lu M, Peng L, Ming X, Wang X, Cui A, Li Y, et al. Enhanced wound healing promotion by immune response-free monkey autologous iPSCs.
and exosomes vs. their allogeneic counterparts. EBioMedicine. 2019; 42: 443-57.

43. Zhu Y-Z, Hu X, Zhang J, Wang Z-H, Wu S, Yi Y-Y. Extracellular vesicles derived from human adipose-derived stem cell prevent the formation of hemangioma in a rabbit model. Ann Plast Surg. 2020; 84: 60-7.

44. Henriques-Antunes H, Cardoso RMS, Zonari A, Correia J, Leal EC, Jiménez-Balsa A, et al. The kinetics of small extracellular vesicle delivery impacts skin tissue regeneration. ACS Nano. 2019; 13: 8694-707.

45. Zhang B, Wang M, Gong A, Zhang X, Wu X, Zhu Y, et al. HuMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing. Stem Cells. 2015; 33: 2158-68.

46. Li X, Wang Y, Shi L, Li B, Li J, Wei Z, et al. Magnetic targeting enhances the cutaneous wound healing effects of human mesenchymal stem cell-derived iron oxide exosomes. J Nanobiotechnology. 2020; 18: 113.

47. Liu J, Yan Z, Yang F, Huang Y, Yu Y, Zhou I, et al. Exosomes derived from human umbilical cord mesenchymal stem cells accelerate cutaneous wound healing by enhancing angiogenesis through delivering angiopoietin-2. Stem Cell Rev Rep. 2020; 17: 305-17.

48. Liang J-X, Liao X, Li S-H, Jiang X, Li Z-H, Wu Y-D, et al. Antiaging properties of exosomes from adipose-derived mesenchymal stem cells in photoaged rat skin. Biomed Res Int. 2020; 2020: 6406395.

49. Sun Y, Zhang J, Chen B, Yang Y, Li H, Niu X, et al. Small extracellular vesicles secreted by urine-derived stem cells enhanced wound healing in aged mice by ameliorating cellular senescence. J Mater Sci Technol. 2021; 65: 216-27.

50. Ti D, Hao H, Tong C, Liu J, Dong L, Zheng J, et al. LPS preconditioned extracellular vesicles from mesenchymal stem cells modulate macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. J Transl Med. 2015; 13: 308.

51. Dong J, Wu Y, Zhang Y, Yu M, Tian W. Comparison of the therapeutic effect of allogeneic and xenogeneic small extracellular vesicles in soft tissue injury repair. Int J Nanomedicine. 2020; 15: 6975-91.

52. Geiger A, Walker A, Nissen E. Human fibrocyte-derived exosomes accelerate wound healing in genetically diabetic mice. Biochem Biophys Res Commun. 2015; 467: 303-9.

53. Sun Y, Zhang J, Chen B, Yang Y, Li H, Niu X, et al. Small extracellular vesicles secreted by urine-derived stem cells enhanced wound healing in aged mice by ameliorating cellular senescence. J Mater Sci Technol. 2021; 65: 216-27.

54. Shi Q, Qian Z, Liu D, Sun J, Wang X, Liu H, et al. GMSC-derived exosomal PD-L1 functions as an immunosuppressant to promote wound healing. J Mol Histol. 2020; 51: 251-63.

55. Wang C, Wang M, Xu T, Zhang X, Lin C, Gao W, et al. Engineering bioactive self-healing antibacterial exosomes hydrogel for promoting chronic diabetic wound healing and complete skin regeneration. Theranostics. 2019; 9: 65-77.

56. Wang M, Wang C, Chen M, Xi Y, Cheng W, Mao C, et al. Efficient angiogenesis-based diabetic wound healing/skin reconstruction through bioactive antibacterial adhesive ultraviolet shielding nanodressing with exosome release. ACS Nano. 2019; 13: 10293-99.

57. Yang J, Chen Z, Pan D, Li H, Shen J. Umbilical cord-derived mesenchymal stem cell-derived exosomes combined with pluronic F127 hydrogel promote chronic diabetic wound healing and complete skin regeneration. Int J Nanomedicine. 2020; 15: 5911-26.

58. Fang S, Xu C, Zhang Y, Xue C, Yang C, Bi H, et al. Umbilical cord-derived mesenchymal stem cell-derived exosomal miRNAs suppress myofibroblast differentiation by inhibiting the transforming growth factor-β/SMA/D2 pathway during wound healing. Stem Cells Transl Med. 2016; 5: 1425-39.

59. Duan M, Zhang Y, Zhang H, Meng Y, Qian M, Zhang G. Epidermal stem cell-derived exosomes promote skin regeneration by downregulating transforming growth factor-β1 in wound healing. Stem Cell Res Ther. 2020; 11: 452.

60. Zhao D, Yu Z, Li Y, Wang Y, Li Q, Han D. GelMA combined with sustained release of HUVECs derived exosomes for promoting cutaneous wound healing and facilitating skin regeneration. J Mol Histol. 2020; 51: 251-63.

61. Shi Q, Qian Z, Liu D, Sun J, Wang X, Liu H, et al. GMSC-derived exosomes combined with a chitosan/silk hydrogel sponge accelerates wound healing in a diabetic rat skin defect model. Front Physiol. 2017; 8.

62. Nooshabadi VT, Khanmohamadi M, Valipour E, Mahdipour S, Salati A, et al. Exosomes derived from clinical-grade oral mucosal epithelial cell-exosome-mediated delivery of miR-135a/SIRT1-mediated autophagy. Am J Physiol Cell Physiol. 2020; 318: C848-C56.

63. Wu D, Kang L, Tian J, Wu Y, Liu J, Li Z, et al. Exosomes derived from bone mesenchymal stem cells with the stimulation of Fe3O4 nanoparticles and static magnetic field enhance wound healing through upregulated miR-21-5p. Int J Nanomedicine. 2020; 15: 7979-93.

64. Wang C, Wang M, Xu T, Zhang X, Lin C, Gao W, et al. Engineering bioactive self-healing antibacterial exosomes hydrogel for promoting chronic diabetic wound healing and complete skin regeneration. Theranostics. 2019; 9: 65-77.

65. Wang M, Wang C, Chen M, Xi Y, Cheng W, Mao C, et al. Efficient angiogenesis-based diabetic wound healing/skin reconstruction through bioactive antibacterial adhesive ultraviolet shielding nanodressing with exosome release. ACS Nano. 2019; 13: 10293-99.

66. Yang J, Chen Z, Pan D, Li H, Shen J. Umbilical cord-derived mesenchymal stem cell-derived exosomes combined with pluronic F127 hydrogel promote chronic diabetic wound healing and complete skin regeneration. Int J Nanomedicine. 2020; 15: 5911-26.

67. Wang C, Wang M, Xu T, Zhang X, Lin C, Gao W, et al. Engineering bioactive self-healing antibacterial exosomes hydrogel for promoting chronic diabetic wound healing and complete skin regeneration. Theranostics. 2019; 9: 65-77.
85. Parvanian S, Yan F, Su D, Coelho-Rato LS, Venu AP, Yang P, et al. Exosomal vimentin from adipocyte progenitors accelerates wound healing. Cytoskeleton (Hoboken). 2020; 77: 399-413.
86. Qin S, Dorschner RA, Masini I, Lavoie GA. Optimizing the payload and biological activity of extracellular vesicles that mediate tissue repair. FASEB J. 2019; 33: 6129-39.
87. Hu Y, Rao SS, Wang ZX, Cao J, Tan YJ, Luo J, et al. Exosomes from human umbilical cord blood accelerate cutaneous wound healing through miR-21-5p-mediated promotion of angiogenesis and fibroblast function. Theranostics. 2018; 8: 169-84.
88. Mi B, Chen L, Xiong Y, Yan C, Xue H, Panayi AC, et al. Saliva exosomes-derived UBE2O mRNA promotes angiogenesis in cutaneous wounds by targeting SMAD6. J Nanobiotechnol. 2020; 18: 68.
89. Wei P, Zhong C, Yang X, Shu F, Xiao S, Gong T, et al. Exosomes derived from human amniotic epithelial cells accelerate diabetic wound healing via PI3K-AKT-mTOR-mediated promotion in angiogenesis and fibroblast function. Burns Trauma. 2020; 8.
90. Xu M, Su X, Xiao Y, Xu H, Li X, Keating A, et al. Hydrogen peroxide-induced senescence reduces the wound healing-promoting effects of mesenchymal stem cell-derived exosomes partially via miR-146a. Aging Dis. 2021; 12: 102-105.
91. Zhao B, Zhang Y, Han S, Zhang W, Zhou Q, Guan H, et al. Exosomes derived from human amniotic epithelial cells accelerate wound healing and inhibit scar formation. J Mol Histol. 2017; 48: 121-32.
92. Li M, Wang T, Tian H, Wei G, Zhao L, Shi Y. Macrophage-derived exosomes accelerate wound healing through their anti-inflammation effects in a diabetic rat model. Artif Cells Nanomed Biotechnol. 2019; 47: 3793-803.
93. Zhang J, Chen C, Hu B, Niu X, Liu X, Zhang G, et al. Exosomes derived from human endothelial progenitor cells accelerate cutaneous wound healing by promoting angiogenesis through Erk1/2 signaling. Int J Biol Sci. 2016; 12: 1472-87.
94. Hu L, Wang J, Zhou X, Xiong Z, Zhao J, Yu R, et al. Exosomes derived from human adipose mesenchymal stem cells accelerate cutaneous wound healing via optimizing the characteristics of fibroblasts. Sci Rep. 2016; 6: 32993.
95. Hooijmans CR, Rovers MM, de Vries RBM, Leenaars M, Hooijmans CR, Rovers MM, de Vries RBM, Leenaars M, Ter Riet MG, Schilder AG. ClinicalTrials.gov study registration: a new tool to aid systematic reviews of clinical trials. J Clin Epidemiol. 2016; 71: 423-30.
96. Dalirfardouei R, Jamialahmadi K, Jafari AH, Madhipur P. Promising effects of exosomes isolated from menstrual blood-derived mesenchymal stem cell on wound-healing process in diabetic mouse model. J Tissue Eng Regen Med. 2019; 13: 555-68.
97. Kobayashi H, Ebisawa K, Kamba M, Kasai T, Suga H, Nakamura K, et al. Effects of exosomes derived from the induced pluripotent stem cells on skin wound healing. Nagoya J Med Sci. 2020; 80: 141-53.
98. Zhao C, Guo X, Xu Y, Hu G, Guo S, Li Q, et al. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. J Transl Med. 2015; 13: 49.
99. Zhao G, Liu F, Liu Z, Zuo K, Wang B, Zhang Y, et al. MSC-derived extracellular vesicles arrest cell death through suppressing AIF nuclear translocation and enhancing cutaneous wound healing. Stem Cell Res Ther. 2020; 11: 174.
100. Bian X, Li B, Yang J, Ma K, Sun M, Zhang C, et al. Regenerative and protective effects of dMSC-derived extracellular vesicles on skin wound healing. J Med. 2020; 24: 9590-604.
101. Cheong S, Xi Z, Chen G, Liu K, Ma R, Zhou C. Extracellular vesicle-carried microRNA-27b derived from mesenchymal stem cells accelerates cutaneous wound healing via E3 ubiquitin ligase ITCH. J Cell Mol Med. 2020; 24: 11254-71.
102. Wei F, Wang A, Wang Q, Han W, Rong R, Wang L, et al. Plasma endothelial cells-derived extracellular vesicles promote wound healing in diabetes through YAP and the PI3K/Akt/mTOR pathway. Aging (Albany NY). 2020; 12: 12002-18.
103. Zhou H, Li X, Yin Y, He X-T, An Y, Tian B-M, et al. The proangiogenic effects of extracellular vesicles secreted by dental pulp stem cells derived from periodontally compromised teeth. Stem Cell Res Ther. 2020; 11: 110.
104. Pintor Aif, Guh DA, Carregal V, Silva FC, Miranda MC, Kunnath-Lima M, et al. Extracellular vesicles from adipose-derived mesenchymal stem/stromal cells accelerate migration and activate AKT pathway in human keratinocytes and fibroblasts independently of miR-205 activity. Stem Cells Int. 2017; 2017: 9841035.
129. Witwer KW, Van Balkom BMW, Bruno S, Choo A, Dominici M, Gimona M, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019; 8: 1609:206.

130. Gimona M, Brückl MF, Choo ABH, Dominici M, Davidson SM, Griller J, et al. Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles. Cytotherapy. 2021; 23: 373-80.

131. Pirkmajer S, Chibalin AV. Serum starvation: caveat emptor. Am J Physiol. 132. Li J, Lee Y, Johansson HJ, Mäger I, Vader P, Nordin JZ, et al. Serum-free media culture alters the quantity and protein composition of neuroblastoma-derived extracellular vesicles. J Extracell Vesicles. 2015; 4: 2688.

133. Liao Z, Muth DC, Ettan E, Travers M, Learman LN, Lehmann E, et al. Serum-free extracellular vesicle depletion processes affect release and infectivity of HIV-1 in culture. Sci Rep. 2017; 7: 2558.

134. Driedons TAP, Nijen Twijllaar MK, Nolte+t Hoen ENM. Technical approaches to reduce interference of fetal calf serum derived RNA in the analysis of extracellular vesicle RNA from cultured cells. J Extracell Vesicles. 2019; 8: 155209.

135. Shelke GV, Lässer C, Gho YS, Lötvall J. Importance of exosome depletion processes in infectivity of HIV-1 in culture. Sci Rep. 2017; 7: 2558.

136. Konoshenko MY, Lekchnov EA, Vlassov AV, Laktionov PP. Isolation of small extracellular vesicles. 2019; 8: 1552059.

137. Staubach S, Bauer FN, Tertel T, Börger V, Stambouli O, Salzig D, et al. Defining mesenchymal stromal cell (MSC) derived small extracellular vesicles therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles. Cytotherapy. 2021; 23: 373-80.

138. Smyth TJ, Redzic JS, Graner MW, Anchoordoyq TJ. Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro. Biochim Biophys Acta Membr. 2014; 1836: 2954-65.
177. Sharma A, Benbrook DM, Woo S. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. PLoS One. 2018; 13: e0194046.

178. Wagner KT, Nash TR, Liu B, Vunjak-Novakovic G, Radisic M. Extracellular vesicles in cardiac regeneration: potential applications for tissues-on-a-chip. Trends Biotechnol. 2021; 39: 755-73.

179. He S, Leanne LG, Feng Y. Artificial intelligence and machine learning assisted drug delivery for effective treatment of infectious diseases. Adv Drug Deliv Rev. 2021; 178: 113922.

180. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012; 400: 187-91.

181. Jin Y, Sanger N, Shams I, Luo C, Shahid H, Li G, et al. Does the medical literature remain inadequately described despite having reporting guidelines for 21 years? - A systematic review of reviews: an update. J Multidiscip Healthc. 2018; 11: 495-510.

182. Poupardin R, Wolf M, Strunk D. Adherence to minimal experimental requirements for defining extracellular vesicles and their functions. Adv Drug Deliv Rev. 2021; 176: 113872.

183. Henderson VC, Demko N, Hakala A, MacKinnon N, Federico CA, Fergusson D, et al. A meta-analysis of threats to valid clinical inference in preclinical research of suritininib. Elife. 2015; 4: e08351.

184. Ferreira GS, Veening-Griffioen DH, Boon WPC, Moors EHM, van Meer PJK. Levelling the translational gap for animal to human efficacy data. Animals (Basel). 2020; 10: 1199.

185. Escudé Martinez de Castilla P, Tong L, Huang C, Sofias AM, Pastorin G, Chen X, et al. Extracellular vesicles as a drug delivery system: a systematic review of preclinical studies. Adv Drug Deliv Rev. 2021; 175: 113801.

186. Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med. 2005; 3: 10-

187. Ghoroghi S, Mary B, Larnicol A, Asokan N, Klein A, Osmani N, et al. Rap GTPases promote breast cancer metastasis by controlling biogenesis and organ targeting of exosomes. Elife. 2021; 10: e61539.

188. Tóth EA, Turiák L, Visnovitz T, Cserép C, Mázló A, Sódar BW, et al. Formation of a protein corona on the surface of extracellular vesicles in blood plasma. J Extracell Vesicles. 2021; 10: e12140.

189. Public safety notification on exosome products FDA, 2019.

190. RevMan. Review manager [computer program] version 5.4.1 The Cochrane Collaboration. 2020.

191. Xiong Y, Chen L, Yu T, Yan C, Zhou W, Cao F, et al. Inhibition of circulating exosomal microRNA-15a-3p accelerates diabetic wound repair. Aging (Albany NY). 2020; 12: 8968-86.

192. Cao G, Chen B, Zhang X, Chen H. Human adipose-derived mesenchymal stem cells-derived exosomal microRNA-196 promotes the healing of skin wounds through modulation of the CCL1/TGF-β signaling axis. Clin Cosmet Investig Dermatol. 2020; 13: 957-71.